<!doctype html>
<html data-n-head-ssr lang="en" data-n-head="%7B%22lang%22:%7B%22ssr%22:%22en%22%7D%7D">

<head >
  <link data-n-head="ssr" rel="icon" type="image/png" sizes="16x16" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_16-tenantFavicon-Frontiers.png">
  <link data-n-head="ssr" rel="icon" type="image/png" sizes="32x32" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_32-tenantFavicon-Frontiers.png">
  <link data-n-head="ssr" rel="apple-touch-icon" type="image/png" sizes="180x180" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_180-tenantFavicon-Frontiers.png">

  <title>Frontiers | Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana</title><meta data-n-head="ssr" charset="utf-8"><meta data-n-head="ssr" name="viewport" content="width=device-width, initial-scale=1"><meta data-n-head="ssr" data-hid="charset" charset="utf-8"><meta data-n-head="ssr" data-hid="mobile-web-app-capable" name="mobile-web-app-capable" content="yes"><meta data-n-head="ssr" data-hid="apple-mobile-web-app-title" name="apple-mobile-web-app-title" content="Frontiers | Articles"><meta data-n-head="ssr" data-hid="theme-color" name="theme-color" content="#0C4DED"><meta data-n-head="ssr" data-hid="description" property="description" name="description" content=""><meta data-n-head="ssr" data-hid="og:title" property="og:title" name="title" content="Frontiers | Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana"><meta data-n-head="ssr" data-hid="og:description" property="og:description" name="description" content=""><meta data-n-head="ssr" data-hid="keywords" name="keywords" content="HIV,ART,viral load,viral rebound,viral suppression"><meta data-n-head="ssr" data-hid="og:site_name" property="og:site_name" name="site_name" content="Frontiers"><meta data-n-head="ssr" data-hid="og:image" property="og:image" name="image" content="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/7CCE4235-8BF4-4D52-8022020C57AC98C1/D992F897-6BC2-466D-90902EADFBEAB887/WebsiteWebP_XL-FPUBH_Main Visual_Cyan_Website.webp"><meta data-n-head="ssr" data-hid="og:type" property="og:type" name="type" content="article"><meta data-n-head="ssr" data-hid="og:url" property="og:url" name="url" content="https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full"><meta data-n-head="ssr" data-hid="twitter:card" name="twitter:card" content="summary_large_image"><meta data-n-head="ssr" data-hid="citation_volume" name="citation_volume" content="13"><meta data-n-head="ssr" data-hid="citation_journal_title" name="citation_journal_title" content="Frontiers in Public Health"><meta data-n-head="ssr" data-hid="citation_publisher" name="citation_publisher" content="Frontiers"><meta data-n-head="ssr" data-hid="citation_journal_abbrev" name="citation_journal_abbrev" content="Front. Public Health"><meta data-n-head="ssr" data-hid="citation_issn" name="citation_issn" content="2296-2565"><meta data-n-head="ssr" data-hid="citation_doi" name="citation_doi" content="10.3389/fpubh.2025.1508793"><meta data-n-head="ssr" data-hid="citation_firstpage" name="citation_firstpage" content="1508793"><meta data-n-head="ssr" data-hid="citation_language" name="citation_language" content="English"><meta data-n-head="ssr" data-hid="citation_title" name="citation_title" content="Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana"><meta data-n-head="ssr" data-hid="citation_keywords" name="citation_keywords" content="HIV; ART; viral load; viral rebound; viral suppression"><meta data-n-head="ssr" data-hid="citation_abstract" name="citation_abstract" content=""><meta data-n-head="ssr" data-hid="citation_pdf_url" name="citation_pdf_url" content="https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/pdf"><meta data-n-head="ssr" data-hid="citation_online_date" name="citation_online_date" content="2025/02/27"><meta data-n-head="ssr" data-hid="citation_publication_date" name="citation_publication_date" content="2025/03/19"><meta data-n-head="ssr" data-hid="citation_author_0" name="citation_author" content="Boateng, Anthony T."><meta data-n-head="ssr" data-hid="citation_author_institution_0" name="citation_author_institution" content="West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_1" name="citation_author" content="Aboagye, James O."><meta data-n-head="ssr" data-hid="citation_author_institution_1" name="citation_author_institution" content="Medical and Scientific Research Center, University of Ghana Medical Center, Ghana"><meta data-n-head="ssr" data-hid="citation_author_2" name="citation_author" content="Lamptey, Helena"><meta data-n-head="ssr" data-hid="citation_author_institution_2" name="citation_author_institution" content="Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_3" name="citation_author" content="Abana, Christopher Z.-Y."><meta data-n-head="ssr" data-hid="citation_author_institution_3" name="citation_author_institution" content="West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_4" name="citation_author" content="Abaidoo-Myles, Araba"><meta data-n-head="ssr" data-hid="citation_author_institution_4" name="citation_author_institution" content="West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_5" name="citation_author" content="Quansah, Darius N. K."><meta data-n-head="ssr" data-hid="citation_author_institution_5" name="citation_author_institution" content="West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_6" name="citation_author" content="Agyemang, Seth"><meta data-n-head="ssr" data-hid="citation_author_institution_6" name="citation_author_institution" content="Central Laboratory, Immunology Department, Korle-Bu Teaching Hospital, Ghana"><meta data-n-head="ssr" data-hid="citation_author_7" name="citation_author" content="Awuku-Larbi, Yaw"><meta data-n-head="ssr" data-hid="citation_author_institution_7" name="citation_author_institution" content="Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_8" name="citation_author" content="Ansa, Gloria"><meta data-n-head="ssr" data-hid="citation_author_institution_8" name="citation_author_institution" content="Public Health Unit, University of Ghana Hospital, Ghana"><meta data-n-head="ssr" data-hid="citation_author_9" name="citation_author" content="Oliver-Commey, Joseph"><meta data-n-head="ssr" data-hid="citation_author_institution_9" name="citation_author_institution" content="LEKMA Hospital, Ghana"><meta data-n-head="ssr" data-hid="citation_author_10" name="citation_author" content="Ganu, Vincent"><meta data-n-head="ssr" data-hid="citation_author_institution_10" name="citation_author_institution" content="Department of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_11" name="citation_author" content="Kyei, George B."><meta data-n-head="ssr" data-hid="citation_author_institution_11" name="citation_author_institution" content="Departments of Medicine and Molecular Microbiology, Washington University School of Medicine, United States"><meta data-n-head="ssr" data-hid="citation_author_12" name="citation_author" content="Puplampu, Peter"><meta data-n-head="ssr" data-hid="citation_author_institution_12" name="citation_author_institution" content="Department of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="citation_author_13" name="citation_author" content="Bonney, Evelyn Y."><meta data-n-head="ssr" data-hid="citation_author_institution_13" name="citation_author_institution" content="Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Ghana"><meta data-n-head="ssr" data-hid="dc.identifier" name="dc.identifier" content="doi:10.3389/fpubh.2025.1508793"><link data-n-head="ssr" rel="manifest" href="/article-pages/_nuxt/manifest.c499fc0a.json" data-hid="manifest"><link data-n-head="ssr" rel="canonical" href="https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full"><script data-n-head="ssr" data-hid="newrelic-browser-script" type="text/javascript">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"588603994","agentToken":null,"applicationTime":11.226307,"transactionName":"MQcDMkECCkNSW0YMWghNIgldDQFTRxd1IGFJTQ==","queueTime":0,"ttGuid":"9cbb3598d22b9463"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594400880",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIXFdSBAgOUg==",licenseKey:"598a124f17",applicationID:"588603994"};;/*! For license information please see nr-loader-spa-1.284.1.min.js.LICENSE.txt */
(()=>{var e,t,r={8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{if(null===e[a]){r[a]=null;continue}Array.isArray(e[a])&&Array.isArray(t[a])?r[a]=Array.from(new Set([...e[a],...t[a]])):"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},2555:(e,t,r)=>{"use strict";r.d(t,{Vp:()=>c,fn:()=>s,x1:()=>u});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){try{const t=c(e);return!!t.licenseKey&&!!t.errorBeacon&&!!t.applicationID}catch(e){return!1}}function c(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function u(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.info=a[e])}},9417:(e,t,r)=>{"use strict";r.d(t,{D0:()=>h,gD:()=>g,xN:()=>p});var n=r(3333);const i=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var o=r(2614),a=r(944),s=r(384),c=r(8122);const u="[data-nr-mask]",d=()=>{const e={feature_flags:[],experimental:{marks:!1,measures:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{get capture_marks(){return e.feature_flags.includes(n.$v.MARKS)||e.experimental.marks},set capture_marks(t){e.experimental.marks=t},get capture_measures(){return e.feature_flags.includes(n.$v.MEASURES)||e.experimental.measures},set capture_measures(t){e.experimental.measures=t},capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(n.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:o.wk,inactiveMs:o.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){i(t)?e.mask_selector="".concat(t,",").concat(u):""===t||null===t?e.mask_selector=u:(0,a.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){i(t)?e.block_selector+=",".concat(t):""!==t&&(0,a.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,a.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}},l={},f="All configuration objects require an agent identifier!";function h(e){if(!e)throw new Error(f);if(!l[e])throw new Error("Configuration for ".concat(e," was never set"));return l[e]}function p(e,t){if(!e)throw new Error(f);l[e]=(0,c.a)(t,d());const r=(0,s.nY)(e);r&&(r.init=l[e])}function g(e,t){if(!e)throw new Error(f);var r=h(e);if(r){for(var n=t.split("."),i=0;i<n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}},5603:(e,t,r)=>{"use strict";r.d(t,{a:()=>c,o:()=>s});var n=r(384),i=r(8122);const o={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},a={};function s(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!a[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.loader_config=a[e])}},3371:(e,t,r)=>{"use strict";r.d(t,{V:()=>f,f:()=>l});var n=r(8122),i=r(384),o=r(6154),a=r(9324);let s=0;const c={buildEnv:a.F3,distMethod:a.Xs,version:a.xv,originTime:o.WN},u={customTransaction:void 0,disabled:!1,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,onerror:void 0,ptid:void 0,releaseIds:{},appMetadata:{},session:void 0,denyList:void 0,timeKeeper:void 0,obfuscator:void 0,harvester:void 0},d={};function l(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!d[e])throw new Error("Runtime for ".concat(e," was never set"));return d[e]}function f(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");d[e]={...(0,n.a)(t,u),...c},Object.hasOwnProperty.call(d[e],"harvestCount")||Object.defineProperty(d[e],"harvestCount",{get:()=>++s});const r=(0,i.nY)(e);r&&(r.runtime=d[e])}},9324:(e,t,r)=>{"use strict";r.d(t,{F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.284.1",i="PROD",o="CDN",a="^2.0.0-alpha.18"},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>s,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>a,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),a=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),s="complete"===a?.document?.readyState,c=Boolean("hidden"===a?.document?.visibilityState),u=""+a?.location,d=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>a,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(s(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function a(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,a;i>0?(o=r.substring(0,i),a=r.substring(i)):(o=r,a="");let[s]=o.split(":");n.push({hostname:s,pathname:a})}}function s(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>c,Ze:()=>l,x3:()=>u});var n=r(7836),i=r(3606),o=r(860),a=r(2646);const s={};function c(e,t){const r={staged:!1,priority:o.P3[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function u(e,t){e&&s[e]&&(s[e].get(t)&&s[e].delete(t),h(e,t,!1),s[e].size&&f(e))}function d(e){if(!e)throw new Error("agentIdentifier required");s[e]||(s[e]=new Map)}function l(e="",t="feature",r=!1){if(d(e),!e||!s[e].get(t)||r)return h(e,t);s[e].get(t).staged=!0,f(e)}function f(e){const t=Array.from(s[e]);t.every((([e,t])=>t.staged))&&(t.sort(((e,t)=>e[1].priority-t[1].priority)),t.forEach((([t])=>{s[e].delete(t),h(e,t)})))}function h(e,t,r=!0){const o=e?n.ee.get(e):n.ee,s=i.i.handlers;if(!o.aborted&&o.backlog&&s){if(r){const e=o.backlog[t],r=s[t];if(r){for(let t=0;e&&t<e.length;++t)p(e[t],r);Object.entries(r).forEach((([e,t])=>{Object.values(t||{}).forEach((t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])}))}))}}o.isolatedBacklog||delete s[t],o.backlog[t]=null,o.emit("drain-"+t,[])}}function p(e,t){var r=e[1];Object.values(t[r]||{}).forEach((t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}}))}},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>c,ee:()=>u});var n=r(384),i=r(8990),o=r(3371),a=r(2646),s=r(5607);const c="nr@context:".concat(s.W),u=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&(0,o.f)(r).isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(u.aborted&&!i)return;t&&o&&t.emit(e,r,n);for(var a=h(n),c=g(e),d=c.length,l=0;l<d;l++)c[l].apply(a,r);var p=v()[s[e]];p&&p.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach((([e,n])=>{s[n]=t,t in r||(r[t]=[])}))},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach((e=>{delete f.backlog[e]}))},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof a.y?e:e?(0,i.I)(e,c,(()=>new a.y(c))):new a.y(c)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),d=(0,n.Zm)();d.ee||(d.ee=u)},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.d,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>s,ZF:()=>c,bz:()=>a,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map((e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const a=[];for(var s=0;s<e;s++)a.push(o(r,i++).toString(16));return a.join("")}function c(){return s(16)}function u(){return s(32)}},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>a,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>s,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,a=18e5,s={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},944:(e,t,r)=>{"use strict";function n(e,t){"function"==typeof console.debug&&console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t)}r.d(t,{R:()=>n})},5284:(e,t,r)=>{"use strict";r.d(t,{t:()=>c,B:()=>s});var n=r(7836),i=r(6154);const o="newrelic";const a=new Set,s={};function c(e,t){const r=n.ee.get(t);s[t]??={},e&&"object"==typeof e&&(a.has(t)||(r.emit("rumresp",[e]),s[t]=e,a.add(t),function(e={}){try{i.gm.dispatchEvent(new CustomEvent(o,{detail:e}))}catch(e){}}({loaded:!0})))}},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout((()=>{i=clearTimeout(i)}),t)),n||(clearTimeout(i),i=setTimeout((()=>{e.apply(this,r)}),t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,sB:()=>a});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function a(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}},384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>o,US:()=>d,Zm:()=>a,bQ:()=>c,dV:()=>s,nY:()=>u,pV:()=>l});var n=r(6154),i=r(1863);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function s(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket}),e}function c(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function u(e){let t=a();return t.initializedAgents?.[e]}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)}),r,i)}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),a=r(6154);const s={},c=a.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(s[t.debugId]++)return t;s[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(a.RI&&h(document,f),c&&h(c.prototype,f),h(a.gm,f)),t.on(u+"-start",(function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var i=(0,o.I)(n,l,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(d+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>c});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W);var a=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const a="-"===n.charAt(0);for(let s=0;s<t.length;s++){const c=t[s],u=e[c];d(u)||(e[c]=r(u,a?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,s,c){return d(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){u([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,d,l;try{a=this,o=[...arguments],d="function"==typeof n?n(o,a):n||{}}catch(t){u([t,"",[o,a,s],d],e)}i(r+"start",[o,a,s],d,c);try{return l=t.apply(a,o)}catch(e){throw i(r+"err",[o,a,e],d,c),e}finally{i(r+"end",[o,a,l],d,c)}}}function i(r,n,i,o){if(!s||t){var a=s;s=!0;try{e.emit(r,n,i,t,o)}catch(t){u([t,r,n,i],e)}s=a}}}function u(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function d(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},9414:(e,t,r)=>{"use strict";r.d(t,{J:()=>c});var n=r(7836),i=r(2646),o=r(944),a=r(3434);const s=new Map;function c(e,t,r,c){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,o.R)(29);const u=function(e){return(e||n.ee).get("logger")}(e),d=(0,a.YM)(u),l=new i.y(n.P);l.level=c.level,l.customAttributes=c.customAttributes;const f=t[r]?.[a.Jt]||t[r];return s.set(f,l),d.inPlace(t,[r],"wrap-logger-",(()=>s.get(f))),u}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>u,TZ:()=>n,Zp:()=>i,kd:()=>c,mq:()=>s,nf:()=>a,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],a=4,s=1e3,c=["PageAction","UserAction","BrowserPerformance"],u={MARKS:"experimental.marks",MEASURES:"experimental.measures",RESOURCES:"experimental.resources"}},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>a,TZ:()=>s,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},a="log",s=n.K7.logging},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),a=r(8154),s=r(993);function c(e,t,r={},c=s.p_.INFO){(0,n.p)(a.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(s.ET,[(0,i.t)(),t,r,c],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(s.p_).some((t=>t===e.toUpperCase().trim()))}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>s,TZ:()=>n,rs:()=>i,xV:()=>a});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,G4:()=>o,Qb:()=>l,TZ:()=>i,Ug:()=>a,_s:()=>s,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o={RECORD:"recordReplay",PAUSE:"pauseReplay",REPLAY_RUNNING:"replayRunning",ERROR_DURING_REPLAY:"errorDuringReplay"},a=.12,s={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api"}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>c,CT:()=>u,SR:()=>s});var n=r(384),i=r(9417),o=r(7767),a=r(6154);function s(e){return!!(0,n.dV)().o.MO&&(0,o.V)(e)&&!0===(0,i.gD)(e,"session_trace.enabled")}function c(e){return!0===(0,i.gD)(e,"session_replay.preload")&&s(e)}function u(e,t){const r=t.correctAbsoluteTimestamp(e);return{originalTimestamp:e,correctedTimestamp:r,timestampDiff:e-r,originTime:a.WN,correctedOriginTime:t.correctedOriginTime,originTimeDiff:Math.floor(a.WN-t.correctedOriginTime)}}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>s,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>a,jx:()=>l,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState",l=1e3},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>o,O2:()=>c,Qu:()=>u,TZ:()=>s,ih:()=>d,pP:()=>a,tC:()=>i});var n=r(860);const i=["click","keydown","submit","popstate"],o="api",a="initialPageLoad",s=n.K7.softNav,c={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},u={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},d={IP:"in progress",FIN:"finished",CAN:"cancelled"}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>A,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>T,uP:()=>s,wW:()=>E,xq:()=>a});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",E="cb"+R,A="jsTime",T="fetch"},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>o});var n=r(9417),i=r(6154);const o=e=>i.RI&&!0===(0,n.gD)(e,"privacy.cookies_enabled")},8969:(e,t,r)=>{"use strict";r.d(t,{j:()=>O});var n=r(860),i=r(2555),o=r(3371),a=r(9908),s=r(7836),c=r(1687),u=r(5289),d=r(6154),l=r(944),f=r(8154),h=r(384),p=r(6344);const g=["setErrorHandler","finished","addToTrace","addRelease","recordCustomEvent","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start",p.G4.RECORD,p.G4.PAUSE,"log","wrapLogger"],m=["setErrorHandler","finished","addToTrace","addRelease"];var v=r(1863),b=r(2614),y=r(993),w=r(3785),R=r(9414);function x(){const e=(0,h.pV)();g.forEach((t=>{e[t]=(...r)=>function(t,...r){let n=[];return Object.values(e.initializedAgents).forEach((e=>{e&&e.api?e.exposed&&e.api[t]&&n.push(e.api[t](...r)):(0,l.R)(38,t)})),n.length>1?n:n[0]}(t,...r)}))}const E={};var A=r(9417),T=r(5603),N=r(5284);const S=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};let _=!1;function O(e,t={},g,O){let{init:I,info:P,loader_config:j,runtime:C={},exposed:k=!0}=t;C.loaderType=g;const L=(0,h.pV)();P||(I=L.init,P=L.info,j=L.loader_config),(0,A.xN)(e.agentIdentifier,I||{}),(0,T.a)(e.agentIdentifier,j||{}),P.jsAttributes??={},d.bv&&(P.jsAttributes.isWorker=!0),(0,i.x1)(e.agentIdentifier,P);const H=(0,A.D0)(e.agentIdentifier),M=[P.beacon,P.errorBeacon];_||(H.proxy.assets&&(S(H.proxy.assets),M.push(H.proxy.assets)),H.proxy.beacon&&M.push(H.proxy.beacon),x(),(0,h.US)("activatedFeatures",N.B),e.runSoftNavOverSpa&&=!0===H.soft_navigations.enabled&&H.feature_flags.includes("soft_nav")),C.denyList=[...H.ajax.deny_list||[],...H.ajax.block_internal?M:[]],C.ptid=e.agentIdentifier,(0,o.V)(e.agentIdentifier,C),e.ee=s.ee.get(e.agentIdentifier),void 0===e.api&&(e.api=function(e,t,h=!1){t||(0,c.Ak)(e,"api");const g={};var x=s.ee.get(e),A=x.get("tracer");E[e]=b.g.OFF,x.on(p.G4.REPLAY_RUNNING,(t=>{E[e]=t}));var T="api-",N=T+"ixn-";function S(t,r,n,o){const a=(0,i.Vp)(e);return null===r?delete a.jsAttributes[t]:(0,i.x1)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),I(T,n,!0,o||null===r?"session":void 0)(t,r)}function _(){}g.log=function(e,{customAttributes:t={},level:r=y.p_.INFO}={}){(0,a.p)(f.xV,["API/log/called"],void 0,n.K7.metrics,x),(0,w.R)(x,e,t,r)},g.wrapLogger=(e,t,{customAttributes:r={},level:i=y.p_.INFO}={})=>{(0,a.p)(f.xV,["API/wrapLogger/called"],void 0,n.K7.metrics,x),(0,R.J)(x,e,t,{customAttributes:r,level:i})},m.forEach((e=>{g[e]=I(T,e,!0,"api")})),g.addPageAction=I(T,"addPageAction",!0,n.K7.genericEvents),g.recordCustomEvent=I(T,"recordCustomEvent",!0,n.K7.genericEvents),g.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,o.f)(e).customTransaction=(r||"http://custom.transaction")+t,I(T,"setPageViewName",!0)()},g.setCustomAttribute=function(e,t,r=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof t)||null===t)return S(e,t,"setCustomAttribute",r);(0,l.R)(40,typeof t)}else(0,l.R)(39,typeof e)},g.setUserId=function(e){if("string"==typeof e||null===e)return S("enduser.id",e,"setUserId",!0);(0,l.R)(41,typeof e)},g.setApplicationVersion=function(e){if("string"==typeof e||null===e)return S("application.version",e,"setApplicationVersion",!1);(0,l.R)(42,typeof e)},g.start=()=>{try{(0,a.p)(f.xV,["API/start/called"],void 0,n.K7.metrics,x),x.emit("manual-start-all")}catch(e){(0,l.R)(23,e)}},g[p.G4.RECORD]=function(){(0,a.p)(f.xV,["API/recordReplay/called"],void 0,n.K7.metrics,x),(0,a.p)(p.G4.RECORD,[],void 0,n.K7.sessionReplay,x)},g[p.G4.PAUSE]=function(){(0,a.p)(f.xV,["API/pauseReplay/called"],void 0,n.K7.metrics,x),(0,a.p)(p.G4.PAUSE,[],void 0,n.K7.sessionReplay,x)},g.interaction=function(e){return(new _).get("object"==typeof e?e:{})};const O=_.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(f.xV,["API/createTracer/called"],void 0,n.K7.metrics,x),h||(0,a.p)(N+"tracer",[(0,v.t)(),e,r],i,n.K7.spa,x),function(){if(A.emit((o?"":"no-")+"fn-start",[(0,v.t)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){const t="string"==typeof e?new Error(e):e;throw A.emit("fn-err",[arguments,this,t],r),t}finally{A.emit("fn-end",[(0,v.t)()],r)}}}};function I(e,t,r,i){return function(){return(0,a.p)(f.xV,["API/"+t+"/called"],void 0,n.K7.metrics,x),i&&(0,a.p)(e+t,[r?(0,v.t)():performance.now(),...arguments],r?null:this,i,x),r?void 0:this}}function P(){r.e(478).then(r.bind(r,8778)).then((({setAPI:t})=>{t(e),(0,c.Ze)(e,"api")})).catch((e=>{(0,l.R)(27,e),x.abort()}))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{O[e]=I(N,e,void 0,h?n.K7.softNav:n.K7.spa)})),g.setCurrentRouteName=h?I(N,"routeName",void 0,n.K7.softNav):I(T,"routeName",!0,n.K7.spa),g.noticeError=function(t,r){"string"==typeof t&&(t=new Error(t)),(0,a.p)(f.xV,["API/noticeError/called"],void 0,n.K7.metrics,x),(0,a.p)("err",[t,(0,v.t)(),!1,r,!!E[e]],void 0,n.K7.jserrors,x)},d.RI?(0,u.GG)((()=>P()),!0):P(),g}(e.agentIdentifier,O,e.runSoftNavOverSpa)),void 0===e.exposed&&(e.exposed=k),_=!0}},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>u,K7:()=>s,P3:()=>c,XX:()=>i,qY:()=>n,v4:()=>a});const n="events",i="jserrors",o="browser/blobs",a="rum",s={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},c={[s.pageViewEvent]:1,[s.pageViewTiming]:2,[s.metrics]:3,[s.jserrors]:4,[s.spa]:5,[s.ajax]:6,[s.sessionTrace]:7,[s.softNav]:8,[s.sessionReplay]:9,[s.logging]:10,[s.genericEvents]:11},u={[s.pageViewEvent]:a,[s.pageViewTiming]:n,[s.ajax]:n,[s.spa]:n,[s.softNav]:n,[s.metrics]:i,[s.jserrors]:i,[s.sessionTrace]:o,[s.sessionReplay]:o,[s.logging]:"browser/logs",[s.genericEvents]:"ins"}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.284.1.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.284.1.PROD:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){s=l;break}}if(!s){c=!0;var f={478:"sha512-VWXyHiJymB8Fhqc5jWlZ1CWrtlNWMPhm+PNnjWX1CfW9gQedReF5MFo3k8skdB5TlR837ofwtBeSzIE69RbCwQ==",249:"sha512-e1fXm1ZkMilKv1yUjmoJw7TU5bCKK/7Xaa/Ta9opkyurmkWtIKPd4CMfU2dRHGr9+brXynQnY3wwY838aQPhVw==",212:"sha512-zX52gEnN9DOzLrxU+zqxDl8R/t9rkdZavljSVjdAYS3BNoZH304PhVRnFEdwyYNCN9QcuGDBMMJ8U6XYtxAL0g=="};(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r,0!==s.src.indexOf(window.location.origin+"/")&&(s.crossOrigin="anonymous"),f[a]&&(s.integrity=f[a])}e[r]=[n];var h=(t,n)=>{s.onerror=s.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=h.bind(null,s.onerror),s.onload=h.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.284.1.PROD"]=self["webpackChunk:NRBA-1.284.1.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(944),t=i(6344),r=i(9566);class n{agentIdentifier;constructor(){this.agentIdentifier=(0,r.LA)(16)}#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}addPageAction(e,t){return this.#e("addPageAction",e,t)}recordCustomEvent(e,t){return this.#e("recordCustomEvent",e,t)}setPageViewName(e,t){return this.#e("setPageViewName",e,t)}setCustomAttribute(e,t,r){return this.#e("setCustomAttribute",e,t,r)}noticeError(e,t){return this.#e("noticeError",e,t)}setUserId(e){return this.#e("setUserId",e)}setApplicationVersion(e){return this.#e("setApplicationVersion",e)}setErrorHandler(e){return this.#e("setErrorHandler",e)}addRelease(e,t){return this.#e("addRelease",e,t)}log(e,t){return this.#e("log",e,t)}}class o extends n{#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}start(){return this.#e("start")}finished(e){return this.#e("finished",e)}recordReplay(){return this.#e(t.G4.RECORD)}pauseReplay(){return this.#e(t.G4.PAUSE)}addToTrace(e){return this.#e("addToTrace",e)}setCurrentRouteName(e){return this.#e("setCurrentRouteName",e)}interaction(){return this.#e("interaction")}wrapLogger(e,t,r){return this.#e("wrapLogger",e,t,r)}}var a=i(860),s=i(9417);const c=Object.values(a.K7);function u(e){const t={};return c.forEach((r=>{t[r]=function(e,t){return!0===(0,s.gD)(t,"".concat(e,".enabled"))}(r,e)})),t}var d=i(8969);var l=i(1687),f=i(4234),h=i(5289),p=i(6154),g=i(5270),m=i(7767),v=i(6389);class b extends f.W{constructor(e,t,r=!0){super(e.agentIdentifier,t),this.auto=r,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===e.init[this.featureName].autoStart&&(this.auto=!1),this.auto?(0,l.Ak)(e.agentIdentifier,t):this.ee.on("manual-start-all",(0,v.J)((()=>{(0,l.Ak)(e.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator(e)})))}importAggregator(t,r={}){if(this.featAggregate||!this.auto)return;let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let o;try{if((0,m.V)(this.agentIdentifier)){const{setupAgentSession:e}=await i.e(478).then(i.bind(i,6526));o=e(t)}}catch(t){(0,e.R)(20,t),this.ee.emit("internal-error",[t]),this.featureName===a.K7.sessionReplay&&this.abortHandler?.()}try{if(!this.#t(this.featureName,o))return(0,l.Ze)(this.agentIdentifier,this.featureName),void n(!1);const{lazyFeatureLoader:e}=await i.e(478).then(i.bind(i,6103)),{Aggregate:a}=await e(this.featureName,"aggregate");this.featAggregate=new a(t,r),t.runtime.harvester.initializedAggregates.push(this.featAggregate),n(!0)}catch(t){(0,e.R)(34,t),this.abortHandler?.(),(0,l.Ze)(this.agentIdentifier,this.featureName,!0),n(!1),this.ee&&this.ee.abort()}};p.RI?(0,h.GG)((()=>o()),!0):o()}#t(e,t){switch(e){case a.K7.sessionReplay:return(0,g.SR)(this.agentIdentifier)&&!!t;case a.K7.sessionTrace:return!!t;default:return!0}}}var y=i(6630);class w extends b{static featureName=y.T;constructor(e,t=!0){super(e,y.T,t),this.importAggregator(e)}}var R=i(384);var x=i(9908),E=i(2843),A=i(3878),T=i(782),N=i(1863);class S extends b{static featureName=T.T;constructor(e,t=!0){super(e,T.T,t),p.RI&&((0,E.u)((()=>(0,x.p)("docHidden",[(0,N.t)()],void 0,T.T,this.ee)),!0),(0,A.sp)("pagehide",(()=>(0,x.p)("winPagehide",[(0,N.t)()],void 0,T.T,this.ee))),this.importAggregator(e))}}var _=i(8154);class O extends b{static featureName=_.TZ;constructor(e,t=!0){super(e,_.TZ,t),p.RI&&document.addEventListener("securitypolicyviolation",(e=>{(0,x.p)(_.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)})),this.importAggregator(e)}}var I=i(6774),P=i(3304);class j{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,P.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function C(e){return H(e)?e:new j(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic)}function k(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(H(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return C(e.reason)}const r=C(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function L(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new j(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic);return t.name=SyntaxError.name,t}return H(e.error)?e.error:C(e)}function H(e){return e instanceof Error&&!!e.stack}class M extends b{static featureName=I.T;#r=!1;constructor(e,r=!0){super(e,I.T,r);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",((e,t)=>{this.abortHandler&&(0,x.p)("ierr",[C(e),(0,N.t)(),!0,{},this.#r,t],void 0,this.featureName,this.ee)})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.#r=e})),p.gm.addEventListener("unhandledrejection",(e=>{this.abortHandler&&(0,x.p)("err",[k(e),(0,N.t)(),!1,{unhandledPromiseRejection:1},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),p.gm.addEventListener("error",(e=>{this.abortHandler&&(0,x.p)("err",[L(e),(0,N.t)(),!1,{},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var D=i(8990);let K=1;const U="nr@id";function V(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===p.gm?0:(0,D.I)(e,U,(function(){return K++}))}function G(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,P.A)(e).length}catch(e){return}}}var F=i(8139),B=i(7836),W=i(3434);const z={},q=["open","send"];function Z(t){var r=t||B.ee;const n=function(e){return(e||B.ee).get("xhr")}(r);if(void 0===p.gm.XMLHttpRequest)return n;if(z[n.debugId]++)return n;z[n.debugId]=1,(0,F.u)(r);var i=(0,W.YM)(n),o=p.gm.XMLHttpRequest,a=p.gm.MutationObserver,s=p.gm.Promise,c=p.gm.setInterval,u="readystatechange",d=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],l=[],f=p.gm.XMLHttpRequest=function(t){const r=new o(t),a=n.context(r);try{n.emit("new-xhr",[r],a),r.addEventListener(u,(s=a,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,n.emit("xhr-resolved",[],e)),i.inPlace(e,d,"fn-",y)}),(0,A.jT)(!1))}catch(t){(0,e.R)(15,t);try{n.emit("internal-error",[t])}catch(e){}}var s;return r};function h(e,t){i.inPlace(t,["onreadystatechange"],"fn-",y)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,f),f.prototype=o.prototype,i.inPlace(f.prototype,q,"-xhr-",y),n.on("send-xhr-start",(function(e,t){h(e,t),function(e){l.push(e),a&&(g?g.then(b):c?c(b):(m=-m,v.data=m))}(t)})),n.on("open-xhr-start",h),a){var g=s&&s.resolve();if(!c&&!s){var m=1,v=document.createTextNode(m);new a(b).observe(v,{characterData:!0})}}else r.on("fn-end",(function(e){e[0]&&e[0].type===u||b()}));function b(){for(var e=0;e<l.length;e++)h(0,l[e]);l.length&&(l=[])}function y(e,t){return t}return n}var Y="fetch-",J=Y+"body-",X=["arrayBuffer","blob","json","text","formData"],Q=p.gm.Request,ee=p.gm.Response,te="prototype";const re={};function ne(e){const t=function(e){return(e||B.ee).get("fetch")}(e);if(!(Q&&ee&&p.gm.fetch))return t;if(re[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[B.P]&&o[B.P].dt&&(e=o[B.P].dt);var a=i.apply(this,r);return t.emit(n+"start",[r,e],a),a.then((function(e){return t.emit(n+"end",[null,e],a),e}),(function(e){throw t.emit(n+"end",[e],a),e}))})}return re[t.debugId]=1,X.forEach((e=>{r(Q[te],e,J),r(ee[te],e,J)})),r(p.gm,"fetch",Y),t.on(Y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(Y+"done",[null,r],n)}else t.emit(Y+"done",[e],n)})),t}var ie=i(7485),oe=i(5603);class ae{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,oe.o)(this.agentIdentifier);if(!t)return null;var n=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,o=(t.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,r.ZF)(),s=(0,r.el)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof p.gm?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,P.A)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,s.gD)(this.agentIdentifier,"distributed_tracing")&&(r=(0,s.D0)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ie.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}isDtEnabled(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.enabled}excludeNewrelicHeader(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.cors_use_tracecontext_headers}}var se=i(9300),ce=i(7295),ue=["load","error","abort","timeout"],de=ue.length,le=(0,R.dV)().o.REQ,fe=(0,R.dV)().o.XHR;const he="X-NewRelic-App-Data";class pe extends b{static featureName=se.T;constructor(e,t=!0){super(e,se.T,t),this.dt=new ae(e.agentIdentifier),this.handler=(e,t,r,n)=>(0,x.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};p.gm?.performance?.getEntriesByType("resource").forEach((t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},n={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};ge(r,t.name),this.handler("xhr",[r,n,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,a.K7.ajax)}}))}catch(e){}ne(this.ee),Z(this.ee),function(e,t,r,n){function i(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=R,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){E(t,e)}),(0,A.jT)(!1)),p.lR||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,A.jT)(!1))}function o(e){this.params={method:e[0]},ge(this,e[1]),this.metrics={}}function s(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var i=n.generateTracePayload(this.parsedOrigin);if(i){var o=!1;i.newrelicHeader&&(r.setRequestHeader("newrelic",i.newrelicHeader),o=!0),i.traceContextParentHeader&&(r.setRequestHeader("traceparent",i.traceContextParentHeader),i.traceContextStateHeader&&r.setRequestHeader("tracestate",i.traceContextStateHeader),o=!0),o&&(this.dt=i)}}function c(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var a=G(i);a&&(n.txSize=a)}this.startTime=(0,N.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s<de;s++)r.addEventListener(ue[s],this.listener,(0,A.jT)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function d(e,t){var r=""+V(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function l(e,t){var r=""+V(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function f(){this.endTime=(0,N.t)()}function h(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function g(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function m(e,t,r){t instanceof fe&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,N.t)()))}function v(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,N.t)()-this.xhrCbStart,this.onload,r],r)}function b(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&p.RI&&(t=""+p.gm.location.href):e[0]&&e[0].url?t=e[0].url:p.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ie.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var i=n.generateTracePayload(this.parsedOrigin);if(i&&(i.newrelicHeader||i.traceContextParentHeader))if(e[0]&&e[0].headers)s(e[0].headers,i)&&(this.dt=i);else{var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),s(o.headers,i)&&(this.dt=i),e.length>1?e[1]=o:e.push(o)}}function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function y(e,t){this.params={},this.metrics={},this.startTime=(0,N.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof le?r=i.url:p.gm?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),ge(this,r);var o=(""+(i&&i instanceof le&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.body=n.body,this.txSize=G(n.body)||0}function w(e,t){if(this.endTime=(0,N.t)(),this.params||(this.params={}),(0,ce.iW)(this.params))return;let n;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);const i={txSize:this.txSize,rxSize:n,duration:(0,N.t)()-this.startTime};r("xhr",[this.params,i,this.startTime,this.endTime,"fetch"],this,a.K7.ajax)}function R(e){const t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<de;t++)e.removeEventListener(ue[t],this.listener,!1);t.aborted||(0,ce.iW)(t)||(n.duration=(0,N.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):E(this,e),n.cbTime=this.cbTime,r("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,a.K7.ajax))}}function E(e,r){e.params.status=r.status;var n=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?G(e.response):"text"===r||""===r||void 0===r?G(e.responseText):void 0}(r,e.lastSize);if(n&&(e.metrics.rxSize=n),e.sameOrigin&&r.getAllResponseHeaders().indexOf(he)>=0){var i=r.getResponseHeader(he);i&&((0,x.p)(_.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,a.K7.metrics,t),e.params.cat=i.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",i),t.on("open-xhr-start",o),t.on("open-xhr-end",s),t.on("send-xhr-start",c),t.on("xhr-cb-time",u),t.on("xhr-load-added",d),t.on("xhr-load-removed",l),t.on("xhr-resolved",f),t.on("addEventListener-end",h),t.on("removeEventListener-end",g),t.on("fn-end",v),t.on("fetch-before-start",b),t.on("fetch-start",y),t.on("fn-start",m),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator(e)}}function ge(e,t){var r=(0,ie.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const me={},ve=["pushState","replaceState"];function be(e){const t=function(e){return(e||B.ee).get("history")}(e);return!p.RI||me[t.debugId]++||(me[t.debugId]=1,(0,W.YM)(t).inPlace(window.history,ve,"-")),t}var ye=i(3738);const{He:we,bD:Re,d3:xe,Kp:Ee,TZ:Ae,Lc:Te,uP:Ne,Rz:Se}=ye;class _e extends b{static featureName=Ae;constructor(e,t=!0){super(e,Ae,t);if(!(0,m.V)(this.agentIdentifier))return void this.deregisterDrain();const r=this.ee;let n;be(r),this.eventsEE=(0,F.u)(r),this.eventsEE.on(Ne,(function(e,t){this.bstStart=(0,N.t)()})),this.eventsEE.on(Te,(function(e,t){(0,x.p)("bst",[e[0],t,this.bstStart,(0,N.t)()],void 0,a.K7.sessionTrace,r)})),r.on(Se+xe,(function(e){this.time=(0,N.t)(),this.startPath=location.pathname+location.hash})),r.on(Se+Ee,(function(e){(0,x.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,a.K7.sessionTrace,r)}));try{n=new PerformanceObserver((e=>{const t=e.getEntries();(0,x.p)(we,[t],void 0,a.K7.sessionTrace,r)})),n.observe({type:Re,buffered:!0})}catch(e){}this.importAggregator(e,{resourceObserver:n})}}var Oe=i(2614);class Ie extends b{static featureName=t.TZ;#i;#o;constructor(e,r=!0){let n;super(e,t.TZ,r),this.replayRunning=!1,this.#o=e;try{n=JSON.parse(localStorage.getItem("".concat(Oe.H3,"_").concat(Oe.uh)))}catch(e){}(0,g.SR)(e.agentIdentifier)&&this.ee.on(t.G4.RECORD,(()=>this.#a())),this.#s(n)?(this.#i=n?.sessionReplayMode,this.#c()):this.importAggregator(e),this.ee.on("err",(e=>{this.replayRunning&&(this.errorNoticed=!0,(0,x.p)(t.G4.ERROR_DURING_REPLAY,[e],void 0,this.featureName,this.ee))})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.replayRunning=e}))}#s(e){return e&&(e.sessionReplayMode===Oe.g.FULL||e.sessionReplayMode===Oe.g.ERROR)||(0,g.Aw)(this.agentIdentifier)}#u=!1;async#c(e){if(!this.#u){this.#u=!0;try{const{Recorder:t}=await Promise.all([i.e(478),i.e(249)]).then(i.bind(i,8589));this.recorder??=new t({mode:this.#i,agentIdentifier:this.agentIdentifier,trigger:e,ee:this.ee,agentRef:this.#o}),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording}catch(e){}this.importAggregator(this.#o,{recorder:this.recorder,errorNoticed:this.errorNoticed})}}#a(){this.featAggregate?this.featAggregate.mode!==Oe.g.FULL&&this.featAggregate.initializeRecording(Oe.g.FULL,!0):(this.#i=Oe.g.FULL,this.#c(t.Qb.API),this.recorder&&this.recorder.parent.mode!==Oe.g.FULL&&(this.recorder.parent.mode=Oe.g.FULL,this.recorder.stopRecording(),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording))}}var Pe=i(3962);class je extends b{static featureName=Pe.TZ;constructor(e,t=!0){if(super(e,Pe.TZ,t),!p.RI||!(0,R.dV)().o.MO)return;const r=be(this.ee);Pe.tC.forEach((e=>{(0,A.sp)(e,(e=>{a(e)}),!0)}));const n=()=>(0,x.p)("newURL",[(0,N.t)(),""+window.location],void 0,this.featureName,this.ee);r.on("pushState-end",n),r.on("replaceState-end",n);try{this.removeOnAbort=new AbortController}catch(e){}(0,A.sp)("popstate",(e=>(0,x.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)),!0,this.removeOnAbort?.signal);let i=!1;const o=new((0,R.dV)().o.MO)(((e,t)=>{i||(i=!0,requestAnimationFrame((()=>{(0,x.p)("newDom",[(0,N.t)()],void 0,this.featureName,this.ee),i=!1})))})),a=(0,v.s)((e=>{(0,x.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})}),100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,{domObserver:o})}}var Ce=i(7378);const ke={},Le=["appendChild","insertBefore","replaceChild"];function He(e){const t=function(e){return(e||B.ee).get("jsonp")}(e);if(!p.RI||ke[t.debugId])return t;ke[t.debugId]=!0;var r=(0,W.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function a(e,t){if(!e)return t;const r=e.match(o),n=r[1];return a(r[3],t[n])}return r.inPlace(Node.prototype,Le,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(s=e.src,c=s.match(n),c?c[1]:null);var s,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:a(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,A.jT)(!1)),e.addEventListener("error",f,(0,A.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}const Me={};function De(e){const t=function(e){return(e||B.ee).get("promise")}(e);if(Me[t.debugId])return t;Me[t.debugId]=!0;var r=t.context,n=(0,W.YM)(t),i=p.gm.Promise;return i&&function(){function e(r){var o=t.context(),a=n(r,"executor-",o,null,!1);const s=Reflect.construct(i,[a],e);return t.context(s).getCtx=function(){return o},s}p.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach((function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,a=r(i);a.promise=i,e[0]=n(e[0],"cb-",a,null,!1),e[1]=n(e[1],"cb-",a,null,!1);const s=o.apply(this,e);return a.nextPromise=s,t.emit("propagate",[i,!0],s,!1,!1),s},i.prototype.then[W.Jt]=o,t.on("executor-start",(function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)})),t.on("executor-err",(function(e,t,r){e[1](r)})),t.on("cb-end",(function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)})),t.on("propagate",(function(e,r,n){this.getCtx&&!r||(this.getCtx=function(){if(e instanceof Promise)var r=t.context(e);return r&&r.getCtx?r.getCtx():this})}))}(),t}const Ke={},Ue="setTimeout",Ve="setInterval",Ge="clearTimeout",Fe="-start",Be=[Ue,"setImmediate",Ve,Ge,"clearImmediate"];function We(e){const t=function(e){return(e||B.ee).get("timer")}(e);if(Ke[t.debugId]++)return t;Ke[t.debugId]=1;var r=(0,W.YM)(t);return r.inPlace(p.gm,Be.slice(0,2),Ue+"-"),r.inPlace(p.gm,Be.slice(2,3),Ve+"-"),r.inPlace(p.gm,Be.slice(3),Ge+"-"),t.on(Ve+Fe,(function(e,t,n){e[0]=r(e[0],"fn-",null,n)})),t.on(Ue+Fe,(function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)})),t}const ze={};function qe(e){const t=function(e){return(e||B.ee).get("mutation")}(e);if(!p.RI||ze[t.debugId])return t;ze[t.debugId]=!0;var r=(0,W.YM)(t),n=p.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:Ze,d3:Ye,Kp:Je,$p:Xe,wW:$e,e5:Qe,tH:et,uP:tt,rw:rt,Lc:nt}=Ce;class it extends b{static featureName=Ze;constructor(e,t=!0){if(super(e,Ze,t),!p.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let r,n=0;const i=this.ee.get("tracer"),o=He(this.ee),a=De(this.ee),s=We(this.ee),c=Z(this.ee),u=this.ee.get("events"),d=ne(this.ee),l=be(this.ee),f=qe(this.ee);function h(e,t){l.emit("newURL",[""+window.location,t])}function g(){n++,r=window.location.hash,this[tt]=(0,N.t)()}function m(){n--,window.location.hash!==r&&h(0,!0);var e=(0,N.t)();this[Qe]=~~this[Qe]+e-this[tt],this[nt]=e}function v(e,t){e.on(t,(function(){this[t]=(0,N.t)()}))}this.ee.on(tt,g),a.on(rt,g),o.on(rt,g),this.ee.on(nt,m),a.on($e,m),o.on($e,m),this.ee.on("fn-err",((...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,x.p)("function-err",[...t],void 0,this.featureName,this.ee)})),this.ee.buffer([tt,nt,"xhr-resolved"],this.featureName),u.buffer([tt],this.featureName),s.buffer(["setTimeout"+Je,"clearTimeout"+Ye,tt],this.featureName),c.buffer([tt,"new-xhr","send-xhr"+Ye],this.featureName),d.buffer([et+Ye,et+"-done",et+Xe+Ye,et+Xe+Je],this.featureName),l.buffer(["newURL"],this.featureName),f.buffer([tt],this.featureName),a.buffer(["propagate",rt,$e,"executor-err","resolve"+Ye],this.featureName),i.buffer([tt,"no-"+tt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),v(d,et+Ye),v(d,et+"-done"),v(o,"new-jsonp"),v(o,"jsonp-end"),v(o,"cb-start"),l.on("pushState-end",h),l.on("replaceState-end",h),window.addEventListener("hashchange",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){h(0,n>1)}),(0,A.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var ot=i(3333);class at extends b{static featureName=ot.TZ;constructor(e,t=!0){super(e,ot.TZ,t);const r=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];if(p.RI&&(e.init.user_actions.enabled&&(ot.Zp.forEach((e=>(0,A.sp)(e,(e=>(0,x.p)("ua",[e],void 0,this.featureName,this.ee)),!0))),ot.qN.forEach((e=>{const t=(0,v.s)((e=>{(0,x.p)("ua",[e],void 0,this.featureName,this.ee)}),500,{leading:!0});(0,A.sp)(e,t)}))),e.init.performance.resources.enabled&&p.gm.PerformanceObserver?.supportedEntryTypes.includes("resource"))){new PerformanceObserver((e=>{e.getEntries().forEach((e=>{(0,x.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)}))})).observe({type:"resource",buffered:!0})}r.some((e=>e))?this.importAggregator(e):this.deregisterDrain()}}var st=i(993),ct=i(3785),ut=i(9414);class dt extends b{static featureName=st.TZ;constructor(e,t=!0){super(e,st.TZ,t);const r=this.ee;(0,ut.J)(r,p.gm.console,"log",{level:"info"}),(0,ut.J)(r,p.gm.console,"error",{level:"error"}),(0,ut.J)(r,p.gm.console,"warn",{level:"warn"}),(0,ut.J)(r,p.gm.console,"info",{level:"info"}),(0,ut.J)(r,p.gm.console,"debug",{level:"debug"}),(0,ut.J)(r,p.gm.console,"trace",{level:"trace"}),this.ee.on("wrap-logger-end",(function([e]){const{level:t,customAttributes:n}=this;(0,ct.R)(r,e,n,t)})),this.importAggregator(e)}}new class extends o{constructor(t){super(),p.gm?(this.features={},(0,R.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(w),this.runSoftNavOverSpa=[...this.desiredFeatures].some((e=>e.featureName===a.K7.softNav)),(0,d.j)(this,t,t.loaderType||"agent"),this.run()):(0,e.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}run(){try{const t=u(this.agentIdentifier),r=[...this.desiredFeatures];r.sort(((e,t)=>a.P3[e.featureName]-a.P3[t.featureName])),r.forEach((r=>{if(!t[r.featureName]&&r.featureName!==a.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&r.featureName===a.K7.spa)return;if(!this.runSoftNavOverSpa&&r.featureName===a.K7.softNav)return;const n=function(e){switch(e){case a.K7.ajax:return[a.K7.jserrors];case a.K7.sessionTrace:return[a.K7.ajax,a.K7.pageViewEvent];case a.K7.sessionReplay:return[a.K7.sessionTrace];case a.K7.pageViewTiming:return[a.K7.pageViewEvent];default:return[]}}(r.featureName).filter((e=>!(e in this.features)));n.length>0&&(0,e.R)(36,{targetFeature:r.featureName,missingDependencies:n}),this.features[r.featureName]=new r(this)}))}catch(t){(0,e.R)(22,t);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,R.Zm)();delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return r.ee.get(this.agentIdentifier).abort(),!1}}}({features:[pe,w,S,_e,Ie,O,M,at,dt,je,it],loaderType:"spa"})})()})();</script><link rel="preload" href="/article-pages/_nuxt/e397d1a.js" as="script"><link rel="preload" href="/article-pages/_nuxt/2abb6c5.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/66101cf.css" as="style"><link rel="preload" href="/article-pages/_nuxt/701e3a3.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/dac93f2.css" as="style"><link rel="preload" href="/article-pages/_nuxt/71728a1.js" as="script"><link rel="preload" href="/article-pages/_nuxt/a5e7651.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/e5cdfa1.css" as="style"><link rel="preload" href="/article-pages/_nuxt/f548f7f.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/868b092.css" as="style"><link rel="preload" href="/article-pages/_nuxt/e3c5a8f.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/97e04e3.css" as="style"><link rel="preload" href="/article-pages/_nuxt/0d6d8e5.js" as="script"><link rel="preload" href="/article-pages/_nuxt/ed7fc59.js" as="script"><link rel="stylesheet" href="/article-pages/_nuxt/css/66101cf.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/dac93f2.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/e5cdfa1.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/868b092.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/97e04e3.css">

  <meta property="fb:admins" content="1841006843">
</head>

<body >
  <button class="BypassBlock__firstEl"></button>
  <a href="#main-content" class="BypassBlock__wrapper">
    <span class="BypassBlock__button">Skip to main content</span>
  </a>

  <!-- Google Tag Manager (noscript) -->
  <noscript>
    <iframe src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x" height="0" width="0" style="display:none;visibility:hidden"></iframe>
  </noscript>
  <!-- End Google Tag Manager (noscript) -->
  <div data-server-rendered="true" id="__nuxt"><div id="__layout"><div theme="cyan" class="ArticleLayout"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button aria-label="Open Menu" data-event="iBar-btn-openMenu" class="Ibar__burger"></button> <div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div> <a aria-label="Frontiers in Public Health" href="//www.frontiersin.org/journals/public-health" data-event="iBar-a-journalHome" class="Ibar__journalName"><div logoClass="Ibar__logo--mixed" class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div parent-data-event="iBar" class="Ibar__dropdown Ibar__dropdown--aboutUs"><button class="Ibar__dropdown__trigger"><!---->
    About us
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About us
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers' impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://progressreport.frontiersin.org/?utm_source=fweb&amp;utm_medium=frep&amp;utm_campaign=pr20" target="_blank" data-event="iBar-aboutUs_1-a_impactAndProgress">Progress Report 2022</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">All annual reports</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR² Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li> <li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li> <li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.orgabout/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li></ul></div></div></div> <a href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals" class="Ibar__link">All journals</a><a href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles" class="Ibar__link">All articles</a> <a href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=70&amp;specialtyid=0&amp;entitytype=2&amp;entityid=609" data-event="iBar-a-submit" class="Ibar__button Ibar__submit">Submit your research</a> <div class="Ibar__spacer"></div> <a href="/search" aria-label="Search" data-event="iBar-a-search" class="Ibar__icon Ibar__icon--search"><span>Search</span></a> <!----> <!----> <!----> <div class="Ibar__userArea"></div></div></div> <div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div> <button aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu" class="Ibar__close"></button></div> <div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/public-health" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div parent-data-event="iBarMenu" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    Sections
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        Sections
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/aging-and-public-health" data-event="iBarJournal-sections-a_id_1560">Aging and Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/children-and-health" data-event="iBarJournal-sections-a_id_621">Children and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/digital-public-health" data-event="iBarJournal-sections-a_id_753">Digital Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/disaster-and-emergency-medicine" data-event="iBarJournal-sections-a_id_702">Disaster and Emergency Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/environmental-health-and-exposome" data-event="iBarJournal-sections-a_id_690">Environmental Health and Exposome</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/health-economics" data-event="iBarJournal-sections-a_id_1310">Health Economics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/infectious-diseases-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_3460">Infectious Diseases: Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/injury-prevention-and-control" data-event="iBarJournal-sections-a_id_3297">Injury Prevention and Control</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/life-course-epidemiology-and-social-inequalities-in-health" data-event="iBarJournal-sections-a_id_1495">Life-Course Epidemiology and Social Inequalities in Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/occupational-health-and-safety" data-event="iBarJournal-sections-a_id_744">Occupational Health and Safety</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/planetary-health" data-event="iBarJournal-sections-a_id_1458">Planetary Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-education-and-promotion" data-event="iBarJournal-sections-a_id_637">Public Health Education and Promotion</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-policy" data-event="iBarJournal-sections-a_id_652">Public Health Policy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-and-nutrition" data-event="iBarJournal-sections-a_id_2192">Public Health and Nutrition</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-mental-health" data-event="iBarJournal-sections-a_id_695">Public Mental Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/radiation-and-health" data-event="iBarJournal-sections-a_id_778">Radiation and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/substance-use-disorders-and-behavioral-addictions" data-event="iBarJournal-sections-a_id_3408">Substance Use Disorders and Behavioral Addictions</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/public-health/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/public-health/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/public-health/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarMenu" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    About journal
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About journal
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div></div> <div parent-data-event="iBarMenu" class="Ibar__dropdown Ibar__dropdown--aboutUs"><button class="Ibar__dropdown__trigger"><!---->
    About us
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About us
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers' impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://progressreport.frontiersin.org/?utm_source=fweb&amp;utm_medium=frep&amp;utm_campaign=pr20" target="_blank" data-event="iBar-aboutUs_1-a_impactAndProgress">Progress Report 2022</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">All annual reports</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR² Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li> <li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li> <li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.orgabout/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li></ul></div></div></div> <a href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals" class="Ibar__link">All journals</a><a href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles" class="Ibar__link">All articles</a> <!----> <!----> <!----> <a href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=70&amp;specialtyid=0&amp;entitytype=2&amp;entityid=609" data-event="iBarMenu-a-submit" class="Ibar__button Ibar__submit">Submit your research</a></div></div> <div class="Ibar__journal"><div class="Ibar__wrapper Ibar__wrapper--journal"><a aria-label="Frontiers in Public Health" href="//www.frontiersin.org/journals/public-health" data-event="iBarJournal-a-journalHome" class="Ibar__journalName"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    Sections
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        Sections
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/aging-and-public-health" data-event="iBarJournal-sections-a_id_1560">Aging and Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/children-and-health" data-event="iBarJournal-sections-a_id_621">Children and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/digital-public-health" data-event="iBarJournal-sections-a_id_753">Digital Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/disaster-and-emergency-medicine" data-event="iBarJournal-sections-a_id_702">Disaster and Emergency Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/environmental-health-and-exposome" data-event="iBarJournal-sections-a_id_690">Environmental Health and Exposome</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/health-economics" data-event="iBarJournal-sections-a_id_1310">Health Economics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/infectious-diseases-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_3460">Infectious Diseases: Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/injury-prevention-and-control" data-event="iBarJournal-sections-a_id_3297">Injury Prevention and Control</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/life-course-epidemiology-and-social-inequalities-in-health" data-event="iBarJournal-sections-a_id_1495">Life-Course Epidemiology and Social Inequalities in Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/occupational-health-and-safety" data-event="iBarJournal-sections-a_id_744">Occupational Health and Safety</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/planetary-health" data-event="iBarJournal-sections-a_id_1458">Planetary Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-education-and-promotion" data-event="iBarJournal-sections-a_id_637">Public Health Education and Promotion</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-policy" data-event="iBarJournal-sections-a_id_652">Public Health Policy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-and-nutrition" data-event="iBarJournal-sections-a_id_2192">Public Health and Nutrition</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-mental-health" data-event="iBarJournal-sections-a_id_695">Public Mental Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/radiation-and-health" data-event="iBarJournal-sections-a_id_778">Radiation and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/substance-use-disorders-and-behavioral-addictions" data-event="iBarJournal-sections-a_id_3408">Substance Use Disorders and Behavioral Addictions</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/public-health/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/public-health/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/public-health/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    About journal
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About journal
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div> <div class="Ibar__spacer"></div></div></div> <div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div> <a aria-label="Frontiers in Public Health" href="//www.frontiersin.org/journals/public-health" data-event="iBarJournal-a-journalHome" class="Ibar__journalName"><div logoClass="Ibar__logo--mixed" class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Public Health</span></div></div></a> <div class="Ibar__spacer"></div> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    Sections
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        Sections
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/aging-and-public-health" data-event="iBarJournal-sections-a_id_1560">Aging and Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/children-and-health" data-event="iBarJournal-sections-a_id_621">Children and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/digital-public-health" data-event="iBarJournal-sections-a_id_753">Digital Public Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/disaster-and-emergency-medicine" data-event="iBarJournal-sections-a_id_702">Disaster and Emergency Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/environmental-health-and-exposome" data-event="iBarJournal-sections-a_id_690">Environmental Health and Exposome</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/health-economics" data-event="iBarJournal-sections-a_id_1310">Health Economics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/infectious-diseases-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_3460">Infectious Diseases: Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/injury-prevention-and-control" data-event="iBarJournal-sections-a_id_3297">Injury Prevention and Control</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/life-course-epidemiology-and-social-inequalities-in-health" data-event="iBarJournal-sections-a_id_1495">Life-Course Epidemiology and Social Inequalities in Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/occupational-health-and-safety" data-event="iBarJournal-sections-a_id_744">Occupational Health and Safety</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/planetary-health" data-event="iBarJournal-sections-a_id_1458">Planetary Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-education-and-promotion" data-event="iBarJournal-sections-a_id_637">Public Health Education and Promotion</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-policy" data-event="iBarJournal-sections-a_id_652">Public Health Policy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-health-and-nutrition" data-event="iBarJournal-sections-a_id_2192">Public Health and Nutrition</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/public-mental-health" data-event="iBarJournal-sections-a_id_695">Public Mental Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/radiation-and-health" data-event="iBarJournal-sections-a_id_778">Radiation and Health</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/public-health/sections/substance-use-disorders-and-behavioral-addictions" data-event="iBarJournal-sections-a_id_3408">Substance Use Disorders and Behavioral Addictions</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/public-health/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/public-health/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/public-health/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!---->
    About journal
  </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title">
        About journal
      </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/public-health/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div> <div class="Ibar__spacer"></div> <a href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=70&amp;specialtyid=0&amp;entitytype=2&amp;entityid=609" data-event="iBarJournal-a-submit" class="Ibar__button Ibar__submit"><span>Submit</span> <span> your research</span></a> <a href="/search" aria-label="Search" data-event="iBar-a-search" class="Ibar__icon Ibar__icon--search"><span>Search</span></a> <!----> <!----> <!----> <div class="Ibar__userArea"></div></div></div></nav> <div class="ArticlePage"><div><div class="Layout Layout--withAside Layout--withIbarMix ArticleDetails"><!----> <main class="Layout__main"><!----> <div class="ArticleDetails__main"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">
      ORIGINAL RESEARCH article
    </p> <p class="ArticleLayoutHeader__info__journalDate"><span>Front. Public Health</span> <span>, 19 March 2025</span></p> <p class="ArticleLayoutHeader__info__journalDate">
      Sec. Infectious Diseases: Epidemiology and Prevention
    </p> <p class="ArticleLayoutHeader__info__doiVolume"><span> Volume 13 - 2025 | </span> <a href="https://doi.org/10.3389/fpubh.2025.1508793" class="ArticleLayoutHeader__info__doi">
        https://doi.org/10.3389/fpubh.2025.1508793
      </a></p> <!----></div> <!----> <p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span> <span class="ArticleLayoutHeader__isPartOfRT__title">Challenges in reaching the UNAIDS 95-95-95 targets in Sub-Saharan Africa: Status, 
innovations, and pathways forward</span> <span class="Link__wrapper"><a aria-label="View all 4 articles" href="https://www.frontiersin.org/research-topics/66743/challenges-in-reaching-the-unaids-95-95-95-targets-in-sub-saharan-africa-status-innovations-and-pathways-forward/articles" target="_self" data-event="customLink-link-a_viewAll4Articles" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View all 4 articles</span></a></span></p></div> <div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana</h1> <!----></div> <!----></div> <div class="JournalFullText"><div class="JournalAbstract"> <a id="h1" name="h1"></a>
 <div class="authors"><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Anthony T. Boateng," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Anthony T. Boateng<sup>1,2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2088681" class="user-id-2088681"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2088681/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="James O. Aboagye,">James O. Aboagye</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1254504" class="user-id-1254504"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1254504/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Helena Lamptey">Helena Lamptey</a><sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Christopher Z.-Y. Abana," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Christopher Z.-Y. Abana<sup>1,2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Araba Abaidoo-Myles," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Araba Abaidoo-Myles<sup>1,2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Darius N. K. Quansah," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Darius N. K. Quansah<sup>1,2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1427882" class="user-id-1427882"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1427882/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Seth Agyemang,">Seth Agyemang</a><sup>2,5</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1952821" class="user-id-1952821"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1952821/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Yaw Awuku-Larbi">Yaw Awuku-Larbi</a><sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Gloria Ansa" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Gloria Ansa<sup>6</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2397851" class="user-id-2397851"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2397851/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Joseph Oliver-Commey">Joseph Oliver-Commey</a><sup>7</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1791348" class="user-id-1791348"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1791348/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Vincent Ganu">Vincent Ganu</a><sup>8</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1308622" class="user-id-1308622"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1308622/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="George B. Kyei,,&#xA;">George B. Kyei</a><sup>1,3,9</sup><sup>&#x0002A;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Peter Puplampu&#xA;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Peter Puplampu<sup>8</sup><sup>&#x0002A;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1307387" class="user-id-1307387"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1307387/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Evelyn Y. Bonney&#xA;">Evelyn Y. Bonney</a><sup>1</sup><sup>&#x0002A;</sup></span></div> <ul class="notes"> <li><span><sup>1</sup></span>Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana</li> <li><span><sup>2</sup></span>West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana</li> <li><span><sup>3</sup></span>Medical and Scientific Research Center, University of Ghana Medical Center, Accra, Ghana</li> <li><span><sup>4</sup></span>Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana</li> <li><span><sup>5</sup></span>Central Laboratory, Immunology Department, Korle-Bu Teaching Hospital, Accra, Ghana</li> <li><span><sup>6</sup></span>Public Health Unit, University of Ghana Hospital, Accra, Ghana</li> <li><span><sup>7</sup></span>LEKMA Hospital, Accra, Ghana</li> <li><span><sup>8</sup></span>Department of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana, Accra, Ghana</li> <li><span><sup>9</sup></span>Departments of Medicine and Molecular Microbiology, Washington University School of Medicine, St Louis, MO, United States</li> </ul>
<p class="mb15"><b>Introduction:</b> Regular viral load (VL) testing for people living with HIV (PLWH) is key to attaining the Joint United Nations Program on HIV/AIDS (UNAIDS) Fast-Track 95&#x2013;95-95 target to end the HIV epidemic by 2030. However, VL testing remains sporadic in routine HIV care in the majority of resource-limited settings, including Ghana, except when provided through research initiatives. In this study, we measured VL among PLWH in Ghana at regular intervals and investigated factors affecting viral suppression (VS) and rebound.</p>
<p class="mb15"><b>Methods:</b> We analyzed data from a hospital-based cohort enrolled in our HIV cure research. Participants were recruited from three hospitals in the Greater Accra region of Ghana. Demographic characteristics were obtained from participants&#x2019; folders, while CD4<sup>+</sup> T cell counts and VLs were measured from blood samples collected at baseline, 6&#x202F;months, and 18&#x202F;months.</p>
<p class="mb15"><b>Results:</b> The study participants were predominantly women (68%) with a median age of 45&#x202F;years (IQR: 21&#x2013;76&#x202F;years). A total of 52% of participants had been on antiretroviral therapy (ART) for more than 6&#x202F;years, and 74% were following dolutegravir-based regimens. At baseline, 74% of participants had a VL of &#x0003C;50 copies/mL, which increased to 88% at 18&#x202F;months, with 80% having a CD4<sup>+</sup> T cell count of &#x0003E;350 cells/&#x03BC;l. Age group [&#x0003C;40 vs.&#x202F;&#x0003E;&#x202F;40&#x202F;years] (OR 2.35, 95% CI; 1.21&#x2013;4.58, <i>p</i>&#x202F;=&#x202F;0.012), CD4<sup>+</sup> T cell count [&#x0003E;350 vs.&#x202F;&#x0003C;&#x202F;350 cells/&#x03BC;l] (OR 4.35, 95% CI; 2.32&#x2013;8.18, <i>p</i>&#x202F;&#x0003C;&#x202F;0.001), and ART regimen [NVP based vs. DTG based] (OR 7.00, 95% CI; 1.15&#x2013;42.57, <i>p</i>&#x202F;=&#x202F;0.034) were associated with VS of &#x0003C;50 copies/mL. The overall viral rebound rate was estimated at 13.61 per 1,000 person-months (95% CI 10.52&#x2013;17.74), with decreasing rates over time. Lower educational levels (up to Junior High School) were significantly associated with viral rebound (<i>p</i>&#x202F;=&#x202F;0.011).</p>
<p class="mb0"><b>Conclusion:</b> A key feature of our study was measuring VL at three time points over 2&#x202F;years, which may explain the high VS levels observed. Viral rebound was linked to low education levels, highlighting the need for targeted education for PLWH with junior high school (JHS) education or less. Regular VL monitoring and the implementation of measures to prevent viral rebound, particularly among PLWH with lower education levels, will help Ghana move closer to attaining the third &#x201C;95&#x201D; of the UNAIDS 95&#x2013;95-95 target by 2030.</p> <div class="clear"></div> </div> <div class="JournalFullText"> <a id="h2" name="h2"></a>
<h2>Introduction</h2>
<p class="mb15">Human immunodeficiency virus (HIV) infection continues to be a global pandemic, with over 38 million people living with the virus; the majority of the infected people are in sub-Saharan Africa (SSA) (<a href="#ref1">1</a>). The widespread use of antiretroviral therapy (ART), which can suppress the virus to undetectable levels, has transformed HIV infection into a manageable chronic disease requiring daily medication (<a href="#ref2">2</a>&#x2013;<a href="#ref4">4</a>).</p>
<p class="mb15">The Joint United Nations Program on HIV/AIDS (UNAIDS) has set ambitious targets to control the HIV epidemic by 2030, aiming for 95% of people living with HIV (PLWH) to know their status, 95% of those diagnosed to be on ART (antiretroviral therapy), and 95% of those on ART to achieve viral suppression (VS). Achieving VS is key to reducing transmission and disease progression, making it a critical goal for everyone receiving treatment (<a href="#ref5">5</a>&#x2013;<a href="#ref11">11</a>).</p>
<p class="mb15">The factors likely to affect VS include the type of antiretroviral (ARV) regimen, patient adherence, and the frequency of VL measurements to facilitate timely regimen adjustments (<a href="#ref12">12</a>). The sporadic nature of viral load testing in SSA and other resource-limited settings (RLS), coupled with less potent first-generation ARVs that have burdensome side effects hindering adherence, promotes drug resistance and viral non-suppression. Therefore, the World Health Organization (WHO) recommended dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), in 2018 to be used in combination with two NRTIs as a first-line regimen for SSA and other RLS to improve VS. Following this recommendation, Ghana transitioned from a first-line regimen based on non-nucleotide reverse transcriptase inhibitors (NNRTIs) such as Nevirapine (NVP) or Efavirenz (EFV), combined with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including Lamivudine (3TC), Zidovudine (AZT), or Tenofovir disoproxil fumarate (TDF), to a DTG-based regimen (<a href="#ref13">13</a>&#x2013;<a href="#ref15">15</a>). This switch aimed to improve adherence, reduce drug resistance, and improve VS rates in SSA (<a href="#ref16">16</a>, <a href="#ref17">17</a>).</p>
<p class="mb15">Therefore, measuring VS is imperative to ascertain the effectiveness of the new drug regimens and determine the factors that affect it.</p>
<p class="mb15">Measuring VL is the primary method for assessing the effectiveness of ART, as it provides critical insights into VS (<a href="#ref18">18</a>, <a href="#ref19">19</a>). However, achieving VS in PLWH is not a stable or permanent condition. Some individuals may lose their VS status over time and experience viral rebounds (<a href="#ref20">20</a>). Viral rebound is known to be associated with active tuberculosis, ART adherence, duration of prior suppression, education levels, and the type of ARVs used (<a href="#ref12">12</a>, <a href="#ref20">20</a>, <a href="#ref21">21</a>). Additionally, socioeconomic factors such as disparities in education and income&#x2014;manifesting as health literacy and financial barriers&#x2014;may improve non-ART adherence, potentially impacting VS and rebound rates. Viral rebounds can undermine the gains made by ART by increasing treatment failure and ART resistance, thus facilitating HIV transmission (<a href="#ref21">21</a>). The WHO recommends initiating treatment and monitoring response by performing the first VL measurement 6&#x202F;months after treatment initiation, followed by yearly intervals if suppression is achieved (<a href="#ref22">22</a>). However, these guidelines are not consistently followed in SSA, hindering the early detection of virologic failure. Previous studies have shown an increase in HIV drug resistance in Africa due to irregular monitoring of VL and the lack of drug resistance testing before changing drug regimens (<a href="#ref23">23</a>, <a href="#ref24">24</a>).</p>
<p class="mb15">According to the Ghana AIDS Commission, Ghana&#x2019;s VS rate is 68%, which is significantly below UNAIDS target of 95%. To assess progress toward the third &#x201C;95&#x201D; of the UNAIDS 95&#x2013;95-95 target and identify necessary interventions to maintain VS, it is crucial to evaluate trends in VS, instances of viral rebound, and the factors influencing these two outcomes.</p>
<p class="mb0">In this study, we report the levels of VS, viral rebound rates, and factors associated with VS and rebound among PLWH over 18&#x202F;months.</p> <a id="h3" name="h3"></a>
<h2>Materials and methods</h2>
<h3>Study design</h3>
<p class="mb0">This is a secondary data analysis using data from a hospital-based cohort study aimed at identifying virologically suppressed individuals for HIV cure research. The cohort study was conducted at three hospitals in the Greater Accra region of Ghana: Korle-Bu Teaching Hospital, LEKMA Hospital, Teshie, and University of Ghana Hospital, Legon. Demographic characteristics were obtained from participants&#x2019; records, and blood samples were collected from patients to measure CD4<sup>+</sup> T cell counts and VLs at baseline, 6&#x202F;months, and 18&#x202F;months.</p>
<h3>Study population and sampling</h3>
<p class="mb15">Between 2019 and 2021, the parent study enrolled 390 PLWH on ART from three hospitals in the Greater Accra region of Ghana. A total of 250 participants were recruited from Korle-Bu Teaching Hospital (KBTH), and 70 each were recruited from LEKMA Hospital and the University of Ghana Hospital, Legon. Details of the study hospitals have been previously published (<a href="#ref25">25</a>). Participants were enrolled at baseline and followed up at 6 and 18&#x202F;months over a 2-year period.</p>
<p class="mb0">At each sampling time point, 10&#x202F;mL of venous blood was collected into EDTA tubes from participants and transported in cool boxes to the Noguchi Memorial Institute for Medical Research (NMIMR). Aliquots of the whole blood were used to estimate CD4<sup>+</sup> T cell count, while the remaining blood was processed into plasma and peripheral blood mononuclear cells (PBMCs) using the sucrose-gradient centrifugation method. Plasma was stored at -20&#x000B0;C and PBMCs at &#x02212;80&#x000B0;C in a freezing medium (FBS with 10% DMSO) until further laboratory analysis. The participants&#x2019; demographics and treatment history, including age, sex, educational status, income level, ART regimen, and occupation, were obtained from hospital records.</p>
<h3>Inclusion/exclusion criteria</h3>
<p class="mb0">All consenting ART-experienced PLWH aged 18&#x202F;years and older were included in the parent study. All PLWH under 18&#x202F;years of age and ART na&#x000EF;ve were excluded. For this study, PLWH from the parent study with VL results at all three follow-up points were analyzed to identify factors associated with VS and rebound.</p>
<h3>Viral load determination</h3>
<p class="mb0">VL was measured from the plasma using the COBAS<sup>&#x000AE;</sup> AmpliPrep/COBAS<sup>&#x000AE;</sup> TaqMan<sup>&#x000AE;</sup> following the manufacturer&#x2019;s instructions (Roche Diagnostic Systems, Branchburg, NJ, United States). For quality control, a negative control, HIV-1 Low Positive Control, and HIV-1 High Positive Control were included in each test batch. This assay can quantify HIV-1 RNA with a lower detection limit of 20 copies/mL and an upper limit of 10,000,000 copies/mL. One copy of HIV-1 RNA is equivalent to 1.7&#x202F;&#x000B1;&#x202F;0.1 International Units (IU) based on the WHO 1st International Standard for HIV-1 RNA for Nucleic Acid-Based Techniques (NAT; NIBSC 97/656).</p>
<h3>CD4<sup>+</sup> T and CD8<sup>+</sup> T cell measurement</h3>
<p class="mb0">Whole blood samples were analyzed for CD4<sup>+</sup> T and CD8 <sup>+</sup>T cell counts using the FACS Count system (Becton Dickinson Biosciences, United States), according to the manufacturer&#x2019;s instructions. Briefly, 50&#x202F;&#x03BC;L of blood was added to CD4 and CD8 reagent tubes and incubated for 1&#x202F;h at room temperature in the dark, in accordance with the manufacturer&#x2019;s protocol. A fixative solution (50&#x202F;&#x03BC;L) was added and analyzed on the FACS Count machine to enumerate the absolute CD4 <sup>+</sup> and CD8<sup>+</sup> T cells per microliter of blood. The equipment was also calibrated to validate the results, and reagent controls were run alongside each batch of samples.</p>
<h3>Statistical analysis</h3>
<p class="mb15">Participants&#x2019; characteristics were analyzed descriptively using frequency distribution tables and graphical presentations. Data capture, cleaning, coding, and analysis were conducted using.</p>
<p class="mb0">Microsoft Excel spreadsheets (Excel 2016) and STATA 16. VS was defined as the proportion of individuals with HIV VL &#x0003C;50 copies/mL and [&#x0003C;1,000 copies/mL for the WHO criteria for resource-limited settings (RLS)]. Frequencies and percentages were used to describe categorical outcomes, while medians and interquartile ranges were used to summarize continuous variables. Odds ratios in the multivariable model were calculated to examine factors associated with VS using a generalized estimating equation with a binomial distribution and logit link function to account for within-subject correlation. The HIV rebound rate was defined as the number of participants who were unsuppressed following VS with results &#x0003C;50 copies/mL over the study period from enrollment to the second follow-up. The viral rebound was calculated as a rate per 1,000 person-months using survival analysis. Confidence intervals were reported, and <i>p</i>-values of &#x0003C;0.05 were considered statistically significant.</p> <a id="h4" name="h4"></a>
<h2>Results</h2>
<h3>Participants&#x2019; characteristics</h3>
<p class="mb0">A total of 390 PLWH in Ghana were recruited from three hospitals in Accra for this study. In total, 265, representing 68% of the participants, were women, while the remaining 32% were men (<a href="#tab1">Table 1</a>). The median age of the participants was 45&#x202F;years (IQR 21&#x2013;76). The majority had only a minimum level of formal education; only 29% of them had completed high school or pursued further education. Participants had a low economic status, with 71% earning less than $100 USD per month. The median duration since the HIV diagnosis was 7&#x202F;years (IQR 0&#x2013;30), and 59% of participants had been on antiretroviral treatment for more than 6&#x202F;years (<a href="#tab1">Table 1</a>). The estimated CD4<sup>+</sup> T cell counts for 80% of the participants were&#x202F;&#x0003E;&#x202F;350 cells/&#x03BC;L. Of the 390 participants, VL results were available for 361 at baseline, 325 at 6&#x202F;months, and 321 at 18&#x202F;months (<a href="#tab1">Table 1</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 1</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t001.jpg" name="table1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t001.jpg" alt="www.frontiersin.org" id="tab1" loading="lazy">
  </picture>
</a>
<p><b>Table 1</b>. Demographic and infection history of study participants.
</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h3>VS per sampling time points</h3>
<p class="mb0">At recruitment, 268 out of 390 participants, representing 74%, had VLs less than 50 copies/mL, and 91% had VLs less than 1,000 copies/mL. At 6&#x202F;months, out of 325 participants, 73% of the participants had VL less than 50 copies/mL, and 91% of the participants had VL less than 1,000 copies/mL. At 18&#x202F;months, 88% of 321 participants had VLs less than 50 copies/mL, and 96% of the participants had VLs less than 1,000 copies/mL (<a href="#fig1">Figure 1</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 1</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g001.jpg" name="figure1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g001.jpg" alt="www.frontiersin.org" id="fig1" loading="lazy">
  </picture>
</a>
<p><b>Figure 1</b>. Percentage viral suppression at sampling timepoints. Viral suppression was based on the thresholds set at &#x0003C;50 copies/ml (purple bars) and &#x0003C;1,000 copies/ml (pink bars).</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h3>VS trends of compliant participants</h3>
<p class="mb15">In total, 275 participants had their VLs measured at all three time points in the study.</p>
<p class="mb0">Among these, VS &#x0003C;50 copies/mL was observed in 74, 73, and 88% at baseline, 6&#x202F;months, and 18&#x202F;months (<a href="#fig2">Figure 2</a>). At all three time points, VS levels exceeded 90% when using the WHO threshold of &#x0003C;1,000 copies/mL (<a href="#fig2">Figure 2</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 2</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g002.jpg" name="figure2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g002.jpg" alt="www.frontiersin.org" id="fig2" loading="lazy">
  </picture>
</a>
<p><b>Figure 2</b>. Viral suppression among patients whose viral loads were successfully measured at all the three sampling timepoints (<i>N</i>&#x202F;=&#x202F;275). The graph shows the trend in the proportion of virally suppressed individuals and their confidence interval in percentages over three-time points; baseline, 6 and 18&#x202F;months according to the two thresholds (&#x0003C;50 copies/ml and &#x0003C;1,000 copies/ml).</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h3>Factors associated with VS</h3>
<p class="mb0">We examined the factors associated with VLS at the thresholds &#x0003C;50 copies/mL and from 51 to 1,000 copies/mL. Age group (OR 2.35, 95% CI; 1.21&#x2013;4.58, <i>p</i>-value&#x202F;=&#x202F;0.012), CD4<sup>+</sup> T cell count (OR 4.35, 95% CI; 2.32&#x2013;8.18, <i>p</i>-value&#x0003C;0.001), and ART regimen [NVP based vs. DTG based] (OR 7.0, 95% CI; 1.15&#x2013;42.57, <i>p</i>-value&#x202F;=&#x202F;0.034) were associated with VLS with threshold of &#x0003C;50 copies/mL, while CD4<sup>+</sup> T cell count (OR 5.39, 95% CI; 1.73&#x2013;16.73, <i>p</i>-value&#x0003C;0.001) was associated an VL of of 51 to 1,000 copies/mL (<a href="#fig3">Figure 3</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Figure 3</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g003.jpg" name="figure3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g003.jpg" alt="www.frontiersin.org" id="fig3" loading="lazy">
  </picture>
</a>
<p><b>Figure 3</b>. Factors associated with Viral suppression for thresholds <b>(A)</b> &#x0003C;50 copies/ml and <b>(B)</b> from 51 to 1,000 copies/ml. The forest plot shows the factors associated with HIV suppression (&#x0003C;50 copies/ml, <i>N</i>&#x202F;=&#x202F;275: 51&#x2013;1,000 copies/ml, <i>N</i>&#x202F;=&#x202F;179). The dashed lines represent the reference point&#x202F;=&#x202F;1, the black dot represents the point odds ratio estimate, and the whiskers represents the confidence intervals. <i>p</i>-values &#x0003C;0.05 are considered significant. VS, Viral suppression.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h3>Viral rebound rates</h3>
<p class="mb0">We followed 275 participants with VL results across the follow-up points, totaling 4,120 person-months (<a href="#tab2">Table 2</a>). During the follow-up period, 56 participants experienced HIV rebound. At 6, 12, and 18&#x202F;months, 43, 11, and 2 participants, respectively, experienced viral rebound (<a href="#fig4">Figure 4</a>). The overall viral rebound rate was estimated at 13.61 per 1,000 person-months (95% CI 10.52&#x2013;17.74; <a href="#tab2">Table 2</a>).</p>
<div class="DottedLine"></div> <div class="Imageheaders">Table 2</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t002.jpg" name="table2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-t002.jpg" alt="www.frontiersin.org" id="tab2" loading="lazy">
  </picture>
</a>
<p><b>Table 2</b>. Showing the distribution of rebound rates by covariates.
</p></div> <div class="clear"></div> <div class="DottedLine mb15"></div>
<div class="Imageheaders">Figure 4</div> <div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g004.jpg" name="figure4" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1508793/fpubh-13-1508793-HTML-r1/image_m/fpubh-13-1508793-g004.jpg" alt="www.frontiersin.org" id="fig4" loading="lazy">
  </picture>
</a>
<p><b>Figure 4</b>. Kaplan Meier curve showing the distribution of rebound cases over the follow-up period.</p></div> <div class="clear"></div> <div class="DottedLine"></div>
<h3>Factors associated with viral rebound</h3>
<p class="mb0">The HIV rebound rate was significantly higher among participants with educational levels up to junior high school (16.55 per 1,000 person-months) compared to those with educational levels from senior secondary school and above (6.33 per 1,000 person-months), <i>p</i>&#x202F;=&#x202F;0.011. However, the years on ART and monthly income were marginally significant (<a href="#tab2">Table 2</a>).</p> <a id="h5" name="h5"></a>
<h2>Discussion</h2>
<p class="mb15">In this study, we determined VS/rebound in participants on ART in Ghana who enrolled in our HIV cure studies and received regular VL measurements over a 2-year period. Prior to our study, regular VL measurements were not routinely conducted for participants.</p>
<p class="mb15">Women constituted 68% of our study population. This aligns with national HIV statistics in Ghana, where women account for two-thirds of PLWH (<a href="#ref26">26</a>). The age group of 41 to 50&#x202F;years represented 42% of the study population, indicating that Ghana has an aging HIV population that requires targeted management to ensure they remain healthy and can contribute to national development. Over 62% had been diagnosed with HIV at least 5&#x202F;years before sampling, and 27% of them had been aware of their status for more than 10&#x202F;years before the study. In total, 59% had been on ART for over 6&#x202F;years before sampling. Some participants did not start ART at the time of diagnosis, probably due to their CD4<sup>+</sup> T cell counts and the policy of initiating ART at a specified CD4<sup>+</sup> T cell threshold.</p>
<p class="mb15">Achieving VS is the optimal goal of antiretroviral therapy, with VL measurements being the best tool for assessment (<a href="#ref27">27</a>). Various factors determine whether patients on therapy will attain VS, including the time from infection to initiation of ART, the type of antiretrovirals prescribed, the duration of treatment, adherence to the treatment regimen, and the patients&#x2019; age and sex. While a longer duration of treatment is generally a positive indicator for achieving VS, remaining on an ineffective regimen for too long could negate the benefits of ART. This study considers educational level and income as key determinants of VS, given their critical role in an individual&#x2019;s ability to access healthcare and adhere to prescribed treatment.</p>
<p class="mb15">Higher levels of education enhance individuals&#x2019; ability to make informed healthcare decisions and understand medical instructions. Similarly, income levels can directly impact one&#x2019;s ability to afford healthcare services and transportation to medical facilities.</p>
<p class="mb15">In resource-limited settings such as Ghana, VL measurements are not routinely conducted for people on ART. However, the treatment guidelines recommend VL measurements at 6-month intervals until suppression and once per year thereafter (<a href="#ref28">28</a>). This is due to limited resources such as equipment, ineffective sample transport systems, a lack of skilled personnel at the peripheral laboratories to analyze the samples, and non-adherence to ART guidelines by healthcare workers.</p>
<p class="mb15">In this study, we measured the VLs for all participants sampled at the three-time points.</p>
<p class="mb15">The unavailability of VL results for some participants (<a href="#tab1">Table 1</a>) was due to either invalid test results or participant loss to follow-up.</p>
<p class="mb15">We found that 74% of participants in our cohort had a VL of &#x0003C;50 copies/mL, which is similar to the 76% VS observed by Opoku et al. in a study conducted at Komfo Anokye Teaching Hospital in Kumasi, Ghana (<a href="#ref20">20</a>). This presents a positive outlook for Ghana&#x2019;s ART program and may suggest that the drugs are generally effective. Among participants with VL&#x202F;&#x02265;&#x202F;50 copies/mL, 62 (17%) had VL of less than 1,000 copies/mL; thus, a total of 91% of participants met the World Health Organization&#x2019;s criteria for VS in RLS. Antiretrovirals used in Ghana were mostly first-generation ARVs until the introduction of DTG into the first-line regimen in 2019 (<a href="#ref29">29</a>). The treatment regimens in Ghana primarily consisted of reverse transcriptase inhibitors, with protease inhibitors introduced during the second-line regimen when the first-line regimen failed (<a href="#ref30">30</a>). The level of VS found in our study corroborates findings from previous studies by Ali et al., who reported 72% VS (&#x0003C;1,000 copies/mL) from Ethiopia; Wakooko et al., with 87.5% VS (&#x0003C;1,000 copies/mL) from Eastern Uganda; Mogosetsi et al., who reported 91% VS (&#x0003C;1,000 copies/mL) in South Africa; Abdullahi et al., who reported 91% VS (&#x0003C;1,000 copies/mL) from northwestern Nigeria; and Djiyou et al., reporting 88.2% VS (&#x0003C;1,000 copies/mL) from Cameroon (<a href="#ref27">27</a>, <a href="#ref31">31</a>&#x2013;<a href="#ref34">34</a>). Other African countries have reported lower levels: 59% in Kenya (<a href="#ref12">12</a>) and 56.2% among pregnant women in South Africa (<a href="#ref35">35</a>).</p>
<p class="mb15">VS levels at the three sampling time points showed an increasing trend, which could be attributed to the introduction of DTG (<a href="#fig1">Figure 1</a>). The slight dip observed in Follow-up 1 (2020) could be due to the impact of the COVID-19 pandemic, which drastically reduced access to healthcare (<a href="#ref36">36</a>). Overall, the high levels of suppression in our participants over the study period could be due to the availability of VL testing for each participant in our cohort, which guided monitoring for improved virologic outcomes.</p>
<p class="mb15">Age, ART regimen, and CD4<sup>+</sup> T cell count were associated with VS (VL&#x202F;&#x0003C;&#x202F;50 copies/mL), while only CD4<sup>+</sup> T cell count was associated with VLs between 51 and 1,000 copies/mL. Participants older than 40&#x202F;years were more likely to be virally suppressed compared to those younger than 40&#x202F;years. This contrasts with findings from a study in Canada, where adults under 29&#x202F;years experienced a lower prevalence of VS (<a href="#ref37">37</a>). This may indicate that Ghana&#x2019;s older population is more receptive to and compliant with their treatment than other populations. A nevirapine-based regimen was more likely to be associated with VS than dolutegravir. This observation could be attributed to factors such as adherence differences, sampling time, and, more importantly, our cohort composition bias. Dolutegravir (DTG) was introduced just before the study, and at baseline, a higher proportion of ART-experienced participants who were doing well were on nevirapine-based regimens, leaving only the newly initiated patients or those with prior virologic failure and higher VLs on DTG-based regimens. However, at month 18, a larger proportion of participants were on a DTG-based regimen and had their VLs below 50 copies/mL, demonstrating the superior efficacy of DTG, which aligns with global evidence.</p>
<p class="mb15">Achieving VS has many benefits for PLWH because it drastically reduces HIV transmission risk (undetectable equals untransmissible). This is particularly beneficial to discordant couples and babies born to women with HIV (<a href="#ref38">38</a>, <a href="#ref39">39</a>).</p>
<p class="mb15">Viral rebounds pose a significant risk to HIV morbidity and mortality. In our study, viral rebound occurred in 20.4% of individuals, with the rebound rate estimated at 13.61 per 1,000 person-years (95% CI 10.52&#x2013;17.74). This is comparable to the findings by Opoku et al., who reported a 21% viral rebound rate among PLWH in Ghana (<a href="#ref20">20</a>). This finding in our cohort confirms that viral rebounds occur frequently among individuals with VS. This has ramifications for HIV management in Ghana, as previously suppressed individuals may potentially become infectious during the period of viral rebounds. Incidence of viral rebound decreased over time, with 43, 11, and 2 participants showing corresponding falls over 6, 12, and 18&#x202F;months. As stated by Campos et al., the switch to a newer ARV like DTG in our cohort is the likely cause of the gradual decrease in viral rebounds (<a href="#ref40">40</a>).</p>
<p class="mb15">An analysis of factors linked to viral rebounds revealed a strong correlation between lower educational attachment (up to Junior High School) and higher rebound rates. This result is consistent with that of Min et al., who found that participants with education levels equivalent to high school had a higher rebound rate than those with higher education levels (<a href="#ref41">41</a>). Our findings also show the importance of some socioeconomic determinants in HIV outcomes. Participants earning less than 500 GHS/month exhibited a marginally higher viral rebound rate than those earning &#x02265;500 GHS/month. This trend mirrors the findings of Leddy et al., who found that low-income individuals experience worse HIV treatment outcomes (<a href="#ref42">42</a>). In this study, 70% of the participants earned less than 500 GHS/month.</p>
<p class="mb15">These economic hardships may pose a barrier to consistent healthcare access, as limited financial resources can lead to difficulties in affording transportation to clinics or even purchasing the nutritious food necessary for optimal ART efficacy. These financial constraints could contribute to inconsistent ART adherence, thereby affecting their viral rebound rates. The predominance of female participants (68%) reflects Ghana&#x2019;s HIV epidemiology, where women represent approximately two-thirds of PLWH. However, viral rebound rates did not significantly vary by gender. While our study did not explore the reasons behind this lack of disparity, other studies have found higher rebound rates in males compared to women, which is attributed to frequent ART treatment interruptions among males (<a href="#ref43">43</a>&#x2013;<a href="#ref46">46</a>). Further research is required to examine this phenomenon within the Ghanaian population.</p>
<p class="mb15">Our study reports high levels of VS over an 18-month period; however, 12% of our cohort could not achieve VS. Among the unsuppressed participants, 67% of them had low-level viremia (VL 50&#x2013;999 copies/ml) and were deemed suppressed according to the WHO guidelines, often receiving little attention. However, low-level viremia is known to promote viral replication, leading to virologic failure, the emergence of drug resistance, and increased HIV transmission (<a href="#ref47">47</a>&#x2013;<a href="#ref50">50</a>). It is critical to pay some attention to the unsuppressed group, including those with low-level viremia, to further reduce their VL to below-detectable levels. Regular VL testing for monitoring ART is a more sensitive, timely, and reliable method for identifying treatment failure than the clinical use of CD4<sup>+</sup> T cell counts and clinical symptoms (<a href="#ref51">51</a>). Therefore, it is recommended that HIV control programs in resource-limited settings invest in infrastructure and logistics to implement regular VL measurements for all PLWH on ART.</p>
<p class="mb15">Our data were obtained from patients enrolled in our HIV cure study, with their VLs measured regularly. In contrast, the general HIV population in Ghana does not have access to routine VL testing and is not consistently monitored for treatment failure until clinical deterioration occurs. We recommend implementing regular VL measurements as part of HIV care in Ghana to ensure effective ART outcomes. Our findings confirm viral rebound among previously suppressed participants, which could impede global efforts to end the AIDS epidemic by 2030. In our situation, this emphasizes the need to target and educate PLWH, particularly those with education up to Junior High School, about the importance of VS in controlling HIV transmission.</p>
<p class="mb15">A major challenge in achieving sustained VS in Ghana is the sporadic nature of viral load monitoring. Strengthening routine VL testing requires addressing costs, feasibility, and potential partnerships with government and non-governmental organizations. Expanding decentralized VL testing to peripheral health centers, reducing test costs through public-private partnerships, and integrating VL monitoring into routine ART services could improve accessibility and sustainability. Furthermore, policies that promote awareness campaigns emphasizing the role of VL monitoring in HIV would support these efforts.</p>
<p class="mb15">Our study has some limitations. First, the participants did not have regular VL measurements from the start of therapy until sampling, making it difficult to determine when they achieved VS and for how long they maintained it. Additionally, we did not assess adherence to ART in our study population. Therefore, we cannot reliably associate the observed suppression and rebound rates with adherence.</p>
<p class="mb0">Future research should incorporate adherence assessments such as pill counts, self-reports, or biomarker tracking to better understand the impact of adherence. While sufficient for initial analysis, the sample size may limit statistical power in detecting smaller effect sizes. Future studies should consider a larger cohort to enhance the robustness of the findings. Additionally, some participants were lost to follow-up, leading to potential missing data that may introduce bias in the results. The study was conducted in three hospitals in the Greater Accra region, which may not be generalizable to PLWH in other regions of Ghana with different healthcare access. Finally, we acknowledge the possibility of recall bias arising from participants self-reporting certain variables such as age. This was mitigated by cross-verifying hospital records. However, socioeconomic variables like income could not be verified due to the lack of documented records.</p> <a id="h6" name="h6"></a>
<h2>Conclusion</h2>
<p class="mb15">Despite the limitations of the study, we found high levels of VS among patients enrolled in our HIV cure study, where regular VL measurements were conducted. However, the general HIV population in Ghana lacks access to routine VL testing, which may result in different suppression levels compared to those observed in our study.</p>
<p class="mb0">We recommend that the national HIV control program prioritize investments in infrastructure and logistics to implement regular VL measurements for all PLWH on ART. This will significantly improve ART outcomes and VS rates across Ghana&#x2019;s broader HIV population. Additionally, further education on the importance of VS for PLWH with up to JHS-level education is essential to maintaining VS and achieving the third &#x201C;95&#x201D; of the UNAIDS 95&#x2013;95-95 target by 2030.</p> <a id="h7" name="h7"></a>
<h2>Data availability statement</h2>
<p class="mb0">The original contributions presented in this study are included in the article and supplementary materials, further inquiries can be directed to the corresponding authors.</p> <a id="h8" name="h8"></a>
<h2>Ethics statement</h2>
<p class="mb0">The studies involving humans were approved by Institutional Review Board, Noguchi Memorial Institute for Medical Research, University of Ghana (NMIMR-IRB CPN002/18-19), Institutional Review Board, Korle-Bu Teaching Hospital (KBTH-IRB/00075/2019) and Ethics Review Committee of the Ghana Health Service (GHS-ERC:013/09/19). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p> <a id="h9" name="h9"></a>
<h2>Author contributions</h2>
<p class="mb0">AB: Data curation, Formal analysis, Investigation, Methodology, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. JA: Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#x2013; review &#x00026; editing. HL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#x2013; review &#x00026; editing. CA: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. AA-M: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. DQ: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. SA: Data curation, Formal analysis, Investigation, Methodology, Supervision, Writing &#x2013; review &#x00026; editing. YA-L: Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#x2013; review &#x00026; editing. GA: Conceptualization, Data curation, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. JO-C: Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing &#x2013; review &#x00026; editing. VG: Data curation, Investigation, Project administration, Supervision, Writing &#x2013; review &#x00026; editing. GK: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing &#x2013; review &#x00026; editing. PP: Data curation, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. EB: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Writing &#x2013; review &#x00026; editing.</p> <a id="h10" name="h10"></a>
<h2>Funding</h2>
<p class="mb0">The author(s) declare that financial support was received for the research and/or publication of this article. This project is part of the EDCTP2 program, which is supported by the European Union (grant number TMA2017SF-1955, H-CRIS) for GBK. The funder had no role in the design, analysis, or publication of the study.</p> <a id="h11" name="h11"></a>
<h2>Acknowledgments</h2>
<p class="mb0">We thank our study participants and our collaborating partners from the hospitals, especially Adjoa Obo-Akwa, Esther Davis Yeboah, Linda Sackey, Rosalyn Baah-Danquah, and all other members of the H-CRIS team.</p> <a id="h12" name="h12"></a>
<h2>Conflict of interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p> <a id="h13" name="h13"></a>
<h2>Generative AI statement</h2>
<p class="mb0">The author(s) declare that no Gen AI was used in the creation of this manuscript.</p> <a id="h14" name="h14"></a>
<h2>Publisher&#x2019;s note</h2>
<p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p> <a id="h15" name="h15"></a>
<h2>References</h2>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref1" id="ref1"></a>1. Global Statistics. (2025). HIV.gov. Available at: <a href="https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics">https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics</a> (Accessed on 2021 Mar 24)</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2025&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref2" id="ref2"></a>2. G&#x000FC;nthard, HF, Saag, MS, Benson, CA, Del Rio, C, Eron, JJ, Gallant, JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. <i>JAMA J Am Med Assoc</i>. (2016) 316:191&#x2013;210. doi: 10.1001/jama.2016.8900 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27404187" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2016.8900" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HF+G&#x000FC;nthard&#x00026;author=MS+Saag&#x00026;author=CA+Benson&#x00026;author=C+Del+Rio&#x00026;author=JJ+Eron&#x00026;author=JE+Gallant&#x00026;publication_year=2016&#x00026;title=Antiretroviral+drugs+for+treatment+and+prevention+of+HIV+infection+in+adults:+2016+recommendations+of+the+international+antiviral+society-USA+panel&#x00026;journal=JAMA+J+Am+Med+Assoc&#x00026;volume=316&#x00026;pages=191-210" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref3" id="ref3"></a>3. Abana, CZ, Sagoe, KWC, Bonney, EY, Maina, EK, Aziati, ID, Agbosu, E, et al. Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana. <i>Med (United States)</i>. (2019) 98:e14313. doi: 10.1097/MD.0000000000014313 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30732150" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/MD.0000000000014313" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CZ+Abana&#x00026;author=KWC+Sagoe&#x00026;author=EY+Bonney&#x00026;author=EK+Maina&#x00026;author=ID+Aziati&#x00026;author=E+Agbosu&#x00026;publication_year=2019&#x00026;title=Drug+resistance+mutations+and+viral+load+in+human+immunodeficiency+virus+type+2+and+dual+HIV-1/HIV-2+infected+patients+in+Ghana&#x00026;journal=Med+(United+States)&#x00026;volume=98&#x00026;pages=e14313" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref4" id="ref4"></a>4. Collaboration TATC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. <i>Lancet</i>. (2008) 372:293&#x2013;9. doi: 10.1016/S0140-6736(08)61113-7</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/S0140-6736(08)61113-7" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?publication_year=2008&#x00026;title=Life+expectancy+of+individuals+on+combination+antiretroviral+therapy+in+high-income+countries:+a+collaborative+analysis+of+14+cohort+studies&#x00026;journal=Lancet&#x00026;volume=372&#x00026;pages=293-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref5" id="ref5"></a>5. Reynolds, SJ, Makumbi, F, Nakigozi, G, Kagaayi, J, Gray, RH, Wawer, M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. <i>AIDS</i>. (2011) 25:473&#x2013;7. doi: 10.1097/QAD.0b013e3283437c2b </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21160416" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/QAD.0b013e3283437c2b" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SJ+Reynolds&#x00026;author=F+Makumbi&#x00026;author=G+Nakigozi&#x00026;author=J+Kagaayi&#x00026;author=RH+Gray&#x00026;author=M+Wawer&#x00026;publication_year=2011&#x00026;title=HIV-1+transmission+among+HIV-1+discordant+couples+before+and+after+the+introduction+of+antiretroviral+therapy&#x00026;journal=AIDS&#x00026;volume=25&#x00026;pages=473-7" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref6" id="ref6"></a>6. Donnell, D, Baeten, JM, Kiarie, J, Thomas, KK, Stevens, W, Cohen, CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. <i>Lancet</i>. (2010) 375:2092&#x2013;8. doi: 10.1016/S0140-6736(10)60705-2 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20537376" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S0140-6736(10)60705-2" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Donnell&#x00026;author=JM+Baeten&#x00026;author=J+Kiarie&#x00026;author=KK+Thomas&#x00026;author=W+Stevens&#x00026;author=CR+Cohen&#x00026;publication_year=2010&#x00026;title=Heterosexual+HIV-1+transmission+after+initiation+of+antiretroviral+therapy:+a+prospective+cohort+analysis&#x00026;journal=Lancet&#x00026;volume=375&#x00026;pages=2092-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref7" id="ref7"></a>7. Del Romero, J, Castilla, J, Hernando, V, Rodr&#x000ED;guez, C, and Gar&#x0107;a, S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. <i>BMJ</i>. (2010) 340:c2205. doi: 10.1136/bmj.c2205 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20472675" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/bmj.c2205" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Del+Romero&#x00026;author=J+Castilla&#x00026;author=V+Hernando&#x00026;author=C+Rodr&#x000ED;guez&#x00026;author=S+Gar&#x0107;a&#x00026;publication_year=2010&#x00026;title=Combined+antiretroviral+treatment+and+heterosexual+transmission+of+HIV-1:+cross+sectional+and+prospective+cohort+study&#x00026;journal=BMJ&#x00026;volume=340&#x00026;pages=c2205" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref8" id="ref8"></a>8. Apondi, R, Bunnell, R, Ekwaru, JP, Moore, D, Bechange, S, Khana, K, et al. Sexual behavior and HIV transmission risk of Ugandan adults taking antiretroviral therapy: 3 year followup. <i>AIDS</i>. (2011) 25:1317&#x2013;27. doi: 10.1097/QAD.0b013e328347f775 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21522005" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/QAD.0b013e328347f775" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Apondi&#x00026;author=R+Bunnell&#x00026;author=JP+Ekwaru&#x00026;author=D+Moore&#x00026;author=S+Bechange&#x00026;author=K+Khana&#x00026;publication_year=2011&#x00026;title=Sexual+behavior+and+HIV+transmission+risk+of+Ugandan+adults+taking+antiretroviral+therapy:+3+year+followup&#x00026;journal=AIDS&#x00026;volume=25&#x00026;pages=1317-27" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref9" id="ref9"></a>9. Cohen, MS, Hosseinipour, MC, Kumarasamy, N, Hakim, JG, Mehendale, S, Chariyalertsak, S, et al. Prevention of HIV-1 infection with early antiretroviral therapy. <i>N Engl J Med</i>. (2011) 365:493&#x2013;505. doi: 10.1056/NEJMoa1105243</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1056/NEJMoa1105243" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MS+Cohen&#x00026;author=MC+Hosseinipour&#x00026;author=N+Kumarasamy&#x00026;author=JG+Hakim&#x00026;author=S+Mehendale&#x00026;author=S+Chariyalertsak&#x00026;publication_year=2011&#x00026;title=Prevention+of+HIV-1+infection+with+early+antiretroviral+therapy&#x00026;journal=N+Engl+J+Med&#x00026;volume=365&#x00026;pages=493-505" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref10" id="ref10"></a>10. Frescura, L, Godfrey-Faussett, P, Ali Feizzadeh, A, El-Sadr, W, Syarif, O, Ghys, PD, et al. Achieving the 95 95 95 targets for all: a pathway to ending AIDS. <i>PLoS One</i>. (2022) 17:e0272405. doi: 10.1371/journal.pone.0272405 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35925943" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0272405" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Frescura&#x00026;author=P+Godfrey-Faussett&#x00026;author=A+Ali+Feizzadeh&#x00026;author=W+El-Sadr&#x00026;author=O+Syarif&#x00026;author=PD+Ghys&#x00026;publication_year=2022&#x00026;title=Achieving+the+95+95+95+targets+for+all:+a+pathway+to+ending+AIDS&#x00026;journal=PLoS+One&#x00026;volume=17&#x00026;pages=e0272405" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref11" id="ref11"></a>11. Heath, K, Levi, J, and Hill, A. The joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture. <i>AIDS</i>. (2021) 35:S197&#x2013;203. doi: 10.1097/QAD.0000000000002983 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34115649" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/QAD.0000000000002983" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Heath&#x00026;author=J+Levi&#x00026;author=A+Hill&#x00026;publication_year=2021&#x00026;title=The+joint+United+Nations+Programme+on+HIV/AIDS+95-95-95+targets:+worldwide+clinical+and+cost+benefits+of+generic+manufacture&#x00026;journal=AIDS&#x00026;volume=35&#x00026;pages=S197-203" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref12" id="ref12"></a>12. Maina, EK, Mureithi, H, Adan, AA, Muriuki, J, Lwembe, RM, and Bukusi, EA. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. <i>Int J Infect Dis</i>. (2020) 97:151&#x2013;8. doi: 10.1016/j.ijid.2020.05.097</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/j.ijid.2020.05.097" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EK+Maina&#x00026;author=H+Mureithi&#x00026;author=AA+Adan&#x00026;author=J+Muriuki&#x00026;author=RM+Lwembe&#x00026;author=EA+Bukusi&#x00026;publication_year=2020&#x00026;title=Incidences+and+factors+associated+with+viral+suppression+or+rebound+among+HIV+patients+on+combination+antiretroviral+therapy+from+three+counties+in+Kenya&#x00026;journal=Int+J+Infect+Dis&#x00026;volume=97&#x00026;pages=151-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref13" id="ref13"></a>13. Taiwo, B, Gallien, S, Aga, E, and Ribaudo, H. Antiretroviral drug resistance in HIV-1 &#x2013; infected patients experiencing persistent low-level viremia during first-line. <i>Therapy</i>. (2011) 204:515&#x2013;20. doi: 10.1093/infdis/jir353 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21791652" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/infdis/jir353" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+Taiwo&#x00026;author=S+Gallien&#x00026;author=E+Aga&#x00026;author=H+Ribaudo&#x00026;publication_year=2011&#x00026;title=Antiretroviral+drug+resistance+in+HIV-1+&#x2013;+infected+patients+experiencing+persistent+low-level+viremia+during+first-line&#x00026;journal=Therapy&#x00026;volume=204&#x00026;pages=515-20" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref14" id="ref14"></a>14. Gregson, J, Tang, M, Ndembi, N, Hamers, RL, Marconi, VC, Brooks, K, et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infect Dis</i>. (2016) 16:565&#x2013;75. doi: 10.1016/S1473-3099(17)30723-5</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/S1473-3099(17)30723-5" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Gregson&#x00026;author=M+Tang&#x00026;author=N+Ndembi&#x00026;author=RL+Hamers&#x00026;author=VC+Marconi&#x00026;author=K+Brooks&#x00026;publication_year=2016&#x00026;title=Global+epidemiology+of+drug+resistance+after+failure+of+WHO+recommended+first-line+regimens+for+adult+HIV-1+infection:+a+multicentre+retrospective+cohort+study&#x00026;journal=Lancet+Infect+Dis&#x00026;volume=16&#x00026;pages=565-75" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref15" id="ref15"></a>15. Kouamou, V, Varyani, B, Shamu, T, and Mapangisana, T. Drug resistance among adolescents and young adults and response to second-line treatment. <i>AIDS Res. Hum. Retrovir</i>. (2020) 36:566&#x2013;73. doi: 10.1089/AID.2019.0232</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1089/AID.2019.0232" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V+Kouamou&#x00026;author=B+Varyani&#x00026;author=T+Shamu&#x00026;author=T+Mapangisana&#x00026;publication_year=2020&#x00026;title=Drug+resistance+among+adolescents+and+young+adults+and+response+to+second-line+treatment&#x00026;journal=AIDS+Res.+Hum.+Retrovir&#x00026;volume=36&#x00026;pages=566-73" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref16" id="ref16"></a>16. Dorward, J, and Hamers, RL. Dolutegravir in sub-Saharan Africa: context is crucial. <i>Lancet HIV</i>. (2019) 6:e72&#x2013;3. doi: 10.1016/S2352-3018(18)30331-X</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/S2352-3018(18)30331-X" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Dorward&#x00026;author=RL+Hamers&#x00026;publication_year=2019&#x00026;title=Dolutegravir+in+sub-Saharan+Africa:+context+is+crucial&#x00026;journal=Lancet+HIV&#x00026;volume=6&#x00026;pages=e72-3" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref17" id="ref17"></a>17. WHO. WHO recommends dolutegravir as preferred HIV treatment option in all populations. (2019). Available at: <a href="https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations">https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations</a> (Accessed on 2021 Mar 26)</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2019&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref18" id="ref18"></a>18. El-sadr, WM, Rabkin, M, Nkengasong, J, and Birx, DL. Realizing the potential of routine viral load testing in sub-Saharan Africa <i>J Int AIDS Soc</i>. (2017) 20:1&#x2013;3. doi: 10.1002/jia2.25010 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29130621" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/jia2.25010" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WM+El-sadr&#x00026;author=M+Rabkin&#x00026;author=J+Nkengasong&#x00026;author=DL+Birx&#x00026;publication_year=2017&#x00026;title=Realizing+the+potential+of+routine+viral+load+testing+in+sub-Saharan+Africa&#x00026;journal=J+Int+AIDS+Soc&#x00026;volume=20&#x00026;pages=1-3" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref19" id="ref19"></a>19. WHO. What&#x2019;s new in treatment monitoring: Viral load and CD4 testing. HIV Treat care. (2017); Available at: <a href="https://www.who.int/publications-detail-redirect/WHO-HIV-2017.22">https://www.who.int/publications-detail-redirect/WHO-HIV-2017.22</a> (Accessed March 26, 2021).</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2017&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref20" id="ref20"></a>20. Opoku, S, Sakyi, SA, Ayisi-Boateng, NK, Enimil, AK, Senu, E, Ansah, RO, et al. Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana. <i>AIDS Res Ther BioMed Central</i>. (2022) 19:1&#x2013;10. doi: 10.1186/s12981-022-00447-2 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/35614510" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12981-022-00447-2" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Opoku&#x00026;author=SA+Sakyi&#x00026;author=NK+Ayisi-Boateng&#x00026;author=AK+Enimil&#x00026;author=E+Senu&#x00026;author=RO+Ansah&#x00026;publication_year=2022&#x00026;title=Factors+associated+with+viral+suppression+and+rebound+among+adult+HIV+patients+on+treatment:+a+retrospective+study+in+Ghana&#x00026;journal=AIDS+Res+Ther+BioMed+Central&#x00026;volume=19&#x00026;pages=1-10" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref21" id="ref21"></a>21. Liu, T, Chambers, LC, Hansen, B, Bazerman, LB, Cachay, ER, Christopoulos, K, et al. Risk of HIV viral rebound in the era of universal treatment in a multi-center sample of persons with HIV in primary care. <i>Open Forum Infect Dis</i>. (2023) 10:1&#x2013;11. doi: 10.1093/ofid/ofad257 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/37351454" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/ofid/ofad257" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Liu&#x00026;author=LC+Chambers&#x00026;author=B+Hansen&#x00026;author=LB+Bazerman&#x00026;author=ER+Cachay&#x00026;author=K+Christopoulos&#x00026;publication_year=2023&#x00026;title=Risk+of+HIV+viral+rebound+in+the+era+of+universal+treatment+in+a+multi-center+sample+of+persons+with+HIV+in+primary+care&#x00026;journal=Open+Forum+Infect+Dis&#x00026;volume=10&#x00026;pages=1-11" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref22" id="ref22"></a>22. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. (2016). Available at: <a href="https://www.who.int/hiv/pub/guidelines/keypopulations-2016/en/">https://www.who.int/hiv/pub/guidelines/keypopulations-2016/en/</a> (Accessed on 2020 Aug 24)</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2016&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref23" id="ref23"></a>23. Ekong, E, Ndembi, N, Okonkwo, P, Dakum, P, Idoko, J, Banigbe, B, et al. Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria. <i>AIDS Res Ther BioMed Central</i>. (2020) 17:7&#x2013;8. doi: 10.1186/s12981-020-0261-z </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32066473" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12981-020-0261-z" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Ekong&#x00026;author=N+Ndembi&#x00026;author=P+Okonkwo&#x00026;author=P+Dakum&#x00026;author=J+Idoko&#x00026;author=B+Banigbe&#x00026;publication_year=2020&#x00026;title=Epidemiologic+and+viral+predictors+of+antiretroviral+drug+resistance+among+persons+living+with+HIV+in+a+large+treatment+program+in+Nigeria&#x00026;journal=AIDS+Res+Ther+BioMed+Central&#x00026;volume=17&#x00026;pages=7-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref24" id="ref24"></a>24. Rossouw, TM, Feucht, UD, Melikian, G, Van Dyk, G, Thomas, W, Du Plessis, NM, et al. Factors associated with the development of drug resistance mutations in HIV-1 infected children failing protease inhibitor-based antiretroviral therapy in South Africa. <i>PLoS One</i>. (2015) 10:1&#x2013;16. doi: 10.1371/journal.pone.0133452 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26196688" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0133452" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TM+Rossouw&#x00026;author=UD+Feucht&#x00026;author=G+Melikian&#x00026;author=G+Van+Dyk&#x00026;author=W+Thomas&#x00026;author=NM+Du+Plessis&#x00026;publication_year=2015&#x00026;title=Factors+associated+with+the+development+of+drug+resistance+mutations+in+HIV-1+infected+children+failing+protease+inhibitor-based+antiretroviral+therapy+in+South+Africa&#x00026;journal=PLoS+One&#x00026;volume=10&#x00026;pages=1-16" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref25" id="ref25"></a>25. Bonney, EY, Lamptey, H, Aboagye, JO, Zaab-Yen Abana, C, Boateng, AT, Quansah, DNK, et al. Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research. <i>J Virus Erad</i>. (2021) 7:100027. doi: 10.1016/j.jve.2020.100027 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33437495" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jve.2020.100027" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EY+Bonney&#x00026;author=H+Lamptey&#x00026;author=JO+Aboagye&#x00026;author=C+Zaab-Yen+Abana&#x00026;author=AT+Boateng&#x00026;author=DNK+Quansah&#x00026;publication_year=2021&#x00026;title=Unwillingness+of+patients+in+Ghana+to+interrupt+antiretroviral+therapy+for+HIV+cure+research&#x00026;journal=J+Virus+Erad&#x00026;volume=7&#x00026;pages=100027" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref26" id="ref26"></a>26. Ghana AIDS Commission. Ghana&#x2019;s HIV fact sheet 2019. (2020). Available at: <a href="https://www.ghanaids.gov.gh/mcadmin/Uploads/2019/FACT/SHEET/22/06/2020/revised(1).pdf">https://www.ghanaids.gov.gh/mcadmin/Uploads/2019/FACT/SHEET/22/06/2020/revised(1).pdf</a> (Accessed on 2023 Mar 21)</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2020&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref27" id="ref27"></a>27. Ali, JH, and Yirtaw, TG. Time to viral load suppression and its associated factors in cohort of patients taking antiretroviral treatment in east Shewa zone, Oromiya, Ethiopia, 2018. <i>BMC Infect Dis</i>. (2019) 19:1&#x2013;6. doi: 10.1186/s12879-019-4702-z</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1186/s12879-019-4702-z" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JH+Ali&#x00026;author=TG+Yirtaw&#x00026;publication_year=2019&#x00026;title=Time+to+viral+load+suppression+and+its+associated+factors+in+cohort+of+patients+taking+antiretroviral+treatment+in+east+Shewa+zone+Oromiya+Ethiopia+2018&#x00026;journal=BMC+Infect+Dis&#x00026;volume=19&#x00026;pages=1-6" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref28" id="ref28"></a>28. Ghana National AIDS Control Programme. Guidelines for antiretroviral therapy in Ghana. (2017). Available at: <a href="https://www.ccmghana.net/index.php/policies-guidelines?download=199:art-guidelinesrevised-2017">https://www.ccmghana.net/index.php/policies-guidelines?download=199:art-guidelinesrevised-2017</a> (Accessed on 2023 Mar 21)</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2017&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref29" id="ref29"></a>29. Alhassan, RK, Ketor, CE, Ashinyo, A, Ashinyo, ME, Nutor, JJ, Adjadeh, C, et al. Quality of antiretroviral therapy services in Ghana: implications for the HIV response in resourceconstrained settings. <i>SAGE Open Med</i>. (2021) 9:205031212110361. doi: 10.1177/20503121211036142 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34377475" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1177/20503121211036142" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RK+Alhassan&#x00026;author=CE+Ketor&#x00026;author=A+Ashinyo&#x00026;author=ME+Ashinyo&#x00026;author=JJ+Nutor&#x00026;author=C+Adjadeh&#x00026;publication_year=2021&#x00026;title=Quality+of+antiretroviral+therapy+services+in+Ghana:+implications+for+the+HIV+response+in+resourceconstrained+settings&#x00026;journal=SAGE+Open+Med&#x00026;volume=9&#x00026;pages=205031212110361" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref30" id="ref30"></a>30. Ghana AIDS Commission. National HIV and AIDS policy: Universal access to HIV prevention, treatment and care services towards ending AIDS as a public health threat. Office of the President. (2019). Available from: <a href="https://www.ghanaids.gov.gh">https://www.ghanaids.gov.gh</a> (Accessed March 21, 2021).</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref31" id="ref31"></a>31. Wakooko, P, Gavamukulya, Y, and Wandabwa, JN. Viral load suppression and associated factors among HIV patients on antiretroviral treatment in Bulambuli District, eastern Uganda: a retrospective cohort study. <i>Infect Dis Res Treat</i>. (2020) 13:117863372097063. doi: 10.1177/1178633720970632 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33223836" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1177/1178633720970632" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Wakooko&#x00026;author=Y+Gavamukulya&#x00026;author=JN+Wandabwa&#x00026;publication_year=2020&#x00026;title=Viral+load+suppression+and+associated+factors+among+HIV+patients+on+antiretroviral+treatment+in+Bulambuli+District+eastern+Uganda:+a+retrospective+cohort+study&#x00026;journal=Infect+Dis+Res+Treat&#x00026;volume=13&#x00026;pages=117863372097063" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref32" id="ref32"></a>32. Mogosetsi, NJ, Mabuza, LH, and Ogunbanjo, GA. The prevalence of HIV load suppression and related factors among patients on ART at Phedisong 4 clinic, Pretoria, South Africa. <i>Open Public Health J</i>. (2018) 11:135&#x2013;46. doi: 10.2174/1874944501811010135</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.2174/1874944501811010135" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=NJ+Mogosetsi&#x00026;author=LH+Mabuza&#x00026;author=GA+Ogunbanjo&#x00026;publication_year=2018&#x00026;title=The+prevalence+of+HIV+load+suppression+and+related+factors+among+patients+on+ART+at+Phedisong+4+clinic+Pretoria+South+Africa&#x00026;journal=Open+Public+Health+J&#x00026;volume=11&#x00026;pages=135-46" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref33" id="ref33"></a>33. Abdullahi, SB, Ibrahim, OR, Okeji, AB, Yandoma, RI, Bashir, I, Haladu, S, et al. Viral suppression among HIV-positive patients on antiretroviral therapy in northwestern Nigeria: an eleven-year review of tertiary care Centre records, January 2009&#x2013;December 2019. <i>BMC Infect Dis BioMed Central</i>. (2021) 21:1&#x2013;8. doi: 10.1186/s12879-021-06722-3 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34600477" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12879-021-06722-3" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SB+Abdullahi&#x00026;author=OR+Ibrahim&#x00026;author=AB+Okeji&#x00026;author=RI+Yandoma&#x00026;author=I+Bashir&#x00026;author=S+Haladu&#x00026;publication_year=2021&#x00026;title=Viral+suppression+among+HIV-positive+patients+on+antiretroviral+therapy+in+northwestern+Nigeria:+an+eleven-year+review+of+tertiary+care+Centre+records+January+2009&#x2013;December+2019&#x00026;journal=BMC+Infect+Dis+BioMed+Central&#x00026;volume=21&#x00026;pages=1-8" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref34" id="ref34"></a>34. ABD, D, Penda, CI, Madec, Y, Ngondi, GD, Moukoko, A, Varloteaux, M, et al. Viral load suppression in HIV-infected adolescents in Cameroon: towards achieving the UNAIDS 95% viral suppression target. <i>BMC Pediatr</i>. (2023) 23:1&#x2013;8.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?author=D+ABD&#x00026;author=CI+Penda&#x00026;author=Y+Madec&#x00026;author=GD+Ngondi&#x00026;author=A+Moukoko&#x00026;author=M+Varloteaux&#x00026;publication_year=2023&#x00026;title=Viral+load+suppression+in+HIV-infected+adolescents+in+Cameroon:+towards+achieving+the+UNAIDS+95%+viral+suppression+target&#x00026;journal=BMC+Pediatr&#x00026;volume=23&#x00026;pages=1-8" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref35" id="ref35"></a>35. Woldesenbet, SA, Kufa, T, Barron, P, Chirombo, BC, Cheyip, M, Ayalew, K, et al. Viral suppression and factors associated with failure to achieve viral suppression among pregnant women in South Africa. <i>AIDS</i>. (2020) 34:589&#x2013;97. doi: 10.1097/QAD.0000000000002457 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31821189" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/QAD.0000000000002457" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SA+Woldesenbet&#x00026;author=T+Kufa&#x00026;author=P+Barron&#x00026;author=BC+Chirombo&#x00026;author=M+Cheyip&#x00026;author=K+Ayalew&#x00026;publication_year=2020&#x00026;title=Viral+suppression+and+factors+associated+with+failure+to+achieve+viral+suppression+among+pregnant+women+in+South+Africa&#x00026;journal=AIDS&#x00026;volume=34&#x00026;pages=589-97" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref36" id="ref36"></a>36. Dzando, G, Salifu, S, Donyi, AB, Akpeke, H, Kumah, A, Dordunu, R, et al. Healthcare in Ghana amidst the coronavirus pandemic: a narrative literature review. <i>J Public Health Res</i>. (2022) 11:2448. doi: 10.4081/jphr.2021.2448 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34351103" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4081/jphr.2021.2448" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Dzando&#x00026;author=S+Salifu&#x00026;author=AB+Donyi&#x00026;author=H+Akpeke&#x00026;author=A+Kumah&#x00026;author=R+Dordunu&#x00026;publication_year=2022&#x00026;title=Healthcare+in+Ghana+amidst+the+coronavirus+pandemic:+a+narrative+literature+review&#x00026;journal=J+Public+Health+Res&#x00026;volume=11&#x00026;pages=2448" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref37" id="ref37"></a>37. Palmer, A, Gabler, K, Rachlis, B, Ding, E, Chia, J, Bacani, N, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. <i>Med (United States)</i>. (2018) 97:e10562. doi: 10.1097/MD.0000000000010562</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1097/MD.0000000000010562" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Palmer&#x00026;author=K+Gabler&#x00026;author=B+Rachlis&#x00026;author=E+Ding&#x00026;author=J+Chia&#x00026;author=N+Bacani&#x00026;publication_year=2018&#x00026;title=Viral+suppression+and+viral+rebound+among+young+adults+living+with+HIV+in+Canada&#x00026;journal=Med+(United+States)&#x00026;volume=97&#x00026;pages=e10562" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref38" id="ref38"></a>38. CATIE. HIV treatment and an undetectable viral load to prevent HIV transmission. Canada&#x2019;s source for HIV and hepatitis C information. (2023). Available at: <a href="https://www.catie.ca/hiv-treatment-and-an-undetectable-viral-load-toprevent-hiv-transmission">https://www.catie.ca/hiv-treatment-and-an-undetectable-viral-load-toprevent-hiv-transmission</a> (Accessed on 2022 Oct 18)</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?publication_year=2023&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref39" id="ref39"></a>39. Centers for Disease Control and Prevention. Evidence of HIV treatment and viral suppression in preventing the sexual transmission of HIV. 2020. Available from: <a href="https://www.cdc.gov">https://www.cdc.gov</a> (Accessed March 26, 2021).</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?title=Evidence+of+HIV+treatment+and+viral+suppression+in+preventing+the+sexual+transmission+of+HIV&#x00026;" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref40" id="ref40"></a>40. Campos, N, Myburgh, R, Garcel, A, Vautrin, A, Lapasset, L, Nadal, ES, et al. Long lasting control of viral rebound with a new drug ABX464 targeting rev - mediated viral RNA biogenesis. <i>Retrovirology</i>. (2015) 12:1&#x2013;15. doi: 10.1186/s12977-015-0159-3 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25889234" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12977-015-0159-3" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Campos&#x00026;author=R+Myburgh&#x00026;author=A+Garcel&#x00026;author=A+Vautrin&#x00026;author=L+Lapasset&#x00026;author=ES+Nadal&#x00026;publication_year=2015&#x00026;title=Long+lasting+control+of+viral+rebound+with+a+new+drug+ABX464+targeting+rev+-+mediated+viral+RNA+biogenesis&#x00026;journal=Retrovirology&#x00026;volume=12&#x00026;pages=1-15" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref41" id="ref41"></a>41. Min, S, Gillani, FS, Aung, S, Garland, JM, and Beckwith, CG. Evaluating HIV viral rebound among persons on suppressive antiretroviral treatment in the era of &#x201C;undetectable equals Untransmittable (U=U).&#x201D;. <i>Open Forum Infect Dis</i>. (2020) 7:1&#x2013;9. doi: 10.1186/s12879-024-10241-2</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1186/s12879-024-10241-2" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Min&#x00026;author=FS+Gillani&#x00026;author=S+Aung&#x00026;author=JM+Garland&#x00026;author=CG+Beckwith&#x00026;publication_year=2020&#x00026;title=Evaluating+HIV+viral+rebound+among+persons+on+suppressive+antiretroviral+treatment+in+the+era+of+&#x201C;undetectable+equals+Untransmittable+(U=U).&#x201D;&#x00026;journal=Open+Forum+Infect+Dis&#x00026;volume=7&#x00026;pages=1-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref42" id="ref42"></a>42. Leddy, AM, Turan, JM, Johnson, MO, Neilands, TB, Kempf, MC, Konkle-Parker, D, et al. Poverty stigma is associated with suboptimal HIV care and treatment outcomes among women living with HIV in the United States. <i>AIDS</i>. (2019) 33:1379&#x2013;84. doi: 10.1097/QAD.0000000000002189 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30870197" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/QAD.0000000000002189" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AM+Leddy&#x00026;author=JM+Turan&#x00026;author=MO+Johnson&#x00026;author=TB+Neilands&#x00026;author=MC+Kempf&#x00026;author=D+Konkle-Parker&#x00026;publication_year=2019&#x00026;title=Poverty+stigma+is+associated+with+suboptimal+HIV+care+and+treatment+outcomes+among+women+living+with+HIV+in+the+United+States&#x00026;journal=AIDS&#x00026;volume=33&#x00026;pages=1379-84" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref43" id="ref43"></a>43. Haas, AD, Radin, E, Hakim, AJ, Jahn, A, Philip, NM, Jonnalagadda, S, et al. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys. <i>J Int AIDS Soc</i>. (2020) 23:1&#x2013;12. doi: 10.1002/jia2.25631 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33225559" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/jia2.25631" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AD+Haas&#x00026;author=E+Radin&#x00026;author=AJ+Hakim&#x00026;author=A+Jahn&#x00026;author=NM+Philip&#x00026;author=S+Jonnalagadda&#x00026;publication_year=2020&#x00026;title=Prevalence+of+nonsuppressed+viral+load+and+associated+factors+among+HIV-positive+adults+receiving+antiretroviral+therapy+in+Eswatini+Lesotho+Malawi+Zambia+and+Zimbabwe+(2015+to+2017):+results+from+population-based+nationally+representative+surveys&#x00026;journal=J+Int+AIDS+Soc&#x00026;volume=23&#x00026;pages=1-12" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref44" id="ref44"></a>44. Ng&#x2019;ambi, W, Estill, J, Jahn, A, Orel, E, Chimpandule, T, Nyirenda, R, et al. Factors associated with the incidence rate of HIV viral rebound among children and adults receiving antiretroviral therapy in Malawi using the laboratory management information system: 2011-2020. <i>medRxiv</i>. (2021) 2021:21264672. doi: 10.1101/2021.10.07.21264672v1.abstract</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1101/2021.10.07.21264672v1.abstract" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W+Ng&#x2019;ambi&#x00026;author=J+Estill&#x00026;author=A+Jahn&#x00026;author=E+Orel&#x00026;author=T+Chimpandule&#x00026;author=R+Nyirenda&#x00026;publication_year=2021&#x00026;title=Factors+associated+with+the+incidence+rate+of+HIV+viral+rebound+among+children+and+adults+receiving+antiretroviral+therapy+in+Malawi+using+the+laboratory+management+information+system:+2011-2020&#x00026;journal=medRxiv&#x00026;volume=2021&#x00026;pages=21264672" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref45" id="ref45"></a>45. Diress, G, Dagne, S, Alemnew, B, Adane, S, and Addisu, A. Viral load suppression after enhanced adherence counseling and its predictors among high viral load HIV seropositive people in north Wollo zone public hospitals, Northeast Ethiopia, 2019: retrospective cohort study. <i>AIDS Res Treat</i>. (2020) 2020:1&#x2013;9. doi: 10.1155/2020/8909232 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32373359" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1155/2020/8909232" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Diress&#x00026;author=S+Dagne&#x00026;author=B+Alemnew&#x00026;author=S+Adane&#x00026;author=A+Addisu&#x00026;publication_year=2020&#x00026;title=Viral+load+suppression+after+enhanced+adherence+counseling+and+its+predictors+among+high+viral+load+HIV+seropositive+people+in+north+Wollo+zone+public+hospitals+Northeast+Ethiopia+2019:+retrospective+cohort+study&#x00026;journal=AIDS+Res+Treat&#x00026;volume=2020&#x00026;pages=1-9" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref46" id="ref46"></a>46. Joseph Davey, D, Abrahams, Z, Feinberg, M, Prins, M, Serrao, C, Medeossi, B, et al. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on firstline antiretroviral therapy in South Africa. <i>Int J STD AIDS</i>. (2018) 29:603&#x2013;10. doi: 10.1177/0956462417748859 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29334886" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1177/0956462417748859" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Joseph+Davey&#x00026;author=Z+Abrahams&#x00026;author=M+Feinberg&#x00026;author=M+Prins&#x00026;author=C+Serrao&#x00026;author=B+Medeossi&#x00026;publication_year=2018&#x00026;title=Factors+associated+with+recent+unsuppressed+viral+load+in+HIV-1-infected+patients+in+care+on+firstline+antiretroviral+therapy+in+South+Africa&#x00026;journal=Int+J+STD+AIDS&#x00026;volume=29&#x00026;pages=603-10" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref47" id="ref47"></a>47. Crespo-bermejo, C, Ram&#x000ED;rez, E, Arellano, D, Lara-aguilar, V, Valle-millares, D, and G&#x000F3;mez-, ML. Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status. <i>Virulence</i>. (2021) 12:2919&#x2013;31. doi: 10.1080/21505594.2021.2004743 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34874239" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/21505594.2021.2004743" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Crespo-bermejo&#x00026;author=E+Ram&#x000ED;rez&#x00026;author=D+Arellano&#x00026;author=V+Lara-aguilar&#x00026;author=D+Valle-millares&#x00026;author=ML+G&#x000F3;mez-&#x00026;publication_year=2021&#x00026;title=Persistent+low-level+viremia+in+persons+living+with+HIV+undertreatment:+an+unresolved+status&#x00026;journal=Virulence&#x00026;volume=12&#x00026;pages=2919-31" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref48" id="ref48"></a>48. Swenson, LC, Min, JE, Woods, CK, Cai, E, Li, JZ, Montaner, JSG, et al. HIV drug resistance detected during low-level viremia is associated with subsequent Virologic failure. <i>AIDS</i>. (2014) 28:1125&#x2013;34. doi: 10.1097/QAD.0000000000000203 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24451160" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/QAD.0000000000000203" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LC+Swenson&#x00026;author=JE+Min&#x00026;author=CK+Woods&#x00026;author=E+Cai&#x00026;author=JZ+Li&#x00026;author=JSG+Montaner&#x00026;publication_year=2014&#x00026;title=HIV+drug+resistance+detected+during+low-level+viremia+is+associated+with+subsequent+Virologic+failure&#x00026;journal=AIDS&#x00026;volume=28&#x00026;pages=1125-34" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref49" id="ref49"></a>49. Joya, C, Won, SH, Schofield, C, Lalani, T, Maves, RC, Kronmann, K, et al. Persistent Lowlevel viremia while on antiretroviral therapy is an independent risk factor for Virologic failure. <i>Clin Infect Dis</i>. (2019) 69:2145&#x2013;52. doi: 10.1093/cid/ciz129</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1093/cid/ciz129" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Joya&#x00026;author=SH+Won&#x00026;author=C+Schofield&#x00026;author=T+Lalani&#x00026;author=RC+Maves&#x00026;author=K+Kronmann&#x00026;publication_year=2019&#x00026;title=Persistent+Lowlevel+viremia+while+on+antiretroviral+therapy+is+an+independent+risk+factor+for+Virologic+failure&#x00026;journal=Clin+Infect+Dis&#x00026;volume=69&#x00026;pages=2145-52" target="_blank">Google Scholar</a></p></div>
<div class="References">
<p class="ReferencesCopy1"><a name="ref50" id="ref50"></a>50. Villalobos, C, Ceballos, ME, Ferr&#x000E9;s, M, and Palma, C. Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia. <i>J Clin Virol</i>. (2020) 132:104657. doi: 10.1016/j.jcv.2020.104657 </p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33049643" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jcv.2020.104657" target="_blank">Crossref Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Villalobos&#x00026;author=ME+Ceballos&#x00026;author=M+Ferr&#x000E9;s&#x00026;author=C+Palma&#x00026;publication_year=2020&#x00026;title=Drug+resistance+mutations+in+proviral+DNA+of+HIV-infected+patients+with+low+level+of+viremia&#x00026;journal=J+Clin+Virol&#x00026;volume=132&#x00026;pages=104657" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="ref51" id="ref51"></a>51. Fhi360. Reaching the Third 95: Viral Load Suppression among Key Population Individuals Living with HIV [Technical brief]. FHI 360. (2019). Available from: <a href="https://www.fhi360.org/LINKAGES">https://www.fhi360.org/LINKAGES</a> (Accessed October 18, 2022).</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?" target="_blank">Google Scholar</a></p></div> <a id="h16" name="h16"></a>
<h2>Glossary</h2>
<p class="mb15"><b>HIV &#x2013;</b>  Human Immunodeficiency Virus<br>
<b>AIDS &#x2013;</b>  Acquired Immunodeficiency Syndrome<br>
<b>PLWH &#x2013;</b>  People living with HIV<br>
<b>ART &#x2013;</b>  Antiretroviral therapy<br>
<b>SSA &#x2013;</b>  Sub-Saharan Africa<br>
<b>NNRTI &#x2013;</b>  Non-nucleoside reverse transcriptase inhibitor<br>
<b>NRTI &#x2013;</b>  Nucleos(t)ide reverse transcriptase inhibitor<br>
<b>INSTI &#x2013;</b>  Integrase strand transfer inhibitor<br>
<b>NVP &#x2013;</b>  Nevirapine<br>
<b>EFV &#x2013;</b>  Efavirenz<br>
<b>3TC &#x2013;</b>  Lamivudine<br>
<b>AZT &#x2013;</b>  Zidovudine<br>
<b>TDF &#x2013;</b>  Tenofovir disoproxil fumarate<br>
<b>DTG &#x2013;</b>  Dolutegravir<br>
<b>H-CRIS &#x2013;</b>  HIV Cure Research Infrastructure Study<br>
<b>NMIMR &#x2013;</b>  Noguchi Memorial Institute for Medical Research<br>
<b>PBMC &#x2013;</b>  Peripheral blood mononuclear cells<br>
<b>PBS &#x2013;</b>  Phosphate buffered saline<br>
<b>FBS &#x2013;</b>  Fetal bovine serum<br>
<b>DMSO &#x2013;</b>  Dimethyl sulfoxide<br>
<b>RLS &#x2013;</b>  Resource-limited setting<br>
<b>Ml &#x2013;</b>  Milliliters<br>
<b>&#x03BC;l &#x2013;</b>  Microliters</p>
</div> <div class="thinLineM20"></div> <div class="AbstractSummary">
<p><span>Keywords:</span> viral rebound, viral suppression, viral load, ART, HIV</p>
<p><span>Citation:</span> Boateng AT, Aboagye JO, Lamptey H, Abana CZ-Y, Abaidoo-Myles A, Quansah DNK, Agyemang S, Awuku-Larbi Y, Ansa G, Oliver-Commey J, Ganu V, Kyei GB, Puplampu P and Bonney EY (2025) Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana. <i>Front. Public Health</i>. 13:1508793. doi: 10.3389/fpubh.2025.1508793</p>
<p class="timestamps"><span>Received:</span> 09 October 2024; <span>Accepted:</span> 27 February 2025;<br> <span>Published:</span> 19 March 2025.</p> <div>
<p>Edited by:</p> <a href="https://loop.frontiersin.org/people/2815320/overview">Benard Kulohoma</a>, International AIDS Vaccine Initiative Inc., United States</div> <div>
<p>Reviewed by:</p> <a href="https://loop.frontiersin.org/people/581433/overview">Adetayo Emmanuel Obasa</a>, Stellenbosch University, South Africa<br> <a href="https://loop.frontiersin.org/people/355398/overview">Olivier Mukuku</a>, University of KwaZulu Natal, South Africa</div>
<p><span>Copyright</span> &#x000A9; 2025 Boateng, Aboagye, Lamptey, Abana, Abaidoo-Myles, Quansah, Agyemang, Awuku-Larbi, Ansa, Oliver-Commey, Ganu, Kyei, Puplampu and Bonney. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>&#x0002A;Correspondence:</span> George B. Kyei, <a id="encmail">Z2t5ZWlAbm9ndWNoaS51Zy5lZHUuZ2g=</a>; Peter Puplampu, <a id="encmail">cHB1cGxhbXB1QHVnLmVkdS5naA==</a>; Evelyn Y. Bonney, <a id="encmail">ZWJvbm5leUBub2d1Y2hpLnVnLmVkdS5naA==</a></p> <div class="clear"></div> </div></div></div> <p class="AbstractSummary__disclaimer"><span>Disclaimer: </span>
      All claims expressed in this article are solely those of the authors and
      do not necessarily represent those of their affiliated organizations, or
      those of the publisher, the editors and the reviewers. Any product that
      may be evaluated in this article or claim that may be made by its
      manufacturer is not guaranteed or endorsed by the publisher.
    </p></div></div></main> <aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div id="FloatingButtonsEl" class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--type ActionsDropDown__button--icon"><span class="ActionsDropDown__button__label">Download article</span></button> <div class="ActionsDropDown__menuWrapper"><!----> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/pdf" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-pdf" class="ActionsDropDown__option">
          Download PDF
        </a></li><li><a href="http://www.readcube.com/articles/10.3389/fpubh.2025.1508793" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-readCube" class="ActionsDropDown__option">
          ReadCube
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/epub" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-epub" class="ActionsDropDown__option">
          epub
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/xml/nlm" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-nlmXml" class="ActionsDropDown__option">
          XML (NLM)
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div> <div class="ArticleDetails__aside__responsiveButtons__items"><!----> <div class="ArticleDetailsShare__responsive"><button aria-label="Open share options" class="ArticleDetailsShare__trigger"></button> <div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p> <ul class="ArticleDetailsShare__list"><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full" target="_blank" title="Share on X" aria-label="Share on X" class="ArticleDetailsShare__link ArticleDetailsShare__link--x"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full" target="_blank" title="Share on Linkedin" aria-label="Share on Linkedin" class="ArticleDetailsShare__link ArticleDetailsShare__link--linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full" target="_blank" title="Share on Facebook" aria-label="Share on Facebook" class="ArticleDetailsShare__link ArticleDetailsShare__link--facebook"></a></li></ul></div></div> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote"><!----></button> <div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">
      Export citation
    </div> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/endNote" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-endNote" class="ActionsDropDown__option">
          EndNote
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/reference" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-referenceManager" class="ActionsDropDown__option">
          Reference Manager
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/text" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-simpleTextFile" class="ActionsDropDown__option">
          Simple Text file
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/bibTex" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-bibTex" class="ActionsDropDown__option">
          BibTex
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div></div></div> <div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">
        87
      </div> <div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div> <!----> <!----> <div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button> <div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button> <div class="ImpactMetricsInfoPopover__tooltip__text">
      Citation numbers are available from Dimensions
    </div></div></div></div> <div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1508793#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View article impact</span></a></span></div> <div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fpubh.2025.1508793" data-condensed="true" data-link-target="new" class="altmetric-embed"></div> <span class="Link__wrapper"><a aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fpubh.2025.1508793" target="_blank" data-event="customLink-link-a_viewAltmetricScore" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View altmetric score</span></a></span></div></div> <div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p> <ul class="ArticleDetailsShare__list"><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full" target="_blank" title="Share on X" aria-label="Share on X" class="ArticleDetailsShare__link ArticleDetailsShare__link--x"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full" target="_blank" title="Share on Linkedin" aria-label="Share on Linkedin" class="ArticleDetailsShare__link ArticleDetailsShare__link--linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1508793/full" target="_blank" title="Share on Facebook" aria-label="Share on Facebook" class="ArticleDetailsShare__link ArticleDetailsShare__link--facebook"></a></li></ul></div> <div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div> <a href="https://loop.frontiersin.org/people/2815320/overview" data-event="editorInfo-a-benardKulohoma" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/2815320/32" alt="Benard Kulohoma" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">
      Benard Kulohoma
    </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">
      
    </div></div></a></div></div> <div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div> <a href="https://loop.frontiersin.org/people/355398/overview" data-event="editorInfo-a-olivierMukuku" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/355398/32" alt="Olivier Mukuku" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">
      Olivier Mukuku
    </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">
      
    </div></div></a><a href="https://loop.frontiersin.org/people/581433/overview" data-event="editorInfo-a-adetayoEmmanuelObasa" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/581433/32" alt="Adetayo Emmanuel Obasa" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">
      Adetayo Emmanuel Obasa
    </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">
      
    </div></div></a></div></div> <div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div> <div class="ArticleDetailsGlossary__header__arrow"></div></button> <div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"> <li><a href="#h1">Abstract</a></li> <li><a href="#h2">Introduction</a></li> <li><a href="#h3">Materials and methods</a></li> <li><a href="#h4">Results</a></li> <li><a href="#h5">Discussion</a></li> <li><a href="#h6">Conclusion</a></li> <li><a href="#h7">Data availability statement</a></li> <li><a href="#h8">Ethics statement</a></li> <li><a href="#h9">Author contributions</a></li> <li><a href="#h10">Funding</a></li> <li><a href="#h11">Acknowledgments</a></li> <li><a href="#h12">Conflict of interest</a></li> <li><a href="#h13">Generative AI statement</a></li> <li><a href="#h14">Publisher&#x2019;s note</a></li> <li><a href="#h15">References</a></li> <li><a href="#h16">Glossary</a></li> </ul></div></div> <!----> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote"><span class="ActionsDropDown__button__label">Export citation</span></button> <div class="ActionsDropDown__menuWrapper"><!----> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/endNote" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-endNote" class="ActionsDropDown__option">
          EndNote
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/reference" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-referenceManager" class="ActionsDropDown__option">
          Reference Manager
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/text" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-simpleTextFile" class="ActionsDropDown__option">
          Simple Text file
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/bibTex" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-bibTex" class="ActionsDropDown__option">
          BibTex
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div> <div class="CheckForUpdates"><button data-target="crossmark" data-event="checkForUpdates-btn-openModal" class="CheckForUpdates__link"><img src="/article-pages/_nuxt/img/crossmark.5c8ec60.svg" alt="Crossmark icon" class="CheckForUpdates__link__img"> <div class="CheckForUpdates__link__text">Check for updates</div></button></div> <div class="Announcement"><p class="Announcement__title">
    Research integrity at Frontiers
  </p> <article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""><source srcset="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""> <img src="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" alt="Man ultramarathon runner in the mountains he trains at sunset" loading="lazy" class="is-inside-mask"></picture> <!----></figure> <div class="CardA__info"><h2 class="CardA__title">94% of researchers rate our articles as excellent or good</h2> <p class="CardA__text">Learn more about the work of our research integrity team to safeguard the quality of each article we publish.</p> <br> <span class="Link__wrapper"><a aria-label="About our research integrity team" href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="customLink-link-a_findOutMore" class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right"><span>Find out more </span></a></span></div></div></article></div> <!----> <!----></div> <!----> <div><div class="FloatingButtons"><!----> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--type ActionsDropDown__button--iconDownload"><span class="ActionsDropDown__button__label">Download article</span></button> <div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">
      Download
    </div> <ul class="ActionsDropDown__menu"><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/pdf" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-pdf" class="ActionsDropDown__option">
          Download PDF
        </a></li><li><a href="http://www.readcube.com/articles/10.3389/fpubh.2025.1508793" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-readCube" class="ActionsDropDown__option">
          ReadCube
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/epub" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-epub" class="ActionsDropDown__option">
          epub
        </a></li><li><a href="/journals/public-health/articles/10.3389/fpubh.2025.1508793/xml/nlm" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-nlmXml" class="ActionsDropDown__option">
          XML (NLM)
        </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div></div> <!----></div></div></aside></div> <div class="Announcement Announcement--Responsive"><p class="Announcement__title">
    Research integrity at Frontiers
  </p> <article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""><source srcset="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" media=""> <img src="https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png" alt="Man ultramarathon runner in the mountains he trains at sunset" loading="lazy" class="is-inside-mask"></picture> <!----></figure> <div class="CardA__info"><h2 class="CardA__title">94% of researchers rate our articles as excellent or good</h2> <p class="CardA__text">Learn more about the work of our research integrity team to safeguard the quality of each article we publish.</p> <br> <span class="Link__wrapper"><a aria-label="About our research integrity team" href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="customLink-link-a_findOutMore" class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right"><span>Find out more </span></a></span></div></div></article></div> <div><!----></div></div></div> <!----> <footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Guidelines</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Explore</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Outreach</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----> <div class="Accordion__title">Connect</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://loop.frontiersin.org/settings/email-preferences?a=publishers" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li></ul></div></li></ul> <div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div> <span class="Link__wrapper"><a aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right"><span></span></a></span></div></div> <div class="Footer__copyright"><div><span>© 2025 Frontiers Media S.A. All rights reserved</span></div> <div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a> <span>|</span> <a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer> <div class="SnackbarWrapper"><ul class="SnackbarContainer"></ul></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB,aC,aD,aE,aF,aG,aH,aI,aJ,aK,aL,aM,aN,aO,aP,aQ,aR,aS,aT,aU,aV,aW,aX,aY,aZ,a_,a$,ba,bb,bc,bd,be,bf,bg,bh,bi,bj,bk,bl,bm,bn,bo,bp,bq,br,bs,bt,bu,bv,bw,bx,by,bz,bA,bB,bC,bD,bE,bF,bG,bH,bI,bJ,bK,bL,bM,bN,bO,bP,bQ,bR,bS,bT,bU,bV,bW,bX,bY,bZ,b_,b$,ca,cb,cc,cd,ce,cf,cg,ch,ci,cj,ck,cl,cm,cn,co,cp,cq,cr,cs,ct,cu,cv,cw,cx,cy,cz,cA,cB,cC,cD,cE,cF,cG,cH,cI,cJ,cK,cL,cM,cN,cO,cP,cQ,cR,cS,cT,cU,cV,cW,cX){aG.id=aH;aG.name=aI;aG.slug=aJ;aG.specialtyId=3773;aG.__typename="journal_section";return {layout:"ArticleLayout",data:[{}],fetch:{},error:f,state:{currentJournal:{identifier:v,name:s,slug:w,banner:[{id:"7CCE4235-8BF4-4D52-8022020C57AC98C1",src:V,name:"FPUBH_Main Visual_Cyan_Website",tags:["pandemic","c","safety","danger","smartphone","commuter","mode","inside","barrier"],type:H,width:3745,height:W,idHash:"199032aaf8eef874",archive:j,brandId:X,limited:j,fileSize:6620585,isPublic:c,original:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002F199032aaf8eef874\u002Foriginal\u002FFPUBH_Main-Visual_Cyan_Website.jpg",copyright:"Copyright (c) 2020 SmartPhotoLab\u002FShutterstock.  No use without permission.",extension:[Y],thumbnails:{mini:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002Fmini-50226AC5-79DE-4DE1-ACC02582A564B0E1.png",thul:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002Fthul-B46E7F8F-CAF8-4A31-B91A262CA70C16DB.png",webimage:V,Guidelines:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FGuidelines-FPUBH_Main Visual_Cyan_Website.png",WebsiteJpg_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteJpg_XL-FPUBH_Main Visual_Cyan_Website.jpg",WebsiteWebP_L:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteWebP_L-FPUBH_Main Visual_Cyan_Website.webp",WebsiteWebP_M:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteWebP_M-FPUBH_Main Visual_Cyan_Website.webp",WebsiteWebP_XL:Z},dateCreated:_,description:"variety of passengers ride the subway car",orientation:I,userCreated:"Caroline Sutter",watermarked:j,dateModified:_,datePublished:"2022-06-27T09:27:09Z",ecsArchiveFiles:[],propertyOptions:["414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF"],property_Channel:["frontiersin_org"],"property_Sub-Type":["Main_Visual"],property_Asset_Type:["Photography"],activeOriginalFocusPoint:{x:1873,y:1249},property_Office_Department:["Publishing"]}],description:"A multidisciplinary journal that promotes discussions on inter-sectoral public health challenges, from health promotion to climate change, transportation, environmental change, and species diversity.",mission:"\u003Cp\u003EFrontiers in Public Health publishes developments in all fields of public health research, aiming to advance our understanding of causal relationships for disease, promote community-based interventions and explore prevention at the community and individual level.\u003C\u002Fp\u003E\n\n\u003Cp\u003ELed by Field Chief Editor Paolo Vineis of Imperial College London, United Kingdom, Frontiers in Public Health welcomes submissions across all areas of the field that advances population health, furthers disease prevention and promotes health for all members of society. Topics include:\u003C\u002Fp\u003E\n \n\u003Cdiv\u003E &bull; aging and public health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; children and health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; clinical diabetes\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; digital public health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; disaster and emergency medicine\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; environmental health and exposome\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; health economics\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; infectious diseases: epidemiology and prevention\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; injury prevention and control\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; life-course epidemiology and social inequalities in health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; occupational health and safety\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; planetary health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public health education and promotion\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public health policy\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public health and nutrition\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; public mental health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; radiation and health\u003C\u002Fdiv\u003E\n\u003Cdiv\u003E &bull; substance use disorders and behavioral addictions.\u003C\u002Fdiv\u003E\n \u003Cbr\u003E\n\u003Cp\u003EThe journal welcomes submissions which advance the UN’s Sustainable Development Goals (SDG), notably SDG 3, Good Health and Well-Being, in the effort to address significant global public health concerns, preparedness and develop appropriate mitigation measures.\u003C\u002Fp\u003E\n\n\u003Cp\u003EManuscripts that focus solely on health services, clinical trials on drugs, medical imaging, and disease-specific studies that do not have a clear public health relevance, are not suitable for publication in this journal. Additionally, studies that are purely predictive or prognostic models without a relevance to public health practice or policy will not be considered. The journal does not accept papers concerning simple bibliometric studies and discourages publication of cross-sectional studies, with exceptions. Authors are welcome to submit Systematic Reviews using publicly available data, but these must adhere to the PRISMA guidelines and have a conclusion related to public health. Manuscripts reporting findings from Mendelian Randomization studies need to be accompanied by a completed \u003Ca href=\"https:\u002F\u002Fwww.strobe-mr.org\u002F\"\u003ESTROBE-MR checklist\u003C\u002Fa\u003E.\u003C\u002Fp\u003E\n\n\u003Cp\u003EFrontiers in Public Health is committed to advancing developments in the field of public health by allowing unrestricted access to articles, welcoming trials on public health interventions, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C\u002Fp\u003E\n\n— \n\n\u003Cp\u003E\u003Cstrong\u003EEthics Statement for the Tobacco Industry\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E\n \n\u003Cp\u003EIn accordance with Frontiers’ Conflict of Interest (COI) policy, for any research article that is sponsored through commercial funding, the role of the funder must be declared to Frontiers in Public Health in full. If that source of funding is tied to the vested interests of the tobacco or commercial nicotine industries or affiliated organisations, it will be rejected without passing into peer review.\u003C\u002Fp\u003E\n\n\u003Cp\u003EIf undeclared funding information of this type comes to light post-publication, a formal correction or retraction in full will take place. If a researcher has past or present affiliations or has received incentives from commercial tobacco or nicotine industries or affiliated organisations, the research article will not pass into peer review.\u003C\u002Fp\u003E\n\n\u003Cp\u003EFor industries other than tobacco or commercial nicotine, a case-by-case evaluation will be made at Editorial level. There are potential situations of conflict of interest arising e.g. from the food or cosmetics industry or other industries that produce goods that are under scrutiny for safety or that may contribute to ill health.\u003C\u002Fp\u003E\n\n\u003Cp\u003EExamples of competing interests include the following: board membership, consultancy, employment, expert testimony grants (including pending), contract research, lectures\u002Fother education events, speakers’ bureaux, patents (planned, pending or issued), receipt of equipment or supplies, royalties, stock\u002Fstock options\u002Fother forms of ownership, additional expenses not included in COIs already specified, other personal or professional relationships that may influence or appear to influence.\u003C\u002Fp\u003E\n\n\u003Cp\u003EFor more information on Frontiers VALID acceptance criteria see: https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Freview-system.\u003C\u002Fp\u003E",palette:"cyan",impactFactor:"5.2",citeScore:"3.8",citations:"140000",showTagline:f,twitter:"@FrontPubHealth",__typename:"Journal"},currentFrontiersJournal:{id:v,name:s,slug:w,printISSN:f,shortName:J,electronicISSN:K,abbreviation:$,specialtyId:f,publicationDate:f,isOnline:h,isOpenForSubmissions:h,spaceId:c,field:{id:aa,domainId:r,__typename:ab},__typename:a},articleHubSlug:e,articleHubPage:L,currentArticle:{id:1508793,doi:ac,title:M,acceptanceDate:new Date(1740645794000),receptionDate:new Date(1728502786000),publicationDate:new Date(1742342400000),isPublished:h,abstract:e,researchTopic:{id:66743,title:"Challenges in reaching the UNAIDS 95-95-95 targets in Sub-Saharan Africa: Status, \r\ninnovations, and pathways forward",articlesCount:t,isMagazinePage:i,slug:"challenges-in-reaching-the-unaids-95-95-95-targets-in-sub-saharan-africa-status-innovations-and-pathways-forward",isOpenForSubmission:h},articleType:{id:24,name:"Original Research"},stage:{id:N,name:e},keywords:["HIV","ART","viral load","viral rebound","viral suppression"],authors:[{id:j,firstName:ad,lastName:"Boateng",givenNames:ad,isCorresponding:i,isProfilePublic:i,userId:j,affiliations:[{organizationName:x,countryName:l,cityName:e,stateName:e,zipCode:e},{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:ae,firstName:af,lastName:"Aboagye",givenNames:af,isCorresponding:i,isProfilePublic:h,userId:ae,affiliations:[{organizationName:ag,countryName:l,cityName:e,stateName:e,zipCode:e},{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:ah,firstName:ai,lastName:"Lamptey",givenNames:ai,isCorresponding:i,isProfilePublic:h,userId:ah,affiliations:[{organizationName:"Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana",countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:j,firstName:aj,lastName:"Abana",givenNames:aj,isCorresponding:i,isProfilePublic:i,userId:j,affiliations:[{organizationName:x,countryName:l,cityName:e,stateName:e,zipCode:e},{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:j,firstName:ak,lastName:"Abaidoo-Myles",givenNames:ak,isCorresponding:i,isProfilePublic:i,userId:j,affiliations:[{organizationName:x,countryName:l,cityName:e,stateName:e,zipCode:e},{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:j,firstName:al,lastName:"Quansah",givenNames:al,isCorresponding:i,isProfilePublic:i,userId:j,affiliations:[{organizationName:x,countryName:l,cityName:e,stateName:e,zipCode:e},{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:am,firstName:an,lastName:"Agyemang",givenNames:an,isCorresponding:i,isProfilePublic:h,userId:am,affiliations:[{organizationName:"Central Laboratory, Immunology Department, Korle-Bu Teaching Hospital",countryName:l,cityName:e,stateName:e,zipCode:e},{organizationName:x,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:ao,firstName:ap,lastName:"Awuku-Larbi",givenNames:ap,isCorresponding:i,isProfilePublic:h,userId:ao,affiliations:[{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:j,firstName:aq,lastName:"Ansa",givenNames:aq,isCorresponding:i,isProfilePublic:i,userId:j,affiliations:[{organizationName:"Public Health Unit, University of Ghana Hospital",countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:ar,firstName:as,lastName:"Oliver-Commey",givenNames:as,isCorresponding:i,isProfilePublic:h,userId:ar,affiliations:[{organizationName:"LEKMA Hospital",countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:at,firstName:au,lastName:"Ganu",givenNames:au,isCorresponding:i,isProfilePublic:h,userId:at,affiliations:[{organizationName:av,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:aw,firstName:ax,lastName:"Kyei",givenNames:ax,isCorresponding:i,isProfilePublic:h,userId:aw,affiliations:[{organizationName:"Departments of Medicine and Molecular Microbiology, Washington University School of Medicine",countryName:"United States",cityName:e,stateName:e,zipCode:e},{organizationName:ag,countryName:l,cityName:e,stateName:e,zipCode:e},{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:j,firstName:ay,lastName:"Puplampu",givenNames:ay,isCorresponding:i,isProfilePublic:i,userId:j,affiliations:[{organizationName:av,countryName:l,cityName:e,stateName:e,zipCode:e}]},{id:az,firstName:aA,lastName:"Bonney",givenNames:aA,isCorresponding:i,isProfilePublic:h,userId:az,affiliations:[{organizationName:q,countryName:l,cityName:e,stateName:e,zipCode:e}]}],editors:[{id:aB,firstName:aC,lastName:"Kulohoma",givenNames:aC,isCorresponding:i,isProfilePublic:h,userId:aB,affiliations:[{organizationName:e,countryName:e,cityName:e,stateName:e,zipCode:e}]}],reviewers:[{id:aD,firstName:aE,lastName:"Mukuku",givenNames:aE,isCorresponding:i,isProfilePublic:h,userId:aD,affiliations:[{organizationName:e,countryName:e,cityName:e,stateName:e,zipCode:e}]},{id:aF,firstName:"Adetayo",lastName:"Obasa",givenNames:"Adetayo Emmanuel",isCorresponding:i,isProfilePublic:h,userId:aF,affiliations:[{organizationName:e,countryName:e,cityName:e,stateName:e,zipCode:e}]}],journal:{id:v,slug:w,name:s,shortName:J,electronicISSN:K,field:{id:aa,domainId:r,__typename:ab},specialtyId:f,journalSectionPaths:[{section:aG,__typename:"journal_journalSectionPath"}],__typename:a},section:aG,impactMetrics:{views:87,downloads:j,citations:j},volume:O,articleVolume:"Volume 13 - 2025",relatedArticles:[],isPublishedV2:h,contents:{titleHtml:M,fullTextHtml:"\u003Cdiv class=\"JournalAbstract\"\u003E \u003Ca id=\"h1\" name=\"h1\"\u003E\u003C\u002Fa\u003E\n \u003Cdiv class=\"authors\"\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Anthony T. Boateng,\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EAnthony T. Boateng\u003Csup\u003E1,2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F2088681\" class=\"user-id-2088681\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F2088681\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"James O. Aboagye,\"\u003EJames O. Aboagye\u003C\u002Fa\u003E\u003Csup\u003E1,3\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1254504\" class=\"user-id-1254504\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1254504\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Helena Lamptey\"\u003EHelena Lamptey\u003C\u002Fa\u003E\u003Csup\u003E4\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Christopher Z.-Y. Abana,\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EChristopher Z.-Y. Abana\u003Csup\u003E1,2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Araba Abaidoo-Myles,\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EAraba Abaidoo-Myles\u003Csup\u003E1,2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Darius N. K. Quansah,\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EDarius N. K. Quansah\u003Csup\u003E1,2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1427882\" class=\"user-id-1427882\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1427882\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Seth Agyemang,\"\u003ESeth Agyemang\u003C\u002Fa\u003E\u003Csup\u003E2,5\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1952821\" class=\"user-id-1952821\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1952821\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Yaw Awuku-Larbi\"\u003EYaw Awuku-Larbi\u003C\u002Fa\u003E\u003Csup\u003E1\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Gloria Ansa\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EGloria Ansa\u003Csup\u003E6\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F2397851\" class=\"user-id-2397851\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F2397851\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Joseph Oliver-Commey\"\u003EJoseph Oliver-Commey\u003C\u002Fa\u003E\u003Csup\u003E7\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1791348\" class=\"user-id-1791348\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1791348\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Vincent Ganu\"\u003EVincent Ganu\u003C\u002Fa\u003E\u003Csup\u003E8\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1308622\" class=\"user-id-1308622\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1308622\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"George B. Kyei,,&#xA;\"\u003EGeorge B. Kyei\u003C\u002Fa\u003E\u003Csup\u003E1,3,9\u003C\u002Fsup\u003E\u003Csup\u003E&#x0002A;\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg\" alt=\"Peter Puplampu&#xA;\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\"\u003EPeter Puplampu\u003Csup\u003E8\u003C\u002Fsup\u003E\u003Csup\u003E&#x0002A;\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003Cspan class=\"author-wrapper notranslate\"\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1307387\" class=\"user-id-1307387\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1307387\u002F74\" onerror=\"this.onerror=null;this.src='https:\u002F\u002Floop.frontiersin.org\u002Fcdn\u002Fimages\u002Fprofile\u002Fdefault_32.jpg';\" alt=\"Evelyn Y. Bonney&#xA;\"\u003EEvelyn Y. Bonney\u003C\u002Fa\u003E\u003Csup\u003E1\u003C\u002Fsup\u003E\u003Csup\u003E&#x0002A;\u003C\u002Fsup\u003E\u003C\u002Fspan\u003E\u003C\u002Fdiv\u003E \u003Cul class=\"notes\"\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E1\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EWest African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E3\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EMedical and Scientific Research Center, University of Ghana Medical Center, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E4\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EDepartment of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E5\u003C\u002Fsup\u003E\u003C\u002Fspan\u003ECentral Laboratory, Immunology Department, Korle-Bu Teaching Hospital, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E6\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EPublic Health Unit, University of Ghana Hospital, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E7\u003C\u002Fsup\u003E\u003C\u002Fspan\u003ELEKMA Hospital, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E8\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EDepartment of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana, Accra, Ghana\u003C\u002Fli\u003E \u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E9\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EDepartments of Medicine and Molecular Microbiology, Washington University School of Medicine, St Louis, MO, United States\u003C\u002Fli\u003E \u003C\u002Ful\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EIntroduction:\u003C\u002Fb\u003E Regular viral load (VL) testing for people living with HIV (PLWH) is key to attaining the Joint United Nations Program on HIV\u002FAIDS (UNAIDS) Fast-Track 95&#x2013;95-95 target to end the HIV epidemic by 2030. However, VL testing remains sporadic in routine HIV care in the majority of resource-limited settings, including Ghana, except when provided through research initiatives. In this study, we measured VL among PLWH in Ghana at regular intervals and investigated factors affecting viral suppression (VS) and rebound.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EMethods:\u003C\u002Fb\u003E We analyzed data from a hospital-based cohort enrolled in our HIV cure research. Participants were recruited from three hospitals in the Greater Accra region of Ghana. Demographic characteristics were obtained from participants&#x2019; folders, while CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell counts and VLs were measured from blood samples collected at baseline, 6&#x202F;months, and 18&#x202F;months.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EResults:\u003C\u002Fb\u003E The study participants were predominantly women (68%) with a median age of 45&#x202F;years (IQR: 21&#x2013;76&#x202F;years). A total of 52% of participants had been on antiretroviral therapy (ART) for more than 6&#x202F;years, and 74% were following dolutegravir-based regimens. At baseline, 74% of participants had a VL of &#x0003C;50 copies\u002FmL, which increased to 88% at 18&#x202F;months, with 80% having a CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell count of &#x0003E;350 cells\u002F&#x03BC;l. Age group [&#x0003C;40 vs.&#x202F;&#x0003E;&#x202F;40&#x202F;years] (OR 2.35, 95% CI; 1.21&#x2013;4.58, \u003Ci\u003Ep\u003C\u002Fi\u003E&#x202F;=&#x202F;0.012), CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell count [&#x0003E;350 vs.&#x202F;&#x0003C;&#x202F;350 cells\u002F&#x03BC;l] (OR 4.35, 95% CI; 2.32&#x2013;8.18, \u003Ci\u003Ep\u003C\u002Fi\u003E&#x202F;&#x0003C;&#x202F;0.001), and ART regimen [NVP based vs. DTG based] (OR 7.00, 95% CI; 1.15&#x2013;42.57, \u003Ci\u003Ep\u003C\u002Fi\u003E&#x202F;=&#x202F;0.034) were associated with VS of &#x0003C;50 copies\u002FmL. The overall viral rebound rate was estimated at 13.61 per 1,000 person-months (95% CI 10.52&#x2013;17.74), with decreasing rates over time. Lower educational levels (up to Junior High School) were significantly associated with viral rebound (\u003Ci\u003Ep\u003C\u002Fi\u003E&#x202F;=&#x202F;0.011).\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003E\u003Cb\u003EConclusion:\u003C\u002Fb\u003E A key feature of our study was measuring VL at three time points over 2&#x202F;years, which may explain the high VS levels observed. Viral rebound was linked to low education levels, highlighting the need for targeted education for PLWH with junior high school (JHS) education or less. Regular VL monitoring and the implementation of measures to prevent viral rebound, particularly among PLWH with lower education levels, will help Ghana move closer to attaining the third &#x201C;95&#x201D; of the UNAIDS 95&#x2013;95-95 target by 2030.\u003C\u002Fp\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003C\u002Fdiv\u003E \u003Cdiv class=\"JournalFullText\"\u003E \u003Ca id=\"h2\" name=\"h2\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EIntroduction\u003C\u002Fh2\u003E\n\u003Cp class=\"mb15\"\u003EHuman immunodeficiency virus (HIV) infection continues to be a global pandemic, with over 38 million people living with the virus; the majority of the infected people are in sub-Saharan Africa (SSA) (\u003Ca href=\"#ref1\"\u003E1\u003C\u002Fa\u003E). The widespread use of antiretroviral therapy (ART), which can suppress the virus to undetectable levels, has transformed HIV infection into a manageable chronic disease requiring daily medication (\u003Ca href=\"#ref2\"\u003E2\u003C\u002Fa\u003E&#x2013;\u003Ca href=\"#ref4\"\u003E4\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EThe Joint United Nations Program on HIV\u002FAIDS (UNAIDS) has set ambitious targets to control the HIV epidemic by 2030, aiming for 95% of people living with HIV (PLWH) to know their status, 95% of those diagnosed to be on ART (antiretroviral therapy), and 95% of those on ART to achieve viral suppression (VS). Achieving VS is key to reducing transmission and disease progression, making it a critical goal for everyone receiving treatment (\u003Ca href=\"#ref5\"\u003E5\u003C\u002Fa\u003E&#x2013;\u003Ca href=\"#ref11\"\u003E11\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EThe factors likely to affect VS include the type of antiretroviral (ARV) regimen, patient adherence, and the frequency of VL measurements to facilitate timely regimen adjustments (\u003Ca href=\"#ref12\"\u003E12\u003C\u002Fa\u003E). The sporadic nature of viral load testing in SSA and other resource-limited settings (RLS), coupled with less potent first-generation ARVs that have burdensome side effects hindering adherence, promotes drug resistance and viral non-suppression. Therefore, the World Health Organization (WHO) recommended dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), in 2018 to be used in combination with two NRTIs as a first-line regimen for SSA and other RLS to improve VS. Following this recommendation, Ghana transitioned from a first-line regimen based on non-nucleotide reverse transcriptase inhibitors (NNRTIs) such as Nevirapine (NVP) or Efavirenz (EFV), combined with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including Lamivudine (3TC), Zidovudine (AZT), or Tenofovir disoproxil fumarate (TDF), to a DTG-based regimen (\u003Ca href=\"#ref13\"\u003E13\u003C\u002Fa\u003E&#x2013;\u003Ca href=\"#ref15\"\u003E15\u003C\u002Fa\u003E). This switch aimed to improve adherence, reduce drug resistance, and improve VS rates in SSA (\u003Ca href=\"#ref16\"\u003E16\u003C\u002Fa\u003E, \u003Ca href=\"#ref17\"\u003E17\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003ETherefore, measuring VS is imperative to ascertain the effectiveness of the new drug regimens and determine the factors that affect it.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EMeasuring VL is the primary method for assessing the effectiveness of ART, as it provides critical insights into VS (\u003Ca href=\"#ref18\"\u003E18\u003C\u002Fa\u003E, \u003Ca href=\"#ref19\"\u003E19\u003C\u002Fa\u003E). However, achieving VS in PLWH is not a stable or permanent condition. Some individuals may lose their VS status over time and experience viral rebounds (\u003Ca href=\"#ref20\"\u003E20\u003C\u002Fa\u003E). Viral rebound is known to be associated with active tuberculosis, ART adherence, duration of prior suppression, education levels, and the type of ARVs used (\u003Ca href=\"#ref12\"\u003E12\u003C\u002Fa\u003E, \u003Ca href=\"#ref20\"\u003E20\u003C\u002Fa\u003E, \u003Ca href=\"#ref21\"\u003E21\u003C\u002Fa\u003E). Additionally, socioeconomic factors such as disparities in education and income&#x2014;manifesting as health literacy and financial barriers&#x2014;may improve non-ART adherence, potentially impacting VS and rebound rates. Viral rebounds can undermine the gains made by ART by increasing treatment failure and ART resistance, thus facilitating HIV transmission (\u003Ca href=\"#ref21\"\u003E21\u003C\u002Fa\u003E). The WHO recommends initiating treatment and monitoring response by performing the first VL measurement 6&#x202F;months after treatment initiation, followed by yearly intervals if suppression is achieved (\u003Ca href=\"#ref22\"\u003E22\u003C\u002Fa\u003E). However, these guidelines are not consistently followed in SSA, hindering the early detection of virologic failure. Previous studies have shown an increase in HIV drug resistance in Africa due to irregular monitoring of VL and the lack of drug resistance testing before changing drug regimens (\u003Ca href=\"#ref23\"\u003E23\u003C\u002Fa\u003E, \u003Ca href=\"#ref24\"\u003E24\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EAccording to the Ghana AIDS Commission, Ghana&#x2019;s VS rate is 68%, which is significantly below UNAIDS target of 95%. To assess progress toward the third &#x201C;95&#x201D; of the UNAIDS 95&#x2013;95-95 target and identify necessary interventions to maintain VS, it is crucial to evaluate trends in VS, instances of viral rebound, and the factors influencing these two outcomes.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EIn this study, we report the levels of VS, viral rebound rates, and factors associated with VS and rebound among PLWH over 18&#x202F;months.\u003C\u002Fp\u003E \u003Ca id=\"h3\" name=\"h3\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EMaterials and methods\u003C\u002Fh2\u003E\n\u003Ch3\u003EStudy design\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThis is a secondary data analysis using data from a hospital-based cohort study aimed at identifying virologically suppressed individuals for HIV cure research. The cohort study was conducted at three hospitals in the Greater Accra region of Ghana: Korle-Bu Teaching Hospital, LEKMA Hospital, Teshie, and University of Ghana Hospital, Legon. Demographic characteristics were obtained from participants&#x2019; records, and blood samples were collected from patients to measure CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell counts and VLs at baseline, 6&#x202F;months, and 18&#x202F;months.\u003C\u002Fp\u003E\n\u003Ch3\u003EStudy population and sampling\u003C\u002Fh3\u003E\n\u003Cp class=\"mb15\"\u003EBetween 2019 and 2021, the parent study enrolled 390 PLWH on ART from three hospitals in the Greater Accra region of Ghana. A total of 250 participants were recruited from Korle-Bu Teaching Hospital (KBTH), and 70 each were recruited from LEKMA Hospital and the University of Ghana Hospital, Legon. Details of the study hospitals have been previously published (\u003Ca href=\"#ref25\"\u003E25\u003C\u002Fa\u003E). Participants were enrolled at baseline and followed up at 6 and 18&#x202F;months over a 2-year period.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EAt each sampling time point, 10&#x202F;mL of venous blood was collected into EDTA tubes from participants and transported in cool boxes to the Noguchi Memorial Institute for Medical Research (NMIMR). Aliquots of the whole blood were used to estimate CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell count, while the remaining blood was processed into plasma and peripheral blood mononuclear cells (PBMCs) using the sucrose-gradient centrifugation method. Plasma was stored at -20&#x000B0;C and PBMCs at &#x02212;80&#x000B0;C in a freezing medium (FBS with 10% DMSO) until further laboratory analysis. The participants&#x2019; demographics and treatment history, including age, sex, educational status, income level, ART regimen, and occupation, were obtained from hospital records.\u003C\u002Fp\u003E\n\u003Ch3\u003EInclusion\u002Fexclusion criteria\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EAll consenting ART-experienced PLWH aged 18&#x202F;years and older were included in the parent study. All PLWH under 18&#x202F;years of age and ART na&#x000EF;ve were excluded. For this study, PLWH from the parent study with VL results at all three follow-up points were analyzed to identify factors associated with VS and rebound.\u003C\u002Fp\u003E\n\u003Ch3\u003EViral load determination\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EVL was measured from the plasma using the COBAS\u003Csup\u003E&#x000AE;\u003C\u002Fsup\u003E AmpliPrep\u002FCOBAS\u003Csup\u003E&#x000AE;\u003C\u002Fsup\u003E TaqMan\u003Csup\u003E&#x000AE;\u003C\u002Fsup\u003E following the manufacturer&#x2019;s instructions (Roche Diagnostic Systems, Branchburg, NJ, United States). For quality control, a negative control, HIV-1 Low Positive Control, and HIV-1 High Positive Control were included in each test batch. This assay can quantify HIV-1 RNA with a lower detection limit of 20 copies\u002FmL and an upper limit of 10,000,000 copies\u002FmL. One copy of HIV-1 RNA is equivalent to 1.7&#x202F;&#x000B1;&#x202F;0.1 International Units (IU) based on the WHO 1st International Standard for HIV-1 RNA for Nucleic Acid-Based Techniques (NAT; NIBSC 97\u002F656).\u003C\u002Fp\u003E\n\u003Ch3\u003ECD4\u003Csup\u003E+\u003C\u002Fsup\u003E T and CD8\u003Csup\u003E+\u003C\u002Fsup\u003E T cell measurement\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EWhole blood samples were analyzed for CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T and CD8 \u003Csup\u003E+\u003C\u002Fsup\u003ET cell counts using the FACS Count system (Becton Dickinson Biosciences, United States), according to the manufacturer&#x2019;s instructions. Briefly, 50&#x202F;&#x03BC;L of blood was added to CD4 and CD8 reagent tubes and incubated for 1&#x202F;h at room temperature in the dark, in accordance with the manufacturer&#x2019;s protocol. A fixative solution (50&#x202F;&#x03BC;L) was added and analyzed on the FACS Count machine to enumerate the absolute CD4 \u003Csup\u003E+\u003C\u002Fsup\u003E and CD8\u003Csup\u003E+\u003C\u002Fsup\u003E T cells per microliter of blood. The equipment was also calibrated to validate the results, and reagent controls were run alongside each batch of samples.\u003C\u002Fp\u003E\n\u003Ch3\u003EStatistical analysis\u003C\u002Fh3\u003E\n\u003Cp class=\"mb15\"\u003EParticipants&#x2019; characteristics were analyzed descriptively using frequency distribution tables and graphical presentations. Data capture, cleaning, coding, and analysis were conducted using.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EMicrosoft Excel spreadsheets (Excel 2016) and STATA 16. VS was defined as the proportion of individuals with HIV VL &#x0003C;50 copies\u002FmL and [&#x0003C;1,000 copies\u002FmL for the WHO criteria for resource-limited settings (RLS)]. Frequencies and percentages were used to describe categorical outcomes, while medians and interquartile ranges were used to summarize continuous variables. Odds ratios in the multivariable model were calculated to examine factors associated with VS using a generalized estimating equation with a binomial distribution and logit link function to account for within-subject correlation. The HIV rebound rate was defined as the number of participants who were unsuppressed following VS with results &#x0003C;50 copies\u002FmL over the study period from enrollment to the second follow-up. The viral rebound was calculated as a rate per 1,000 person-months using survival analysis. Confidence intervals were reported, and \u003Ci\u003Ep\u003C\u002Fi\u003E-values of &#x0003C;0.05 were considered statistically significant.\u003C\u002Fp\u003E \u003Ca id=\"h4\" name=\"h4\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EResults\u003C\u002Fh2\u003E\n\u003Ch3\u003EParticipants&#x2019; characteristics\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EA total of 390 PLWH in Ghana were recruited from three hospitals in Accra for this study. In total, 265, representing 68% of the participants, were women, while the remaining 32% were men (\u003Ca href=\"#tab1\"\u003ETable 1\u003C\u002Fa\u003E). The median age of the participants was 45&#x202F;years (IQR 21&#x2013;76). The majority had only a minimum level of formal education; only 29% of them had completed high school or pursued further education. Participants had a low economic status, with 71% earning less than $100 USD per month. The median duration since the HIV diagnosis was 7&#x202F;years (IQR 0&#x2013;30), and 59% of participants had been on antiretroviral treatment for more than 6&#x202F;years (\u003Ca href=\"#tab1\"\u003ETable 1\u003C\u002Fa\u003E). The estimated CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell counts for 80% of the participants were&#x202F;&#x0003E;&#x202F;350 cells\u002F&#x03BC;L. Of the 390 participants, VL results were available for 361 at baseline, 325 at 6&#x202F;months, and 321 at 18&#x202F;months (\u003Ca href=\"#tab1\"\u003ETable 1\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003ETable 1\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t001.jpg\" name=\"table1\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t001.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t001.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t001.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t001.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t001.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t001.jpg\" alt=\"www.frontiersin.org\" id=\"tab1\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003ETable 1\u003C\u002Fb\u003E. Demographic and infection history of study participants.\n\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\n\u003Ch3\u003EVS per sampling time points\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EAt recruitment, 268 out of 390 participants, representing 74%, had VLs less than 50 copies\u002FmL, and 91% had VLs less than 1,000 copies\u002FmL. At 6&#x202F;months, out of 325 participants, 73% of the participants had VL less than 50 copies\u002FmL, and 91% of the participants had VL less than 1,000 copies\u002FmL. At 18&#x202F;months, 88% of 321 participants had VLs less than 50 copies\u002FmL, and 96% of the participants had VLs less than 1,000 copies\u002FmL (\u003Ca href=\"#fig1\"\u003EFigure 1\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003EFigure 1\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g001.jpg\" name=\"figure1\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g001.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g001.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g001.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g001.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g001.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g001.jpg\" alt=\"www.frontiersin.org\" id=\"fig1\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003EFigure 1\u003C\u002Fb\u003E. Percentage viral suppression at sampling timepoints. Viral suppression was based on the thresholds set at &#x0003C;50 copies\u002Fml (purple bars) and &#x0003C;1,000 copies\u002Fml (pink bars).\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\n\u003Ch3\u003EVS trends of compliant participants\u003C\u002Fh3\u003E\n\u003Cp class=\"mb15\"\u003EIn total, 275 participants had their VLs measured at all three time points in the study.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EAmong these, VS &#x0003C;50 copies\u002FmL was observed in 74, 73, and 88% at baseline, 6&#x202F;months, and 18&#x202F;months (\u003Ca href=\"#fig2\"\u003EFigure 2\u003C\u002Fa\u003E). At all three time points, VS levels exceeded 90% when using the WHO threshold of &#x0003C;1,000 copies\u002FmL (\u003Ca href=\"#fig2\"\u003EFigure 2\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003EFigure 2\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g002.jpg\" name=\"figure2\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g002.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g002.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g002.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g002.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g002.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g002.jpg\" alt=\"www.frontiersin.org\" id=\"fig2\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003EFigure 2\u003C\u002Fb\u003E. Viral suppression among patients whose viral loads were successfully measured at all the three sampling timepoints (\u003Ci\u003EN\u003C\u002Fi\u003E&#x202F;=&#x202F;275). The graph shows the trend in the proportion of virally suppressed individuals and their confidence interval in percentages over three-time points; baseline, 6 and 18&#x202F;months according to the two thresholds (&#x0003C;50 copies\u002Fml and &#x0003C;1,000 copies\u002Fml).\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\n\u003Ch3\u003EFactors associated with VS\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EWe examined the factors associated with VLS at the thresholds &#x0003C;50 copies\u002FmL and from 51 to 1,000 copies\u002FmL. Age group (OR 2.35, 95% CI; 1.21&#x2013;4.58, \u003Ci\u003Ep\u003C\u002Fi\u003E-value&#x202F;=&#x202F;0.012), CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell count (OR 4.35, 95% CI; 2.32&#x2013;8.18, \u003Ci\u003Ep\u003C\u002Fi\u003E-value&#x0003C;0.001), and ART regimen [NVP based vs. DTG based] (OR 7.0, 95% CI; 1.15&#x2013;42.57, \u003Ci\u003Ep\u003C\u002Fi\u003E-value&#x202F;=&#x202F;0.034) were associated with VLS with threshold of &#x0003C;50 copies\u002FmL, while CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell count (OR 5.39, 95% CI; 1.73&#x2013;16.73, \u003Ci\u003Ep\u003C\u002Fi\u003E-value&#x0003C;0.001) was associated an VL of of 51 to 1,000 copies\u002FmL (\u003Ca href=\"#fig3\"\u003EFigure 3\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003EFigure 3\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g003.jpg\" name=\"figure3\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g003.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g003.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g003.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g003.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g003.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g003.jpg\" alt=\"www.frontiersin.org\" id=\"fig3\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003EFigure 3\u003C\u002Fb\u003E. Factors associated with Viral suppression for thresholds \u003Cb\u003E(A)\u003C\u002Fb\u003E &#x0003C;50 copies\u002Fml and \u003Cb\u003E(B)\u003C\u002Fb\u003E from 51 to 1,000 copies\u002Fml. The forest plot shows the factors associated with HIV suppression (&#x0003C;50 copies\u002Fml, \u003Ci\u003EN\u003C\u002Fi\u003E&#x202F;=&#x202F;275: 51&#x2013;1,000 copies\u002Fml, \u003Ci\u003EN\u003C\u002Fi\u003E&#x202F;=&#x202F;179). The dashed lines represent the reference point&#x202F;=&#x202F;1, the black dot represents the point odds ratio estimate, and the whiskers represents the confidence intervals. \u003Ci\u003Ep\u003C\u002Fi\u003E-values &#x0003C;0.05 are considered significant. VS, Viral suppression.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\n\u003Ch3\u003EViral rebound rates\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EWe followed 275 participants with VL results across the follow-up points, totaling 4,120 person-months (\u003Ca href=\"#tab2\"\u003ETable 2\u003C\u002Fa\u003E). During the follow-up period, 56 participants experienced HIV rebound. At 6, 12, and 18&#x202F;months, 43, 11, and 2 participants, respectively, experienced viral rebound (\u003Ca href=\"#fig4\"\u003EFigure 4\u003C\u002Fa\u003E). The overall viral rebound rate was estimated at 13.61 per 1,000 person-months (95% CI 10.52&#x2013;17.74; \u003Ca href=\"#tab2\"\u003ETable 2\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"Imageheaders\"\u003ETable 2\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t002.jpg\" name=\"table2\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t002.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t002.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t002.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t002.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t002.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-t002.jpg\" alt=\"www.frontiersin.org\" id=\"tab2\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003ETable 2\u003C\u002Fb\u003E. Showing the distribution of rebound rates by covariates.\n\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine mb15\"\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"Imageheaders\"\u003EFigure 4\u003C\u002Fdiv\u003E \u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g004.jpg\" name=\"figure4\" target=\"_blank\"\u003E\n  \u003Cpicture\u003E\n    \u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=480&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g004.jpg\" media=\"(max-width: 563px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=370&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g004.jpg\" media=\"(max-width: 1024px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=290&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g004.jpg\" media=\"(max-width: 1441px)\"\u003E\u003Csource type=\"image\u002Fwebp\" srcset=\"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=410&f=webp\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g004.jpg\" media=\"\"\u003E\u003Csource type=\"image\u002Fjpg\" srcset=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g004.jpg\" media=\"\"\u003E \u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1508793\u002Ffpubh-13-1508793-HTML-r1\u002Fimage_m\u002Ffpubh-13-1508793-g004.jpg\" alt=\"www.frontiersin.org\" id=\"fig4\" loading=\"lazy\"\u003E\n  \u003C\u002Fpicture\u003E\n\u003C\u002Fa\u003E\n\u003Cp\u003E\u003Cb\u003EFigure 4\u003C\u002Fb\u003E. Kaplan Meier curve showing the distribution of rebound cases over the follow-up period.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\n\u003Ch3\u003EFactors associated with viral rebound\u003C\u002Fh3\u003E\n\u003Cp class=\"mb0\"\u003EThe HIV rebound rate was significantly higher among participants with educational levels up to junior high school (16.55 per 1,000 person-months) compared to those with educational levels from senior secondary school and above (6.33 per 1,000 person-months), \u003Ci\u003Ep\u003C\u002Fi\u003E&#x202F;=&#x202F;0.011. However, the years on ART and monthly income were marginally significant (\u003Ca href=\"#tab2\"\u003ETable 2\u003C\u002Fa\u003E).\u003C\u002Fp\u003E \u003Ca id=\"h5\" name=\"h5\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EDiscussion\u003C\u002Fh2\u003E\n\u003Cp class=\"mb15\"\u003EIn this study, we determined VS\u002Frebound in participants on ART in Ghana who enrolled in our HIV cure studies and received regular VL measurements over a 2-year period. Prior to our study, regular VL measurements were not routinely conducted for participants.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EWomen constituted 68% of our study population. This aligns with national HIV statistics in Ghana, where women account for two-thirds of PLWH (\u003Ca href=\"#ref26\"\u003E26\u003C\u002Fa\u003E). The age group of 41 to 50&#x202F;years represented 42% of the study population, indicating that Ghana has an aging HIV population that requires targeted management to ensure they remain healthy and can contribute to national development. Over 62% had been diagnosed with HIV at least 5&#x202F;years before sampling, and 27% of them had been aware of their status for more than 10&#x202F;years before the study. In total, 59% had been on ART for over 6&#x202F;years before sampling. Some participants did not start ART at the time of diagnosis, probably due to their CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell counts and the policy of initiating ART at a specified CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell threshold.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EAchieving VS is the optimal goal of antiretroviral therapy, with VL measurements being the best tool for assessment (\u003Ca href=\"#ref27\"\u003E27\u003C\u002Fa\u003E). Various factors determine whether patients on therapy will attain VS, including the time from infection to initiation of ART, the type of antiretrovirals prescribed, the duration of treatment, adherence to the treatment regimen, and the patients&#x2019; age and sex. While a longer duration of treatment is generally a positive indicator for achieving VS, remaining on an ineffective regimen for too long could negate the benefits of ART. This study considers educational level and income as key determinants of VS, given their critical role in an individual&#x2019;s ability to access healthcare and adhere to prescribed treatment.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EHigher levels of education enhance individuals&#x2019; ability to make informed healthcare decisions and understand medical instructions. Similarly, income levels can directly impact one&#x2019;s ability to afford healthcare services and transportation to medical facilities.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EIn resource-limited settings such as Ghana, VL measurements are not routinely conducted for people on ART. However, the treatment guidelines recommend VL measurements at 6-month intervals until suppression and once per year thereafter (\u003Ca href=\"#ref28\"\u003E28\u003C\u002Fa\u003E). This is due to limited resources such as equipment, ineffective sample transport systems, a lack of skilled personnel at the peripheral laboratories to analyze the samples, and non-adherence to ART guidelines by healthcare workers.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EIn this study, we measured the VLs for all participants sampled at the three-time points.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EThe unavailability of VL results for some participants (\u003Ca href=\"#tab1\"\u003ETable 1\u003C\u002Fa\u003E) was due to either invalid test results or participant loss to follow-up.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EWe found that 74% of participants in our cohort had a VL of &#x0003C;50 copies\u002FmL, which is similar to the 76% VS observed by Opoku et al. in a study conducted at Komfo Anokye Teaching Hospital in Kumasi, Ghana (\u003Ca href=\"#ref20\"\u003E20\u003C\u002Fa\u003E). This presents a positive outlook for Ghana&#x2019;s ART program and may suggest that the drugs are generally effective. Among participants with VL&#x202F;&#x02265;&#x202F;50 copies\u002FmL, 62 (17%) had VL of less than 1,000 copies\u002FmL; thus, a total of 91% of participants met the World Health Organization&#x2019;s criteria for VS in RLS. Antiretrovirals used in Ghana were mostly first-generation ARVs until the introduction of DTG into the first-line regimen in 2019 (\u003Ca href=\"#ref29\"\u003E29\u003C\u002Fa\u003E). The treatment regimens in Ghana primarily consisted of reverse transcriptase inhibitors, with protease inhibitors introduced during the second-line regimen when the first-line regimen failed (\u003Ca href=\"#ref30\"\u003E30\u003C\u002Fa\u003E). The level of VS found in our study corroborates findings from previous studies by Ali et al., who reported 72% VS (&#x0003C;1,000 copies\u002FmL) from Ethiopia; Wakooko et al., with 87.5% VS (&#x0003C;1,000 copies\u002FmL) from Eastern Uganda; Mogosetsi et al., who reported 91% VS (&#x0003C;1,000 copies\u002FmL) in South Africa; Abdullahi et al., who reported 91% VS (&#x0003C;1,000 copies\u002FmL) from northwestern Nigeria; and Djiyou et al., reporting 88.2% VS (&#x0003C;1,000 copies\u002FmL) from Cameroon (\u003Ca href=\"#ref27\"\u003E27\u003C\u002Fa\u003E, \u003Ca href=\"#ref31\"\u003E31\u003C\u002Fa\u003E&#x2013;\u003Ca href=\"#ref34\"\u003E34\u003C\u002Fa\u003E). Other African countries have reported lower levels: 59% in Kenya (\u003Ca href=\"#ref12\"\u003E12\u003C\u002Fa\u003E) and 56.2% among pregnant women in South Africa (\u003Ca href=\"#ref35\"\u003E35\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EVS levels at the three sampling time points showed an increasing trend, which could be attributed to the introduction of DTG (\u003Ca href=\"#fig1\"\u003EFigure 1\u003C\u002Fa\u003E). The slight dip observed in Follow-up 1 (2020) could be due to the impact of the COVID-19 pandemic, which drastically reduced access to healthcare (\u003Ca href=\"#ref36\"\u003E36\u003C\u002Fa\u003E). Overall, the high levels of suppression in our participants over the study period could be due to the availability of VL testing for each participant in our cohort, which guided monitoring for improved virologic outcomes.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EAge, ART regimen, and CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell count were associated with VS (VL&#x202F;&#x0003C;&#x202F;50 copies\u002FmL), while only CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell count was associated with VLs between 51 and 1,000 copies\u002FmL. Participants older than 40&#x202F;years were more likely to be virally suppressed compared to those younger than 40&#x202F;years. This contrasts with findings from a study in Canada, where adults under 29&#x202F;years experienced a lower prevalence of VS (\u003Ca href=\"#ref37\"\u003E37\u003C\u002Fa\u003E). This may indicate that Ghana&#x2019;s older population is more receptive to and compliant with their treatment than other populations. A nevirapine-based regimen was more likely to be associated with VS than dolutegravir. This observation could be attributed to factors such as adherence differences, sampling time, and, more importantly, our cohort composition bias. Dolutegravir (DTG) was introduced just before the study, and at baseline, a higher proportion of ART-experienced participants who were doing well were on nevirapine-based regimens, leaving only the newly initiated patients or those with prior virologic failure and higher VLs on DTG-based regimens. However, at month 18, a larger proportion of participants were on a DTG-based regimen and had their VLs below 50 copies\u002FmL, demonstrating the superior efficacy of DTG, which aligns with global evidence.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EAchieving VS has many benefits for PLWH because it drastically reduces HIV transmission risk (undetectable equals untransmissible). This is particularly beneficial to discordant couples and babies born to women with HIV (\u003Ca href=\"#ref38\"\u003E38\u003C\u002Fa\u003E, \u003Ca href=\"#ref39\"\u003E39\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EViral rebounds pose a significant risk to HIV morbidity and mortality. In our study, viral rebound occurred in 20.4% of individuals, with the rebound rate estimated at 13.61 per 1,000 person-years (95% CI 10.52&#x2013;17.74). This is comparable to the findings by Opoku et al., who reported a 21% viral rebound rate among PLWH in Ghana (\u003Ca href=\"#ref20\"\u003E20\u003C\u002Fa\u003E). This finding in our cohort confirms that viral rebounds occur frequently among individuals with VS. This has ramifications for HIV management in Ghana, as previously suppressed individuals may potentially become infectious during the period of viral rebounds. Incidence of viral rebound decreased over time, with 43, 11, and 2 participants showing corresponding falls over 6, 12, and 18&#x202F;months. As stated by Campos et al., the switch to a newer ARV like DTG in our cohort is the likely cause of the gradual decrease in viral rebounds (\u003Ca href=\"#ref40\"\u003E40\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EAn analysis of factors linked to viral rebounds revealed a strong correlation between lower educational attachment (up to Junior High School) and higher rebound rates. This result is consistent with that of Min et al., who found that participants with education levels equivalent to high school had a higher rebound rate than those with higher education levels (\u003Ca href=\"#ref41\"\u003E41\u003C\u002Fa\u003E). Our findings also show the importance of some socioeconomic determinants in HIV outcomes. Participants earning less than 500 GHS\u002Fmonth exhibited a marginally higher viral rebound rate than those earning &#x02265;500 GHS\u002Fmonth. This trend mirrors the findings of Leddy et al., who found that low-income individuals experience worse HIV treatment outcomes (\u003Ca href=\"#ref42\"\u003E42\u003C\u002Fa\u003E). In this study, 70% of the participants earned less than 500 GHS\u002Fmonth.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EThese economic hardships may pose a barrier to consistent healthcare access, as limited financial resources can lead to difficulties in affording transportation to clinics or even purchasing the nutritious food necessary for optimal ART efficacy. These financial constraints could contribute to inconsistent ART adherence, thereby affecting their viral rebound rates. The predominance of female participants (68%) reflects Ghana&#x2019;s HIV epidemiology, where women represent approximately two-thirds of PLWH. However, viral rebound rates did not significantly vary by gender. While our study did not explore the reasons behind this lack of disparity, other studies have found higher rebound rates in males compared to women, which is attributed to frequent ART treatment interruptions among males (\u003Ca href=\"#ref43\"\u003E43\u003C\u002Fa\u003E&#x2013;\u003Ca href=\"#ref46\"\u003E46\u003C\u002Fa\u003E). Further research is required to examine this phenomenon within the Ghanaian population.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EOur study reports high levels of VS over an 18-month period; however, 12% of our cohort could not achieve VS. Among the unsuppressed participants, 67% of them had low-level viremia (VL 50&#x2013;999 copies\u002Fml) and were deemed suppressed according to the WHO guidelines, often receiving little attention. However, low-level viremia is known to promote viral replication, leading to virologic failure, the emergence of drug resistance, and increased HIV transmission (\u003Ca href=\"#ref47\"\u003E47\u003C\u002Fa\u003E&#x2013;\u003Ca href=\"#ref50\"\u003E50\u003C\u002Fa\u003E). It is critical to pay some attention to the unsuppressed group, including those with low-level viremia, to further reduce their VL to below-detectable levels. Regular VL testing for monitoring ART is a more sensitive, timely, and reliable method for identifying treatment failure than the clinical use of CD4\u003Csup\u003E+\u003C\u002Fsup\u003E T cell counts and clinical symptoms (\u003Ca href=\"#ref51\"\u003E51\u003C\u002Fa\u003E). Therefore, it is recommended that HIV control programs in resource-limited settings invest in infrastructure and logistics to implement regular VL measurements for all PLWH on ART.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EOur data were obtained from patients enrolled in our HIV cure study, with their VLs measured regularly. In contrast, the general HIV population in Ghana does not have access to routine VL testing and is not consistently monitored for treatment failure until clinical deterioration occurs. We recommend implementing regular VL measurements as part of HIV care in Ghana to ensure effective ART outcomes. Our findings confirm viral rebound among previously suppressed participants, which could impede global efforts to end the AIDS epidemic by 2030. In our situation, this emphasizes the need to target and educate PLWH, particularly those with education up to Junior High School, about the importance of VS in controlling HIV transmission.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EA major challenge in achieving sustained VS in Ghana is the sporadic nature of viral load monitoring. Strengthening routine VL testing requires addressing costs, feasibility, and potential partnerships with government and non-governmental organizations. Expanding decentralized VL testing to peripheral health centers, reducing test costs through public-private partnerships, and integrating VL monitoring into routine ART services could improve accessibility and sustainability. Furthermore, policies that promote awareness campaigns emphasizing the role of VL monitoring in HIV would support these efforts.\u003C\u002Fp\u003E\n\u003Cp class=\"mb15\"\u003EOur study has some limitations. First, the participants did not have regular VL measurements from the start of therapy until sampling, making it difficult to determine when they achieved VS and for how long they maintained it. Additionally, we did not assess adherence to ART in our study population. Therefore, we cannot reliably associate the observed suppression and rebound rates with adherence.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EFuture research should incorporate adherence assessments such as pill counts, self-reports, or biomarker tracking to better understand the impact of adherence. While sufficient for initial analysis, the sample size may limit statistical power in detecting smaller effect sizes. Future studies should consider a larger cohort to enhance the robustness of the findings. Additionally, some participants were lost to follow-up, leading to potential missing data that may introduce bias in the results. The study was conducted in three hospitals in the Greater Accra region, which may not be generalizable to PLWH in other regions of Ghana with different healthcare access. Finally, we acknowledge the possibility of recall bias arising from participants self-reporting certain variables such as age. This was mitigated by cross-verifying hospital records. However, socioeconomic variables like income could not be verified due to the lack of documented records.\u003C\u002Fp\u003E \u003Ca id=\"h6\" name=\"h6\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EConclusion\u003C\u002Fh2\u003E\n\u003Cp class=\"mb15\"\u003EDespite the limitations of the study, we found high levels of VS among patients enrolled in our HIV cure study, where regular VL measurements were conducted. However, the general HIV population in Ghana lacks access to routine VL testing, which may result in different suppression levels compared to those observed in our study.\u003C\u002Fp\u003E\n\u003Cp class=\"mb0\"\u003EWe recommend that the national HIV control program prioritize investments in infrastructure and logistics to implement regular VL measurements for all PLWH on ART. This will significantly improve ART outcomes and VS rates across Ghana&#x2019;s broader HIV population. Additionally, further education on the importance of VS for PLWH with up to JHS-level education is essential to maintaining VS and achieving the third &#x201C;95&#x201D; of the UNAIDS 95&#x2013;95-95 target by 2030.\u003C\u002Fp\u003E \u003Ca id=\"h7\" name=\"h7\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EData availability statement\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe original contributions presented in this study are included in the article and supplementary materials, further inquiries can be directed to the corresponding authors.\u003C\u002Fp\u003E \u003Ca id=\"h8\" name=\"h8\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EEthics statement\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe studies involving humans were approved by Institutional Review Board, Noguchi Memorial Institute for Medical Research, University of Ghana (NMIMR-IRB CPN002\u002F18-19), Institutional Review Board, Korle-Bu Teaching Hospital (KBTH-IRB\u002F00075\u002F2019) and Ethics Review Committee of the Ghana Health Service (GHS-ERC:013\u002F09\u002F19). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.\u003C\u002Fp\u003E \u003Ca id=\"h9\" name=\"h9\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EAuthor contributions\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EAB: Data curation, Formal analysis, Investigation, Methodology, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x00026; editing. JA: Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#x2013; review &#x00026; editing. HL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#x2013; review &#x00026; editing. CA: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. AA-M: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. DQ: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. SA: Data curation, Formal analysis, Investigation, Methodology, Supervision, Writing &#x2013; review &#x00026; editing. YA-L: Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#x2013; review &#x00026; editing. GA: Conceptualization, Data curation, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. JO-C: Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing &#x2013; review &#x00026; editing. VG: Data curation, Investigation, Project administration, Supervision, Writing &#x2013; review &#x00026; editing. GK: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing &#x2013; review &#x00026; editing. PP: Data curation, Investigation, Methodology, Writing &#x2013; review &#x00026; editing. EB: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Writing &#x2013; review &#x00026; editing.\u003C\u002Fp\u003E \u003Ca id=\"h10\" name=\"h10\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EFunding\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe author(s) declare that financial support was received for the research and\u002For publication of this article. This project is part of the EDCTP2 program, which is supported by the European Union (grant number TMA2017SF-1955, H-CRIS) for GBK. The funder had no role in the design, analysis, or publication of the study.\u003C\u002Fp\u003E \u003Ca id=\"h11\" name=\"h11\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EAcknowledgments\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EWe thank our study participants and our collaborating partners from the hospitals, especially Adjoa Obo-Akwa, Esther Davis Yeboah, Linda Sackey, Rosalyn Baah-Danquah, and all other members of the H-CRIS team.\u003C\u002Fp\u003E \u003Ca id=\"h12\" name=\"h12\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EConflict of interest\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C\u002Fp\u003E \u003Ca id=\"h13\" name=\"h13\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EGenerative AI statement\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EThe author(s) declare that no Gen AI was used in the creation of this manuscript.\u003C\u002Fp\u003E \u003Ca id=\"h14\" name=\"h14\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EPublisher&#x2019;s note\u003C\u002Fh2\u003E\n\u003Cp class=\"mb0\"\u003EAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C\u002Fp\u003E \u003Ca id=\"h15\" name=\"h15\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EReferences\u003C\u002Fh2\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref1\" id=\"ref1\"\u003E\u003C\u002Fa\u003E1. Global Statistics. (2025). HIV.gov. Available at: \u003Ca href=\"https:\u002F\u002Fwww.hiv.gov\u002Fhiv-basics\u002Foverview\u002Fdata-and-trends\u002Fglobal-statistics\"\u003Ehttps:\u002F\u002Fwww.hiv.gov\u002Fhiv-basics\u002Foverview\u002Fdata-and-trends\u002Fglobal-statistics\u003C\u002Fa\u003E (Accessed on 2021 Mar 24)\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2025&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref2\" id=\"ref2\"\u003E\u003C\u002Fa\u003E2. G&#x000FC;nthard, HF, Saag, MS, Benson, CA, Del Rio, C, Eron, JJ, Gallant, JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. \u003Ci\u003EJAMA J Am Med Assoc\u003C\u002Fi\u003E. (2016) 316:191&#x2013;210. doi: 10.1001\u002Fjama.2016.8900 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F27404187\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1001\u002Fjama.2016.8900\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=HF+G&#x000FC;nthard&#x00026;author=MS+Saag&#x00026;author=CA+Benson&#x00026;author=C+Del+Rio&#x00026;author=JJ+Eron&#x00026;author=JE+Gallant&#x00026;publication_year=2016&#x00026;title=Antiretroviral+drugs+for+treatment+and+prevention+of+HIV+infection+in+adults:+2016+recommendations+of+the+international+antiviral+society-USA+panel&#x00026;journal=JAMA+J+Am+Med+Assoc&#x00026;volume=316&#x00026;pages=191-210\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref3\" id=\"ref3\"\u003E\u003C\u002Fa\u003E3. Abana, CZ, Sagoe, KWC, Bonney, EY, Maina, EK, Aziati, ID, Agbosu, E, et al. Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1\u002FHIV-2 infected patients in Ghana. \u003Ci\u003EMed (United States)\u003C\u002Fi\u003E. (2019) 98:e14313. doi: 10.1097\u002FMD.0000000000014313 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F30732150\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FMD.0000000000014313\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=CZ+Abana&#x00026;author=KWC+Sagoe&#x00026;author=EY+Bonney&#x00026;author=EK+Maina&#x00026;author=ID+Aziati&#x00026;author=E+Agbosu&#x00026;publication_year=2019&#x00026;title=Drug+resistance+mutations+and+viral+load+in+human+immunodeficiency+virus+type+2+and+dual+HIV-1\u002FHIV-2+infected+patients+in+Ghana&#x00026;journal=Med+(United+States)&#x00026;volume=98&#x00026;pages=e14313\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref4\" id=\"ref4\"\u003E\u003C\u002Fa\u003E4. Collaboration TATC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. \u003Ci\u003ELancet\u003C\u002Fi\u003E. (2008) 372:293&#x2013;9. doi: 10.1016\u002FS0140-6736(08)61113-7\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002FS0140-6736(08)61113-7\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2008&#x00026;title=Life+expectancy+of+individuals+on+combination+antiretroviral+therapy+in+high-income+countries:+a+collaborative+analysis+of+14+cohort+studies&#x00026;journal=Lancet&#x00026;volume=372&#x00026;pages=293-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref5\" id=\"ref5\"\u003E\u003C\u002Fa\u003E5. Reynolds, SJ, Makumbi, F, Nakigozi, G, Kagaayi, J, Gray, RH, Wawer, M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. \u003Ci\u003EAIDS\u003C\u002Fi\u003E. (2011) 25:473&#x2013;7. doi: 10.1097\u002FQAD.0b013e3283437c2b \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F21160416\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FQAD.0b013e3283437c2b\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=SJ+Reynolds&#x00026;author=F+Makumbi&#x00026;author=G+Nakigozi&#x00026;author=J+Kagaayi&#x00026;author=RH+Gray&#x00026;author=M+Wawer&#x00026;publication_year=2011&#x00026;title=HIV-1+transmission+among+HIV-1+discordant+couples+before+and+after+the+introduction+of+antiretroviral+therapy&#x00026;journal=AIDS&#x00026;volume=25&#x00026;pages=473-7\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref6\" id=\"ref6\"\u003E\u003C\u002Fa\u003E6. Donnell, D, Baeten, JM, Kiarie, J, Thomas, KK, Stevens, W, Cohen, CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. \u003Ci\u003ELancet\u003C\u002Fi\u003E. (2010) 375:2092&#x2013;8. doi: 10.1016\u002FS0140-6736(10)60705-2 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F20537376\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002FS0140-6736(10)60705-2\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=D+Donnell&#x00026;author=JM+Baeten&#x00026;author=J+Kiarie&#x00026;author=KK+Thomas&#x00026;author=W+Stevens&#x00026;author=CR+Cohen&#x00026;publication_year=2010&#x00026;title=Heterosexual+HIV-1+transmission+after+initiation+of+antiretroviral+therapy:+a+prospective+cohort+analysis&#x00026;journal=Lancet&#x00026;volume=375&#x00026;pages=2092-8\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref7\" id=\"ref7\"\u003E\u003C\u002Fa\u003E7. Del Romero, J, Castilla, J, Hernando, V, Rodr&#x000ED;guez, C, and Gar&#x0107;a, S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. \u003Ci\u003EBMJ\u003C\u002Fi\u003E. (2010) 340:c2205. doi: 10.1136\u002Fbmj.c2205 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F20472675\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1136\u002Fbmj.c2205\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Del+Romero&#x00026;author=J+Castilla&#x00026;author=V+Hernando&#x00026;author=C+Rodr&#x000ED;guez&#x00026;author=S+Gar&#x0107;a&#x00026;publication_year=2010&#x00026;title=Combined+antiretroviral+treatment+and+heterosexual+transmission+of+HIV-1:+cross+sectional+and+prospective+cohort+study&#x00026;journal=BMJ&#x00026;volume=340&#x00026;pages=c2205\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref8\" id=\"ref8\"\u003E\u003C\u002Fa\u003E8. Apondi, R, Bunnell, R, Ekwaru, JP, Moore, D, Bechange, S, Khana, K, et al. Sexual behavior and HIV transmission risk of Ugandan adults taking antiretroviral therapy: 3 year followup. \u003Ci\u003EAIDS\u003C\u002Fi\u003E. (2011) 25:1317&#x2013;27. doi: 10.1097\u002FQAD.0b013e328347f775 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F21522005\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FQAD.0b013e328347f775\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=R+Apondi&#x00026;author=R+Bunnell&#x00026;author=JP+Ekwaru&#x00026;author=D+Moore&#x00026;author=S+Bechange&#x00026;author=K+Khana&#x00026;publication_year=2011&#x00026;title=Sexual+behavior+and+HIV+transmission+risk+of+Ugandan+adults+taking+antiretroviral+therapy:+3+year+followup&#x00026;journal=AIDS&#x00026;volume=25&#x00026;pages=1317-27\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref9\" id=\"ref9\"\u003E\u003C\u002Fa\u003E9. Cohen, MS, Hosseinipour, MC, Kumarasamy, N, Hakim, JG, Mehendale, S, Chariyalertsak, S, et al. Prevention of HIV-1 infection with early antiretroviral therapy. \u003Ci\u003EN Engl J Med\u003C\u002Fi\u003E. (2011) 365:493&#x2013;505. doi: 10.1056\u002FNEJMoa1105243\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa1105243\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=MS+Cohen&#x00026;author=MC+Hosseinipour&#x00026;author=N+Kumarasamy&#x00026;author=JG+Hakim&#x00026;author=S+Mehendale&#x00026;author=S+Chariyalertsak&#x00026;publication_year=2011&#x00026;title=Prevention+of+HIV-1+infection+with+early+antiretroviral+therapy&#x00026;journal=N+Engl+J+Med&#x00026;volume=365&#x00026;pages=493-505\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref10\" id=\"ref10\"\u003E\u003C\u002Fa\u003E10. Frescura, L, Godfrey-Faussett, P, Ali Feizzadeh, A, El-Sadr, W, Syarif, O, Ghys, PD, et al. Achieving the 95 95 95 targets for all: a pathway to ending AIDS. \u003Ci\u003EPLoS One\u003C\u002Fi\u003E. (2022) 17:e0272405. doi: 10.1371\u002Fjournal.pone.0272405 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35925943\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0272405\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=L+Frescura&#x00026;author=P+Godfrey-Faussett&#x00026;author=A+Ali+Feizzadeh&#x00026;author=W+El-Sadr&#x00026;author=O+Syarif&#x00026;author=PD+Ghys&#x00026;publication_year=2022&#x00026;title=Achieving+the+95+95+95+targets+for+all:+a+pathway+to+ending+AIDS&#x00026;journal=PLoS+One&#x00026;volume=17&#x00026;pages=e0272405\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref11\" id=\"ref11\"\u003E\u003C\u002Fa\u003E11. Heath, K, Levi, J, and Hill, A. The joint United Nations Programme on HIV\u002FAIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture. \u003Ci\u003EAIDS\u003C\u002Fi\u003E. (2021) 35:S197&#x2013;203. doi: 10.1097\u002FQAD.0000000000002983 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34115649\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FQAD.0000000000002983\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=K+Heath&#x00026;author=J+Levi&#x00026;author=A+Hill&#x00026;publication_year=2021&#x00026;title=The+joint+United+Nations+Programme+on+HIV\u002FAIDS+95-95-95+targets:+worldwide+clinical+and+cost+benefits+of+generic+manufacture&#x00026;journal=AIDS&#x00026;volume=35&#x00026;pages=S197-203\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref12\" id=\"ref12\"\u003E\u003C\u002Fa\u003E12. Maina, EK, Mureithi, H, Adan, AA, Muriuki, J, Lwembe, RM, and Bukusi, EA. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. \u003Ci\u003EInt J Infect Dis\u003C\u002Fi\u003E. (2020) 97:151&#x2013;8. doi: 10.1016\u002Fj.ijid.2020.05.097\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijid.2020.05.097\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=EK+Maina&#x00026;author=H+Mureithi&#x00026;author=AA+Adan&#x00026;author=J+Muriuki&#x00026;author=RM+Lwembe&#x00026;author=EA+Bukusi&#x00026;publication_year=2020&#x00026;title=Incidences+and+factors+associated+with+viral+suppression+or+rebound+among+HIV+patients+on+combination+antiretroviral+therapy+from+three+counties+in+Kenya&#x00026;journal=Int+J+Infect+Dis&#x00026;volume=97&#x00026;pages=151-8\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref13\" id=\"ref13\"\u003E\u003C\u002Fa\u003E13. Taiwo, B, Gallien, S, Aga, E, and Ribaudo, H. Antiretroviral drug resistance in HIV-1 &#x2013; infected patients experiencing persistent low-level viremia during first-line. \u003Ci\u003ETherapy\u003C\u002Fi\u003E. (2011) 204:515&#x2013;20. doi: 10.1093\u002Finfdis\u002Fjir353 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F21791652\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Finfdis\u002Fjir353\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=B+Taiwo&#x00026;author=S+Gallien&#x00026;author=E+Aga&#x00026;author=H+Ribaudo&#x00026;publication_year=2011&#x00026;title=Antiretroviral+drug+resistance+in+HIV-1+&#x2013;+infected+patients+experiencing+persistent+low-level+viremia+during+first-line&#x00026;journal=Therapy&#x00026;volume=204&#x00026;pages=515-20\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref14\" id=\"ref14\"\u003E\u003C\u002Fa\u003E14. Gregson, J, Tang, M, Ndembi, N, Hamers, RL, Marconi, VC, Brooks, K, et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. \u003Ci\u003ELancet Infect Dis\u003C\u002Fi\u003E. (2016) 16:565&#x2013;75. doi: 10.1016\u002FS1473-3099(17)30723-5\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002FS1473-3099(17)30723-5\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Gregson&#x00026;author=M+Tang&#x00026;author=N+Ndembi&#x00026;author=RL+Hamers&#x00026;author=VC+Marconi&#x00026;author=K+Brooks&#x00026;publication_year=2016&#x00026;title=Global+epidemiology+of+drug+resistance+after+failure+of+WHO+recommended+first-line+regimens+for+adult+HIV-1+infection:+a+multicentre+retrospective+cohort+study&#x00026;journal=Lancet+Infect+Dis&#x00026;volume=16&#x00026;pages=565-75\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref15\" id=\"ref15\"\u003E\u003C\u002Fa\u003E15. Kouamou, V, Varyani, B, Shamu, T, and Mapangisana, T. Drug resistance among adolescents and young adults and response to second-line treatment. \u003Ci\u003EAIDS Res. Hum. Retrovir\u003C\u002Fi\u003E. (2020) 36:566&#x2013;73. doi: 10.1089\u002FAID.2019.0232\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1089\u002FAID.2019.0232\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=V+Kouamou&#x00026;author=B+Varyani&#x00026;author=T+Shamu&#x00026;author=T+Mapangisana&#x00026;publication_year=2020&#x00026;title=Drug+resistance+among+adolescents+and+young+adults+and+response+to+second-line+treatment&#x00026;journal=AIDS+Res.+Hum.+Retrovir&#x00026;volume=36&#x00026;pages=566-73\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref16\" id=\"ref16\"\u003E\u003C\u002Fa\u003E16. Dorward, J, and Hamers, RL. Dolutegravir in sub-Saharan Africa: context is crucial. \u003Ci\u003ELancet HIV\u003C\u002Fi\u003E. (2019) 6:e72&#x2013;3. doi: 10.1016\u002FS2352-3018(18)30331-X\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002FS2352-3018(18)30331-X\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Dorward&#x00026;author=RL+Hamers&#x00026;publication_year=2019&#x00026;title=Dolutegravir+in+sub-Saharan+Africa:+context+is+crucial&#x00026;journal=Lancet+HIV&#x00026;volume=6&#x00026;pages=e72-3\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref17\" id=\"ref17\"\u003E\u003C\u002Fa\u003E17. WHO. WHO recommends dolutegravir as preferred HIV treatment option in all populations. (2019). Available at: \u003Ca href=\"https:\u002F\u002Fwww.who.int\u002Fnews\u002Fitem\u002F22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations\"\u003Ehttps:\u002F\u002Fwww.who.int\u002Fnews\u002Fitem\u002F22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations\u003C\u002Fa\u003E (Accessed on 2021 Mar 26)\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2019&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref18\" id=\"ref18\"\u003E\u003C\u002Fa\u003E18. El-sadr, WM, Rabkin, M, Nkengasong, J, and Birx, DL. Realizing the potential of routine viral load testing in sub-Saharan Africa \u003Ci\u003EJ Int AIDS Soc\u003C\u002Fi\u003E. (2017) 20:1&#x2013;3. doi: 10.1002\u002Fjia2.25010 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29130621\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fjia2.25010\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=WM+El-sadr&#x00026;author=M+Rabkin&#x00026;author=J+Nkengasong&#x00026;author=DL+Birx&#x00026;publication_year=2017&#x00026;title=Realizing+the+potential+of+routine+viral+load+testing+in+sub-Saharan+Africa&#x00026;journal=J+Int+AIDS+Soc&#x00026;volume=20&#x00026;pages=1-3\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref19\" id=\"ref19\"\u003E\u003C\u002Fa\u003E19. WHO. What&#x2019;s new in treatment monitoring: Viral load and CD4 testing. HIV Treat care. (2017); Available at: \u003Ca href=\"https:\u002F\u002Fwww.who.int\u002Fpublications-detail-redirect\u002FWHO-HIV-2017.22\"\u003Ehttps:\u002F\u002Fwww.who.int\u002Fpublications-detail-redirect\u002FWHO-HIV-2017.22\u003C\u002Fa\u003E (Accessed March 26, 2021).\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2017&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref20\" id=\"ref20\"\u003E\u003C\u002Fa\u003E20. Opoku, S, Sakyi, SA, Ayisi-Boateng, NK, Enimil, AK, Senu, E, Ansah, RO, et al. Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana. \u003Ci\u003EAIDS Res Ther BioMed Central\u003C\u002Fi\u003E. (2022) 19:1&#x2013;10. doi: 10.1186\u002Fs12981-022-00447-2 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35614510\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12981-022-00447-2\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=S+Opoku&#x00026;author=SA+Sakyi&#x00026;author=NK+Ayisi-Boateng&#x00026;author=AK+Enimil&#x00026;author=E+Senu&#x00026;author=RO+Ansah&#x00026;publication_year=2022&#x00026;title=Factors+associated+with+viral+suppression+and+rebound+among+adult+HIV+patients+on+treatment:+a+retrospective+study+in+Ghana&#x00026;journal=AIDS+Res+Ther+BioMed+Central&#x00026;volume=19&#x00026;pages=1-10\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref21\" id=\"ref21\"\u003E\u003C\u002Fa\u003E21. Liu, T, Chambers, LC, Hansen, B, Bazerman, LB, Cachay, ER, Christopoulos, K, et al. Risk of HIV viral rebound in the era of universal treatment in a multi-center sample of persons with HIV in primary care. \u003Ci\u003EOpen Forum Infect Dis\u003C\u002Fi\u003E. (2023) 10:1&#x2013;11. doi: 10.1093\u002Fofid\u002Fofad257 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37351454\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Fofid\u002Fofad257\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=T+Liu&#x00026;author=LC+Chambers&#x00026;author=B+Hansen&#x00026;author=LB+Bazerman&#x00026;author=ER+Cachay&#x00026;author=K+Christopoulos&#x00026;publication_year=2023&#x00026;title=Risk+of+HIV+viral+rebound+in+the+era+of+universal+treatment+in+a+multi-center+sample+of+persons+with+HIV+in+primary+care&#x00026;journal=Open+Forum+Infect+Dis&#x00026;volume=10&#x00026;pages=1-11\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref22\" id=\"ref22\"\u003E\u003C\u002Fa\u003E22. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. (2016). Available at: \u003Ca href=\"https:\u002F\u002Fwww.who.int\u002Fhiv\u002Fpub\u002Fguidelines\u002Fkeypopulations-2016\u002Fen\u002F\"\u003Ehttps:\u002F\u002Fwww.who.int\u002Fhiv\u002Fpub\u002Fguidelines\u002Fkeypopulations-2016\u002Fen\u002F\u003C\u002Fa\u003E (Accessed on 2020 Aug 24)\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2016&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref23\" id=\"ref23\"\u003E\u003C\u002Fa\u003E23. Ekong, E, Ndembi, N, Okonkwo, P, Dakum, P, Idoko, J, Banigbe, B, et al. Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria. \u003Ci\u003EAIDS Res Ther BioMed Central\u003C\u002Fi\u003E. (2020) 17:7&#x2013;8. doi: 10.1186\u002Fs12981-020-0261-z \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32066473\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12981-020-0261-z\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=E+Ekong&#x00026;author=N+Ndembi&#x00026;author=P+Okonkwo&#x00026;author=P+Dakum&#x00026;author=J+Idoko&#x00026;author=B+Banigbe&#x00026;publication_year=2020&#x00026;title=Epidemiologic+and+viral+predictors+of+antiretroviral+drug+resistance+among+persons+living+with+HIV+in+a+large+treatment+program+in+Nigeria&#x00026;journal=AIDS+Res+Ther+BioMed+Central&#x00026;volume=17&#x00026;pages=7-8\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref24\" id=\"ref24\"\u003E\u003C\u002Fa\u003E24. Rossouw, TM, Feucht, UD, Melikian, G, Van Dyk, G, Thomas, W, Du Plessis, NM, et al. Factors associated with the development of drug resistance mutations in HIV-1 infected children failing protease inhibitor-based antiretroviral therapy in South Africa. \u003Ci\u003EPLoS One\u003C\u002Fi\u003E. (2015) 10:1&#x2013;16. doi: 10.1371\u002Fjournal.pone.0133452 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26196688\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0133452\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=TM+Rossouw&#x00026;author=UD+Feucht&#x00026;author=G+Melikian&#x00026;author=G+Van+Dyk&#x00026;author=W+Thomas&#x00026;author=NM+Du+Plessis&#x00026;publication_year=2015&#x00026;title=Factors+associated+with+the+development+of+drug+resistance+mutations+in+HIV-1+infected+children+failing+protease+inhibitor-based+antiretroviral+therapy+in+South+Africa&#x00026;journal=PLoS+One&#x00026;volume=10&#x00026;pages=1-16\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref25\" id=\"ref25\"\u003E\u003C\u002Fa\u003E25. Bonney, EY, Lamptey, H, Aboagye, JO, Zaab-Yen Abana, C, Boateng, AT, Quansah, DNK, et al. Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research. \u003Ci\u003EJ Virus Erad\u003C\u002Fi\u003E. (2021) 7:100027. doi: 10.1016\u002Fj.jve.2020.100027 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33437495\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jve.2020.100027\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=EY+Bonney&#x00026;author=H+Lamptey&#x00026;author=JO+Aboagye&#x00026;author=C+Zaab-Yen+Abana&#x00026;author=AT+Boateng&#x00026;author=DNK+Quansah&#x00026;publication_year=2021&#x00026;title=Unwillingness+of+patients+in+Ghana+to+interrupt+antiretroviral+therapy+for+HIV+cure+research&#x00026;journal=J+Virus+Erad&#x00026;volume=7&#x00026;pages=100027\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref26\" id=\"ref26\"\u003E\u003C\u002Fa\u003E26. Ghana AIDS Commission. Ghana&#x2019;s HIV fact sheet 2019. (2020). Available at: \u003Ca href=\"https:\u002F\u002Fwww.ghanaids.gov.gh\u002Fmcadmin\u002FUploads\u002F2019\u002FFACT\u002FSHEET\u002F22\u002F06\u002F2020\u002Frevised(1).pdf\"\u003Ehttps:\u002F\u002Fwww.ghanaids.gov.gh\u002Fmcadmin\u002FUploads\u002F2019\u002FFACT\u002FSHEET\u002F22\u002F06\u002F2020\u002Frevised(1).pdf\u003C\u002Fa\u003E (Accessed on 2023 Mar 21)\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2020&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref27\" id=\"ref27\"\u003E\u003C\u002Fa\u003E27. Ali, JH, and Yirtaw, TG. Time to viral load suppression and its associated factors in cohort of patients taking antiretroviral treatment in east Shewa zone, Oromiya, Ethiopia, 2018. \u003Ci\u003EBMC Infect Dis\u003C\u002Fi\u003E. (2019) 19:1&#x2013;6. doi: 10.1186\u002Fs12879-019-4702-z\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12879-019-4702-z\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=JH+Ali&#x00026;author=TG+Yirtaw&#x00026;publication_year=2019&#x00026;title=Time+to+viral+load+suppression+and+its+associated+factors+in+cohort+of+patients+taking+antiretroviral+treatment+in+east+Shewa+zone+Oromiya+Ethiopia+2018&#x00026;journal=BMC+Infect+Dis&#x00026;volume=19&#x00026;pages=1-6\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref28\" id=\"ref28\"\u003E\u003C\u002Fa\u003E28. Ghana National AIDS Control Programme. Guidelines for antiretroviral therapy in Ghana. (2017). Available at: \u003Ca href=\"https:\u002F\u002Fwww.ccmghana.net\u002Findex.php\u002Fpolicies-guidelines?download=199:art-guidelinesrevised-2017\"\u003Ehttps:\u002F\u002Fwww.ccmghana.net\u002Findex.php\u002Fpolicies-guidelines?download=199:art-guidelinesrevised-2017\u003C\u002Fa\u003E (Accessed on 2023 Mar 21)\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2017&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref29\" id=\"ref29\"\u003E\u003C\u002Fa\u003E29. Alhassan, RK, Ketor, CE, Ashinyo, A, Ashinyo, ME, Nutor, JJ, Adjadeh, C, et al. Quality of antiretroviral therapy services in Ghana: implications for the HIV response in resourceconstrained settings. \u003Ci\u003ESAGE Open Med\u003C\u002Fi\u003E. (2021) 9:205031212110361. doi: 10.1177\u002F20503121211036142 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34377475\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1177\u002F20503121211036142\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=RK+Alhassan&#x00026;author=CE+Ketor&#x00026;author=A+Ashinyo&#x00026;author=ME+Ashinyo&#x00026;author=JJ+Nutor&#x00026;author=C+Adjadeh&#x00026;publication_year=2021&#x00026;title=Quality+of+antiretroviral+therapy+services+in+Ghana:+implications+for+the+HIV+response+in+resourceconstrained+settings&#x00026;journal=SAGE+Open+Med&#x00026;volume=9&#x00026;pages=205031212110361\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref30\" id=\"ref30\"\u003E\u003C\u002Fa\u003E30. Ghana AIDS Commission. National HIV and AIDS policy: Universal access to HIV prevention, treatment and care services towards ending AIDS as a public health threat. Office of the President. (2019). Available from: \u003Ca href=\"https:\u002F\u002Fwww.ghanaids.gov.gh\"\u003Ehttps:\u002F\u002Fwww.ghanaids.gov.gh\u003C\u002Fa\u003E (Accessed March 21, 2021).\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref31\" id=\"ref31\"\u003E\u003C\u002Fa\u003E31. Wakooko, P, Gavamukulya, Y, and Wandabwa, JN. Viral load suppression and associated factors among HIV patients on antiretroviral treatment in Bulambuli District, eastern Uganda: a retrospective cohort study. \u003Ci\u003EInfect Dis Res Treat\u003C\u002Fi\u003E. (2020) 13:117863372097063. doi: 10.1177\u002F1178633720970632 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33223836\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1177\u002F1178633720970632\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=P+Wakooko&#x00026;author=Y+Gavamukulya&#x00026;author=JN+Wandabwa&#x00026;publication_year=2020&#x00026;title=Viral+load+suppression+and+associated+factors+among+HIV+patients+on+antiretroviral+treatment+in+Bulambuli+District+eastern+Uganda:+a+retrospective+cohort+study&#x00026;journal=Infect+Dis+Res+Treat&#x00026;volume=13&#x00026;pages=117863372097063\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref32\" id=\"ref32\"\u003E\u003C\u002Fa\u003E32. Mogosetsi, NJ, Mabuza, LH, and Ogunbanjo, GA. The prevalence of HIV load suppression and related factors among patients on ART at Phedisong 4 clinic, Pretoria, South Africa. \u003Ci\u003EOpen Public Health J\u003C\u002Fi\u003E. (2018) 11:135&#x2013;46. doi: 10.2174\u002F1874944501811010135\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.2174\u002F1874944501811010135\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=NJ+Mogosetsi&#x00026;author=LH+Mabuza&#x00026;author=GA+Ogunbanjo&#x00026;publication_year=2018&#x00026;title=The+prevalence+of+HIV+load+suppression+and+related+factors+among+patients+on+ART+at+Phedisong+4+clinic+Pretoria+South+Africa&#x00026;journal=Open+Public+Health+J&#x00026;volume=11&#x00026;pages=135-46\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref33\" id=\"ref33\"\u003E\u003C\u002Fa\u003E33. Abdullahi, SB, Ibrahim, OR, Okeji, AB, Yandoma, RI, Bashir, I, Haladu, S, et al. Viral suppression among HIV-positive patients on antiretroviral therapy in northwestern Nigeria: an eleven-year review of tertiary care Centre records, January 2009&#x2013;December 2019. \u003Ci\u003EBMC Infect Dis BioMed Central\u003C\u002Fi\u003E. (2021) 21:1&#x2013;8. doi: 10.1186\u002Fs12879-021-06722-3 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34600477\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12879-021-06722-3\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=SB+Abdullahi&#x00026;author=OR+Ibrahim&#x00026;author=AB+Okeji&#x00026;author=RI+Yandoma&#x00026;author=I+Bashir&#x00026;author=S+Haladu&#x00026;publication_year=2021&#x00026;title=Viral+suppression+among+HIV-positive+patients+on+antiretroviral+therapy+in+northwestern+Nigeria:+an+eleven-year+review+of+tertiary+care+Centre+records+January+2009&#x2013;December+2019&#x00026;journal=BMC+Infect+Dis+BioMed+Central&#x00026;volume=21&#x00026;pages=1-8\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref34\" id=\"ref34\"\u003E\u003C\u002Fa\u003E34. ABD, D, Penda, CI, Madec, Y, Ngondi, GD, Moukoko, A, Varloteaux, M, et al. Viral load suppression in HIV-infected adolescents in Cameroon: towards achieving the UNAIDS 95% viral suppression target. \u003Ci\u003EBMC Pediatr\u003C\u002Fi\u003E. (2023) 23:1&#x2013;8.\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=D+ABD&#x00026;author=CI+Penda&#x00026;author=Y+Madec&#x00026;author=GD+Ngondi&#x00026;author=A+Moukoko&#x00026;author=M+Varloteaux&#x00026;publication_year=2023&#x00026;title=Viral+load+suppression+in+HIV-infected+adolescents+in+Cameroon:+towards+achieving+the+UNAIDS+95%+viral+suppression+target&#x00026;journal=BMC+Pediatr&#x00026;volume=23&#x00026;pages=1-8\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref35\" id=\"ref35\"\u003E\u003C\u002Fa\u003E35. Woldesenbet, SA, Kufa, T, Barron, P, Chirombo, BC, Cheyip, M, Ayalew, K, et al. Viral suppression and factors associated with failure to achieve viral suppression among pregnant women in South Africa. \u003Ci\u003EAIDS\u003C\u002Fi\u003E. (2020) 34:589&#x2013;97. doi: 10.1097\u002FQAD.0000000000002457 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F31821189\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FQAD.0000000000002457\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=SA+Woldesenbet&#x00026;author=T+Kufa&#x00026;author=P+Barron&#x00026;author=BC+Chirombo&#x00026;author=M+Cheyip&#x00026;author=K+Ayalew&#x00026;publication_year=2020&#x00026;title=Viral+suppression+and+factors+associated+with+failure+to+achieve+viral+suppression+among+pregnant+women+in+South+Africa&#x00026;journal=AIDS&#x00026;volume=34&#x00026;pages=589-97\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref36\" id=\"ref36\"\u003E\u003C\u002Fa\u003E36. Dzando, G, Salifu, S, Donyi, AB, Akpeke, H, Kumah, A, Dordunu, R, et al. Healthcare in Ghana amidst the coronavirus pandemic: a narrative literature review. \u003Ci\u003EJ Public Health Res\u003C\u002Fi\u003E. (2022) 11:2448. doi: 10.4081\u002Fjphr.2021.2448 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34351103\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.4081\u002Fjphr.2021.2448\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=G+Dzando&#x00026;author=S+Salifu&#x00026;author=AB+Donyi&#x00026;author=H+Akpeke&#x00026;author=A+Kumah&#x00026;author=R+Dordunu&#x00026;publication_year=2022&#x00026;title=Healthcare+in+Ghana+amidst+the+coronavirus+pandemic:+a+narrative+literature+review&#x00026;journal=J+Public+Health+Res&#x00026;volume=11&#x00026;pages=2448\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref37\" id=\"ref37\"\u003E\u003C\u002Fa\u003E37. Palmer, A, Gabler, K, Rachlis, B, Ding, E, Chia, J, Bacani, N, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. \u003Ci\u003EMed (United States)\u003C\u002Fi\u003E. (2018) 97:e10562. doi: 10.1097\u002FMD.0000000000010562\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FMD.0000000000010562\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=A+Palmer&#x00026;author=K+Gabler&#x00026;author=B+Rachlis&#x00026;author=E+Ding&#x00026;author=J+Chia&#x00026;author=N+Bacani&#x00026;publication_year=2018&#x00026;title=Viral+suppression+and+viral+rebound+among+young+adults+living+with+HIV+in+Canada&#x00026;journal=Med+(United+States)&#x00026;volume=97&#x00026;pages=e10562\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref38\" id=\"ref38\"\u003E\u003C\u002Fa\u003E38. CATIE. HIV treatment and an undetectable viral load to prevent HIV transmission. Canada&#x2019;s source for HIV and hepatitis C information. (2023). Available at: \u003Ca href=\"https:\u002F\u002Fwww.catie.ca\u002Fhiv-treatment-and-an-undetectable-viral-load-toprevent-hiv-transmission\"\u003Ehttps:\u002F\u002Fwww.catie.ca\u002Fhiv-treatment-and-an-undetectable-viral-load-toprevent-hiv-transmission\u003C\u002Fa\u003E (Accessed on 2022 Oct 18)\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?publication_year=2023&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref39\" id=\"ref39\"\u003E\u003C\u002Fa\u003E39. Centers for Disease Control and Prevention. Evidence of HIV treatment and viral suppression in preventing the sexual transmission of HIV. 2020. Available from: \u003Ca href=\"https:\u002F\u002Fwww.cdc.gov\"\u003Ehttps:\u002F\u002Fwww.cdc.gov\u003C\u002Fa\u003E (Accessed March 26, 2021).\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?title=Evidence+of+HIV+treatment+and+viral+suppression+in+preventing+the+sexual+transmission+of+HIV&#x00026;\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref40\" id=\"ref40\"\u003E\u003C\u002Fa\u003E40. Campos, N, Myburgh, R, Garcel, A, Vautrin, A, Lapasset, L, Nadal, ES, et al. Long lasting control of viral rebound with a new drug ABX464 targeting rev - mediated viral RNA biogenesis. \u003Ci\u003ERetrovirology\u003C\u002Fi\u003E. (2015) 12:1&#x2013;15. doi: 10.1186\u002Fs12977-015-0159-3 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F25889234\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12977-015-0159-3\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=N+Campos&#x00026;author=R+Myburgh&#x00026;author=A+Garcel&#x00026;author=A+Vautrin&#x00026;author=L+Lapasset&#x00026;author=ES+Nadal&#x00026;publication_year=2015&#x00026;title=Long+lasting+control+of+viral+rebound+with+a+new+drug+ABX464+targeting+rev+-+mediated+viral+RNA+biogenesis&#x00026;journal=Retrovirology&#x00026;volume=12&#x00026;pages=1-15\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref41\" id=\"ref41\"\u003E\u003C\u002Fa\u003E41. Min, S, Gillani, FS, Aung, S, Garland, JM, and Beckwith, CG. Evaluating HIV viral rebound among persons on suppressive antiretroviral treatment in the era of &#x201C;undetectable equals Untransmittable (U=U).&#x201D;. \u003Ci\u003EOpen Forum Infect Dis\u003C\u002Fi\u003E. (2020) 7:1&#x2013;9. doi: 10.1186\u002Fs12879-024-10241-2\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12879-024-10241-2\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=S+Min&#x00026;author=FS+Gillani&#x00026;author=S+Aung&#x00026;author=JM+Garland&#x00026;author=CG+Beckwith&#x00026;publication_year=2020&#x00026;title=Evaluating+HIV+viral+rebound+among+persons+on+suppressive+antiretroviral+treatment+in+the+era+of+&#x201C;undetectable+equals+Untransmittable+(U=U).&#x201D;&#x00026;journal=Open+Forum+Infect+Dis&#x00026;volume=7&#x00026;pages=1-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref42\" id=\"ref42\"\u003E\u003C\u002Fa\u003E42. Leddy, AM, Turan, JM, Johnson, MO, Neilands, TB, Kempf, MC, Konkle-Parker, D, et al. Poverty stigma is associated with suboptimal HIV care and treatment outcomes among women living with HIV in the United States. \u003Ci\u003EAIDS\u003C\u002Fi\u003E. (2019) 33:1379&#x2013;84. doi: 10.1097\u002FQAD.0000000000002189 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F30870197\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FQAD.0000000000002189\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=AM+Leddy&#x00026;author=JM+Turan&#x00026;author=MO+Johnson&#x00026;author=TB+Neilands&#x00026;author=MC+Kempf&#x00026;author=D+Konkle-Parker&#x00026;publication_year=2019&#x00026;title=Poverty+stigma+is+associated+with+suboptimal+HIV+care+and+treatment+outcomes+among+women+living+with+HIV+in+the+United+States&#x00026;journal=AIDS&#x00026;volume=33&#x00026;pages=1379-84\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref43\" id=\"ref43\"\u003E\u003C\u002Fa\u003E43. Haas, AD, Radin, E, Hakim, AJ, Jahn, A, Philip, NM, Jonnalagadda, S, et al. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys. \u003Ci\u003EJ Int AIDS Soc\u003C\u002Fi\u003E. (2020) 23:1&#x2013;12. doi: 10.1002\u002Fjia2.25631 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33225559\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1002\u002Fjia2.25631\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=AD+Haas&#x00026;author=E+Radin&#x00026;author=AJ+Hakim&#x00026;author=A+Jahn&#x00026;author=NM+Philip&#x00026;author=S+Jonnalagadda&#x00026;publication_year=2020&#x00026;title=Prevalence+of+nonsuppressed+viral+load+and+associated+factors+among+HIV-positive+adults+receiving+antiretroviral+therapy+in+Eswatini+Lesotho+Malawi+Zambia+and+Zimbabwe+(2015+to+2017):+results+from+population-based+nationally+representative+surveys&#x00026;journal=J+Int+AIDS+Soc&#x00026;volume=23&#x00026;pages=1-12\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref44\" id=\"ref44\"\u003E\u003C\u002Fa\u003E44. Ng&#x2019;ambi, W, Estill, J, Jahn, A, Orel, E, Chimpandule, T, Nyirenda, R, et al. Factors associated with the incidence rate of HIV viral rebound among children and adults receiving antiretroviral therapy in Malawi using the laboratory management information system: 2011-2020. \u003Ci\u003EmedRxiv\u003C\u002Fi\u003E. (2021) 2021:21264672. doi: 10.1101\u002F2021.10.07.21264672v1.abstract\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1101\u002F2021.10.07.21264672v1.abstract\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=W+Ng&#x2019;ambi&#x00026;author=J+Estill&#x00026;author=A+Jahn&#x00026;author=E+Orel&#x00026;author=T+Chimpandule&#x00026;author=R+Nyirenda&#x00026;publication_year=2021&#x00026;title=Factors+associated+with+the+incidence+rate+of+HIV+viral+rebound+among+children+and+adults+receiving+antiretroviral+therapy+in+Malawi+using+the+laboratory+management+information+system:+2011-2020&#x00026;journal=medRxiv&#x00026;volume=2021&#x00026;pages=21264672\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref45\" id=\"ref45\"\u003E\u003C\u002Fa\u003E45. Diress, G, Dagne, S, Alemnew, B, Adane, S, and Addisu, A. Viral load suppression after enhanced adherence counseling and its predictors among high viral load HIV seropositive people in north Wollo zone public hospitals, Northeast Ethiopia, 2019: retrospective cohort study. \u003Ci\u003EAIDS Res Treat\u003C\u002Fi\u003E. (2020) 2020:1&#x2013;9. doi: 10.1155\u002F2020\u002F8909232 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32373359\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1155\u002F2020\u002F8909232\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=G+Diress&#x00026;author=S+Dagne&#x00026;author=B+Alemnew&#x00026;author=S+Adane&#x00026;author=A+Addisu&#x00026;publication_year=2020&#x00026;title=Viral+load+suppression+after+enhanced+adherence+counseling+and+its+predictors+among+high+viral+load+HIV+seropositive+people+in+north+Wollo+zone+public+hospitals+Northeast+Ethiopia+2019:+retrospective+cohort+study&#x00026;journal=AIDS+Res+Treat&#x00026;volume=2020&#x00026;pages=1-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref46\" id=\"ref46\"\u003E\u003C\u002Fa\u003E46. Joseph Davey, D, Abrahams, Z, Feinberg, M, Prins, M, Serrao, C, Medeossi, B, et al. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on firstline antiretroviral therapy in South Africa. \u003Ci\u003EInt J STD AIDS\u003C\u002Fi\u003E. (2018) 29:603&#x2013;10. doi: 10.1177\u002F0956462417748859 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29334886\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1177\u002F0956462417748859\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=D+Joseph+Davey&#x00026;author=Z+Abrahams&#x00026;author=M+Feinberg&#x00026;author=M+Prins&#x00026;author=C+Serrao&#x00026;author=B+Medeossi&#x00026;publication_year=2018&#x00026;title=Factors+associated+with+recent+unsuppressed+viral+load+in+HIV-1-infected+patients+in+care+on+firstline+antiretroviral+therapy+in+South+Africa&#x00026;journal=Int+J+STD+AIDS&#x00026;volume=29&#x00026;pages=603-10\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref47\" id=\"ref47\"\u003E\u003C\u002Fa\u003E47. Crespo-bermejo, C, Ram&#x000ED;rez, E, Arellano, D, Lara-aguilar, V, Valle-millares, D, and G&#x000F3;mez-, ML. Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status. \u003Ci\u003EVirulence\u003C\u002Fi\u003E. (2021) 12:2919&#x2013;31. doi: 10.1080\u002F21505594.2021.2004743 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34874239\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1080\u002F21505594.2021.2004743\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=C+Crespo-bermejo&#x00026;author=E+Ram&#x000ED;rez&#x00026;author=D+Arellano&#x00026;author=V+Lara-aguilar&#x00026;author=D+Valle-millares&#x00026;author=ML+G&#x000F3;mez-&#x00026;publication_year=2021&#x00026;title=Persistent+low-level+viremia+in+persons+living+with+HIV+undertreatment:+an+unresolved+status&#x00026;journal=Virulence&#x00026;volume=12&#x00026;pages=2919-31\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref48\" id=\"ref48\"\u003E\u003C\u002Fa\u003E48. Swenson, LC, Min, JE, Woods, CK, Cai, E, Li, JZ, Montaner, JSG, et al. HIV drug resistance detected during low-level viremia is associated with subsequent Virologic failure. \u003Ci\u003EAIDS\u003C\u002Fi\u003E. (2014) 28:1125&#x2013;34. doi: 10.1097\u002FQAD.0000000000000203 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F24451160\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FQAD.0000000000000203\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=LC+Swenson&#x00026;author=JE+Min&#x00026;author=CK+Woods&#x00026;author=E+Cai&#x00026;author=JZ+Li&#x00026;author=JSG+Montaner&#x00026;publication_year=2014&#x00026;title=HIV+drug+resistance+detected+during+low-level+viremia+is+associated+with+subsequent+Virologic+failure&#x00026;journal=AIDS&#x00026;volume=28&#x00026;pages=1125-34\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref49\" id=\"ref49\"\u003E\u003C\u002Fa\u003E49. Joya, C, Won, SH, Schofield, C, Lalani, T, Maves, RC, Kronmann, K, et al. Persistent Lowlevel viremia while on antiretroviral therapy is an independent risk factor for Virologic failure. \u003Ci\u003EClin Infect Dis\u003C\u002Fi\u003E. (2019) 69:2145&#x2013;52. doi: 10.1093\u002Fcid\u002Fciz129\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcid\u002Fciz129\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=C+Joya&#x00026;author=SH+Won&#x00026;author=C+Schofield&#x00026;author=T+Lalani&#x00026;author=RC+Maves&#x00026;author=K+Kronmann&#x00026;publication_year=2019&#x00026;title=Persistent+Lowlevel+viremia+while+on+antiretroviral+therapy+is+an+independent+risk+factor+for+Virologic+failure&#x00026;journal=Clin+Infect+Dis&#x00026;volume=69&#x00026;pages=2145-52\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref50\" id=\"ref50\"\u003E\u003C\u002Fa\u003E50. Villalobos, C, Ceballos, ME, Ferr&#x000E9;s, M, and Palma, C. Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia. \u003Ci\u003EJ Clin Virol\u003C\u002Fi\u003E. (2020) 132:104657. doi: 10.1016\u002Fj.jcv.2020.104657 \u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33049643\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jcv.2020.104657\" target=\"_blank\"\u003ECrossref Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=C+Villalobos&#x00026;author=ME+Ceballos&#x00026;author=M+Ferr&#x000E9;s&#x00026;author=C+Palma&#x00026;publication_year=2020&#x00026;title=Drug+resistance+mutations+in+proviral+DNA+of+HIV-infected+patients+with+low+level+of+viremia&#x00026;journal=J+Clin+Virol&#x00026;volume=132&#x00026;pages=104657\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\"\u003E\n\u003Cp class=\"ReferencesCopy1\"\u003E\u003Ca name=\"ref51\" id=\"ref51\"\u003E\u003C\u002Fa\u003E51. Fhi360. Reaching the Third 95: Viral Load Suppression among Key Population Individuals Living with HIV [Technical brief]. FHI 360. (2019). Available from: \u003Ca href=\"https:\u002F\u002Fwww.fhi360.org\u002FLINKAGES\"\u003Ehttps:\u002F\u002Fwww.fhi360.org\u002FLINKAGES\u003C\u002Fa\u003E (Accessed October 18, 2022).\u003C\u002Fp\u003E\n\u003Cp class=\"ReferencesCopy2\"\u003E\u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E \u003Ca id=\"h16\" name=\"h16\"\u003E\u003C\u002Fa\u003E\n\u003Ch2\u003EGlossary\u003C\u002Fh2\u003E\n\u003Cp class=\"mb15\"\u003E\u003Cb\u003EHIV &#x2013;\u003C\u002Fb\u003E  Human Immunodeficiency Virus\u003Cbr\u003E\n\u003Cb\u003EAIDS &#x2013;\u003C\u002Fb\u003E  Acquired Immunodeficiency Syndrome\u003Cbr\u003E\n\u003Cb\u003EPLWH &#x2013;\u003C\u002Fb\u003E  People living with HIV\u003Cbr\u003E\n\u003Cb\u003EART &#x2013;\u003C\u002Fb\u003E  Antiretroviral therapy\u003Cbr\u003E\n\u003Cb\u003ESSA &#x2013;\u003C\u002Fb\u003E  Sub-Saharan Africa\u003Cbr\u003E\n\u003Cb\u003ENNRTI &#x2013;\u003C\u002Fb\u003E  Non-nucleoside reverse transcriptase inhibitor\u003Cbr\u003E\n\u003Cb\u003ENRTI &#x2013;\u003C\u002Fb\u003E  Nucleos(t)ide reverse transcriptase inhibitor\u003Cbr\u003E\n\u003Cb\u003EINSTI &#x2013;\u003C\u002Fb\u003E  Integrase strand transfer inhibitor\u003Cbr\u003E\n\u003Cb\u003ENVP &#x2013;\u003C\u002Fb\u003E  Nevirapine\u003Cbr\u003E\n\u003Cb\u003EEFV &#x2013;\u003C\u002Fb\u003E  Efavirenz\u003Cbr\u003E\n\u003Cb\u003E3TC &#x2013;\u003C\u002Fb\u003E  Lamivudine\u003Cbr\u003E\n\u003Cb\u003EAZT &#x2013;\u003C\u002Fb\u003E  Zidovudine\u003Cbr\u003E\n\u003Cb\u003ETDF &#x2013;\u003C\u002Fb\u003E  Tenofovir disoproxil fumarate\u003Cbr\u003E\n\u003Cb\u003EDTG &#x2013;\u003C\u002Fb\u003E  Dolutegravir\u003Cbr\u003E\n\u003Cb\u003EH-CRIS &#x2013;\u003C\u002Fb\u003E  HIV Cure Research Infrastructure Study\u003Cbr\u003E\n\u003Cb\u003ENMIMR &#x2013;\u003C\u002Fb\u003E  Noguchi Memorial Institute for Medical Research\u003Cbr\u003E\n\u003Cb\u003EPBMC &#x2013;\u003C\u002Fb\u003E  Peripheral blood mononuclear cells\u003Cbr\u003E\n\u003Cb\u003EPBS &#x2013;\u003C\u002Fb\u003E  Phosphate buffered saline\u003Cbr\u003E\n\u003Cb\u003EFBS &#x2013;\u003C\u002Fb\u003E  Fetal bovine serum\u003Cbr\u003E\n\u003Cb\u003EDMSO &#x2013;\u003C\u002Fb\u003E  Dimethyl sulfoxide\u003Cbr\u003E\n\u003Cb\u003ERLS &#x2013;\u003C\u002Fb\u003E  Resource-limited setting\u003Cbr\u003E\n\u003Cb\u003EMl &#x2013;\u003C\u002Fb\u003E  Milliliters\u003Cbr\u003E\n\u003Cb\u003E&#x03BC;l &#x2013;\u003C\u002Fb\u003E  Microliters\u003C\u002Fp\u003E\n\u003C\u002Fdiv\u003E \u003Cdiv class=\"thinLineM20\"\u003E\u003C\u002Fdiv\u003E \u003Cdiv class=\"AbstractSummary\"\u003E\n\u003Cp\u003E\u003Cspan\u003EKeywords:\u003C\u002Fspan\u003E viral rebound, viral suppression, viral load, ART, HIV\u003C\u002Fp\u003E\n\u003Cp\u003E\u003Cspan\u003ECitation:\u003C\u002Fspan\u003E Boateng AT, Aboagye JO, Lamptey H, Abana CZ-Y, Abaidoo-Myles A, Quansah DNK, Agyemang S, Awuku-Larbi Y, Ansa G, Oliver-Commey J, Ganu V, Kyei GB, Puplampu P and Bonney EY (2025) Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana. \u003Ci\u003EFront. Public Health\u003C\u002Fi\u003E. 13:1508793. doi: 10.3389\u002Ffpubh.2025.1508793\u003C\u002Fp\u003E\n\u003Cp class=\"timestamps\"\u003E\u003Cspan\u003EReceived:\u003C\u002Fspan\u003E 09 October 2024; \u003Cspan\u003EAccepted:\u003C\u002Fspan\u003E 27 February 2025;\u003Cbr\u003E \u003Cspan\u003EPublished:\u003C\u002Fspan\u003E 19 March 2025.\u003C\u002Fp\u003E \u003Cdiv\u003E\n\u003Cp\u003EEdited by:\u003C\u002Fp\u003E \u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F2815320\u002Foverview\"\u003EBenard Kulohoma\u003C\u002Fa\u003E, International AIDS Vaccine Initiative Inc., United States\u003C\u002Fdiv\u003E \u003Cdiv\u003E\n\u003Cp\u003EReviewed by:\u003C\u002Fp\u003E \u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F581433\u002Foverview\"\u003EAdetayo Emmanuel Obasa\u003C\u002Fa\u003E, Stellenbosch University, South Africa\u003Cbr\u003E \u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F355398\u002Foverview\"\u003EOlivier Mukuku\u003C\u002Fa\u003E, University of KwaZulu Natal, South Africa\u003C\u002Fdiv\u003E\n\u003Cp\u003E\u003Cspan\u003ECopyright\u003C\u002Fspan\u003E &#x000A9; 2025 Boateng, Aboagye, Lamptey, Abana, Abaidoo-Myles, Quansah, Agyemang, Awuku-Larbi, Ansa, Oliver-Commey, Ganu, Kyei, Puplampu and Bonney. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http:\u002F\u002Fcreativecommons.org\u002Flicenses\u002Fby\u002F4.0\u002F\" target=\"_blank\"\u003ECreative Commons Attribution License (CC BY)\u003C\u002Fa\u003E. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C\u002Fp\u003E\n\u003Cp\u003E\u003Cspan\u003E&#x0002A;Correspondence:\u003C\u002Fspan\u003E George B. Kyei, \u003Ca id=\"encmail\"\u003EZ2t5ZWlAbm9ndWNoaS51Zy5lZHUuZ2g=\u003C\u002Fa\u003E; Peter Puplampu, \u003Ca id=\"encmail\"\u003EcHB1cGxhbXB1QHVnLmVkdS5naA==\u003C\u002Fa\u003E; Evelyn Y. Bonney, \u003Ca id=\"encmail\"\u003EZWJvbm5leUBub2d1Y2hpLnVnLmVkdS5naA==\u003C\u002Fa\u003E\u003C\u002Fp\u003E \u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E \u003C\u002Fdiv\u003E",menuHtml:"\u003Cul class=\"flyoutJournal\"\u003E \u003Cli\u003E\u003Ca href=\"#h1\"\u003EAbstract\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h2\"\u003EIntroduction\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h3\"\u003EMaterials and methods\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h4\"\u003EResults\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h5\"\u003EDiscussion\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h6\"\u003EConclusion\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h7\"\u003EData availability statement\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h8\"\u003EEthics statement\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h9\"\u003EAuthor contributions\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h10\"\u003EFunding\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h11\"\u003EAcknowledgments\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h12\"\u003EConflict of interest\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h13\"\u003EGenerative AI statement\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h14\"\u003EPublisher&#x2019;s note\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h15\"\u003EReferences\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003Cli\u003E\u003Ca href=\"#h16\"\u003EGlossary\u003C\u002Fa\u003E\u003C\u002Fli\u003E \u003C\u002Ful\u003E"},files:[{name:"fpubh-13-1508793.xml",fileServerPackageEntryId:"fpubh-13-1508793-r1\u002Ffpubh-13-1508793.xml",type:{code:"NLM_XML",name:"xml"}},{name:"Publishers-proof.pdf",fileServerPackageEntryId:e,type:{code:"PDF",name:"pdf"}},{name:"EPUB.epub",fileServerPackageEntryId:e,type:{code:"EPUB",name:"epub"}}]},currentArticlePageMetaInfo:{title:aK,link:[{rel:"canonical",href:aL}],meta:[{hid:z,property:z,name:z,content:e},{hid:aM,property:aM,name:"title",content:aK},{hid:aN,property:aN,name:z,content:e},{hid:aO,name:aO,content:"HIV,ART,viral load,viral rebound,viral suppression"},{hid:aP,property:aP,name:"site_name",content:A},{hid:aQ,property:aQ,name:H,content:Z},{hid:aR,property:aR,name:"type",content:"article"},{hid:aS,property:aS,name:"url",content:aL},{hid:aT,name:aT,content:"summary_large_image"},{hid:aU,name:aU,content:"13"},{hid:aV,name:aV,content:s},{hid:aW,name:aW,content:A},{hid:aX,name:aX,content:J},{hid:aY,name:aY,content:K},{hid:aZ,name:aZ,content:ac},{hid:a_,name:a_,content:"1508793"},{hid:a$,name:a$,content:"English"},{hid:ba,name:ba,content:M},{hid:bb,name:bb,content:"HIV; ART; viral load; viral rebound; viral suppression"},{hid:bc,name:bc,content:e},{hid:bd,name:bd,content:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Farticles\u002F10.3389\u002Ffpubh.2025.1508793\u002Fpdf"},{hid:be,name:be,content:"2025\u002F02\u002F27"},{hid:bf,name:bf,content:"2025\u002F03\u002F19"},{hid:"citation_author_0",name:o,content:"Boateng, Anthony T."},{hid:"citation_author_institution_0",name:p,content:B},{hid:"citation_author_1",name:o,content:"Aboagye, James O."},{hid:"citation_author_institution_1",name:p,content:"Medical and Scientific Research Center, University of Ghana Medical Center, Ghana"},{hid:"citation_author_2",name:o,content:"Lamptey, Helena"},{hid:"citation_author_institution_2",name:p,content:"Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Ghana"},{hid:"citation_author_3",name:o,content:"Abana, Christopher Z.-Y."},{hid:"citation_author_institution_3",name:p,content:B},{hid:"citation_author_4",name:o,content:"Abaidoo-Myles, Araba"},{hid:"citation_author_institution_4",name:p,content:B},{hid:"citation_author_5",name:o,content:"Quansah, Darius N. K."},{hid:"citation_author_institution_5",name:p,content:B},{hid:"citation_author_6",name:o,content:"Agyemang, Seth"},{hid:"citation_author_institution_6",name:p,content:"Central Laboratory, Immunology Department, Korle-Bu Teaching Hospital, Ghana"},{hid:"citation_author_7",name:o,content:"Awuku-Larbi, Yaw"},{hid:"citation_author_institution_7",name:p,content:bg},{hid:"citation_author_8",name:o,content:"Ansa, Gloria"},{hid:"citation_author_institution_8",name:p,content:"Public Health Unit, University of Ghana Hospital, Ghana"},{hid:"citation_author_9",name:o,content:"Oliver-Commey, Joseph"},{hid:"citation_author_institution_9",name:p,content:"LEKMA Hospital, Ghana"},{hid:"citation_author_10",name:o,content:"Ganu, Vincent"},{hid:"citation_author_institution_10",name:p,content:bh},{hid:"citation_author_11",name:o,content:"Kyei, George B."},{hid:"citation_author_institution_11",name:p,content:"Departments of Medicine and Molecular Microbiology, Washington University School of Medicine, United States"},{hid:"citation_author_12",name:o,content:"Puplampu, Peter"},{hid:"citation_author_institution_12",name:p,content:bh},{hid:"citation_author_13",name:o,content:"Bonney, Evelyn Y."},{hid:"citation_author_institution_13",name:p,content:bg},{hid:bi,name:bi,content:"doi:10.3389\u002Ffpubh.2025.1508793"}],script:[{src:"https:\u002F\u002Fcdnjs.cloudflare.com\u002Fpolyfill\u002Fv3\u002Fpolyfill.min.js?features=es6",body:h,async:h},{src:"https:\u002F\u002Fcdnjs.cloudflare.com\u002Fajax\u002Flibs\u002Fmathjax\u002F2.7.1\u002FMathJax.js?config=TeX-MML-AM_CHTML",body:h,async:h},{src:"https:\u002F\u002Fd1bxh8uas1mnw7.cloudfront.net\u002Fassets\u002Faltmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",body:h,async:h},{src:"https:\u002F\u002Fapi.altmetric.com\u002Fv1\u002Fdoi\u002F10.3389\u002Ffpubh.2025.1508793?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",body:h,async:h},{src:"https:\u002F\u002Fcrossmark-cdn.crossref.org\u002Fwidget\u002Fv2.0\u002Fwidget.js",body:h,async:h}]},articleHubArticlesList:[],showCrossmarkWidget:h,hasSupplementalData:i,isPreviewArticlePage:i,settingsFeaturesSwitchers:{displayTitlePillLabels:h,displayRelatedArticlesBox:h,showEditors:h,showReviewers:h,showLoopImpactLink:h,enableFigshare:i},tenantConfig:{spaceId:c,name:A,availableJournalPages:[bj,bk,bl,"volumes","about"],announcement:{sys:{id:"2tE5oIdYfULBQILAgR2OSx",__typename:"Sys"},preHeader:"Research integrity at Frontiers",title:"94% of researchers rate our articles as excellent or good",description:"Learn more about the work of our research integrity team to safeguard the quality of each article we publish.",image:[{id:"0B4B1380-42EB-4FD5-9D7E2DBC603E79F8",src:bm,name:bn,tags:["ultra","sunset","achieving","summer","challenge","winning","extreme","workout","hike","path","action","uphill","effort","athlete","physical","height","activity","mountaineering","endurance","mount","runner","nordic","race","male","achieve","nature","run","adventure",I,"perseverance","freedom","fitness","backcountry","altitude","sports","man","hill","mountain","outdoor","exercise","energetic","trail","climb","skyrunning","lifestyle"],type:H,width:7100,height:4733,archive:j,brandId:X,limited:j,fileSize:16838862,isPublic:j,original:f,copyright:f,extension:[Y],thumbnails:{mini:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002Fmini-C4875379-1478-416F-B03DF68FE3D8DBB5.png",thul:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002Fthul-C4875379-1478-416F-B03DF68FE3D8DBB5.png",webimage:bm,Guidelines:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FGuidelines-C4875379-1478-416F-B03DF68FE3D8DBB5.png",WebsiteJpg_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteJpg_XL-C4875379-1478-416F-B03DF68FE3D8DBB5.jpg",WebsiteWebP_L:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteWebP_L-C4875379-1478-416F-B03DF68FE3D8DBB5.webp",WebsiteWebP_M:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteWebP_M-C4875379-1478-416F-B03DF68FE3D8DBB5.webp",WebsiteWebP_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002FWebsiteWebP_XL-C4875379-1478-416F-B03DF68FE3D8DBB5.webp"},dateCreated:"2022-12-14T15:44:00Z",description:bn,orientation:I,watermarked:j,dateModified:"2023-01-26T09:08:47Z",datePublished:"2022-12-14T16:40:06Z",videoPreviewURLs:[],textMetaproperties:[]}],link:{text:"Find out more ",url:bo,target:g,ariaLabel:"About our research integrity team",__typename:y},__typename:"Announcement"}},components:{ibar:{tenantLogo:e,journalLogo:e,aboutUs:[{title:"Who we are",links:[{text:"Mission and values",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fmission",target:g,ariaLabel:f},{text:"History",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fhistory",target:g,ariaLabel:f},{text:"Leadership",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fleadership",target:g,ariaLabel:f},{text:"Awards",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fawards",target:g,ariaLabel:f}]},{title:"Impact and progress",links:[{text:"Frontiers' impact",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fimpact",target:g,ariaLabel:f},{text:"Progress Report 2022",url:"https:\u002F\u002Fprogressreport.frontiersin.org\u002F?utm_source=fweb&utm_medium=frep&utm_campaign=pr20",target:n,ariaLabel:f},{text:"All annual reports",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fannual-reports",target:g,ariaLabel:f}]},{title:"Publishing model",links:[{text:bp,url:bq,target:g,ariaLabel:f},{text:"Open access",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fopen-access",target:g,ariaLabel:f},{text:"Peer review",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fpeer-review",target:g,ariaLabel:f},{text:"Research integrity",url:bo,target:g,ariaLabel:f},{text:br,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fresearch-topics",target:g,ariaLabel:f},{text:"FAIR² Data Management",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Ffair-data-management",target:g,ariaLabel:f},{text:bs,url:bt,target:g,ariaLabel:f}]},{title:"Services",links:[{text:"Societies",url:"https:\u002F\u002Fpublishingpartnerships.frontiersin.org\u002F",target:n,ariaLabel:f},{text:"National consortia",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fopen-access-agreements\u002Fconsortia",target:g,ariaLabel:f},{text:"Institutional partnerships",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fopen-access-agreements",target:g,ariaLabel:f},{text:"Collaborators",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fcollaborators",target:g,ariaLabel:f}]},{title:"More from Frontiers",links:[{text:"Frontiers Forum",url:bu,target:n,ariaLabel:"this link will take you to the Frontiers Forum website"},{text:bv,url:bw,target:n,ariaLabel:bx},{text:"Press office",url:"https:\u002F\u002Fpressoffice.frontiersin.org\u002F",target:n,ariaLabel:"this link will take you to the Frontiers press office website"},{text:"Sustainability",url:"https:\u002F\u002Fwww.frontiersin.orgabout\u002Fsustainability",target:g,ariaLabel:"link to information about Frontiers' sustainability"},{text:by,url:bz,target:n,ariaLabel:"this link will take you to the Frontiers careers website"},{text:"Contact us",url:bA,target:g,ariaLabel:"this link will take you to the help pages to contact our support team"}]}],submitUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Fsubmission\u002Fsubmit?domainid=2&fieldid=70&specialtyid=0&entitytype=2&entityid=609",showSubmitButton:h,journal:{id:v,name:s,slug:w,sections:[{id:1560,name:"Aging and Public Health",slug:"aging-and-public-health"},{id:621,name:"Children and Health",slug:"children-and-health"},{id:753,name:"Digital Public Health",slug:"digital-public-health"},{id:702,name:"Disaster and Emergency Medicine",slug:bB},{id:690,name:"Environmental Health and Exposome",slug:"environmental-health-and-exposome"},{id:1310,name:"Health Economics",slug:"health-economics"},{id:aH,name:aI,slug:aJ},{id:3297,name:"Injury Prevention and Control",slug:"injury-prevention-and-control"},{id:1495,name:"Life-Course Epidemiology and Social Inequalities in Health",slug:"life-course-epidemiology-and-social-inequalities-in-health"},{id:744,name:"Occupational Health and Safety",slug:"occupational-health-and-safety"},{id:1458,name:"Planetary Health",slug:"planetary-health"},{id:637,name:"Public Health Education and Promotion",slug:"public-health-education-and-promotion"},{id:652,name:"Public Health Policy",slug:"public-health-policy"},{id:2192,name:"Public Health and Nutrition",slug:"public-health-and-nutrition"},{id:695,name:"Public Mental Health",slug:"public-mental-health"},{id:778,name:"Radiation and Health",slug:"radiation-and-health"},{id:3408,name:"Substance Use Disorders and Behavioral Addictions",slug:"substance-use-disorders-and-behavioral-addictions"}]},sectionTerm:"Sections",aboutJournal:[{title:"Scope",links:[{text:"Field chief editors",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-editors",target:g,ariaLabel:f},{text:"Mission & scope",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-scope",target:g,ariaLabel:f},{text:"Facts",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-facts",target:g,ariaLabel:f},{text:"Journal sections",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-submission",target:g,ariaLabel:f},{text:"Open access statement",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-open",target:g,ariaLabel:f},{text:"Copyright statement",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#copyright-statement",target:g,ariaLabel:f},{text:"Quality",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Fabout#about-quality",target:g,ariaLabel:f}]},{title:"For authors",links:[{text:"Why submit?",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fwhy-submit",target:g,ariaLabel:f},{text:"Article types",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Farticle-types",target:g,ariaLabel:f},{text:bC,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fauthor-guidelines",target:g,ariaLabel:f},{text:bD,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Feditor-guidelines",target:g,ariaLabel:f},{text:"Publishing fees",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fpublishing-fees",target:g,ariaLabel:f},{text:"Submission checklist",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fsubmission-checklist",target:g,ariaLabel:f},{text:"Contact editorial office",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Ffor-authors\u002Fcontact-editorial-office",target:g,ariaLabel:f}]}],mainLinks:[{text:"All journals",url:bE,target:g,ariaLabel:f},{text:"All articles",url:bF,target:g,ariaLabel:f}],journalLinks:[{text:bG,url:bj,target:g,ariaLabel:f},{text:br,url:bl,target:g,ariaLabel:f},{text:"Editorial board",url:bk,target:g,ariaLabel:f}],helpCenterLink:{text:C,url:bH,target:n,ariaLabel:C}},footer:{blocks:[{title:"Guidelines",links:[{text:bC,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Fauthor-guidelines",target:g,ariaLabel:f},{text:bD,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Feditor-guidelines",target:g,ariaLabel:f},{text:"Policies and publication ethics",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Fpolicies-and-publication-ethics",target:g,ariaLabel:f},{text:bs,url:bt,target:g,ariaLabel:f}]},{title:"Explore",links:[{text:bG,url:bF,target:g,ariaLabel:f},{text:"Research Topics ",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fresearch-topics",target:g,ariaLabel:f},{text:"Journals",url:bE,target:g,ariaLabel:f},{text:bp,url:bq,target:g,ariaLabel:f}]},{title:"Outreach",links:[{text:"Frontiers Forum ",url:bu,target:n,ariaLabel:"Frontiers Forum website"},{text:"Frontiers Policy Labs ",url:"https:\u002F\u002Fpolicylabs.frontiersin.org\u002F",target:n,ariaLabel:f},{text:bI,url:"https:\u002F\u002Fkids.frontiersin.org\u002F",target:n,ariaLabel:"Frontiers for Young Minds journal"},{text:bv,url:bw,target:n,ariaLabel:bx}]},{title:"Connect",links:[{text:C,url:bH,target:n,ariaLabel:C},{text:"Emails and alerts ",url:"https:\u002F\u002Floop.frontiersin.org\u002Fsettings\u002Femail-preferences?a=publishers",target:n,ariaLabel:"Subscribe to Frontiers emails"},{text:"Contact us ",url:bA,target:g,ariaLabel:"Subscribe to newsletter"},{text:"Submit",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fsubmission\u002Fsubmit",target:g,ariaLabel:f},{text:by,url:bz,target:n,ariaLabel:f}]}],socialLinks:[{link:{text:bJ,url:"https:\u002F\u002Fwww.facebook.com\u002FFrontiersin",target:n,ariaLabel:bJ},type:y,color:D,icon:"Facebook",size:E,hiddenText:h},{link:{text:"Frontiers Twitter",url:"https:\u002F\u002Ftwitter.com\u002Ffrontiersin",target:n,ariaLabel:f},type:y,color:D,icon:"Twitter",size:E,hiddenText:h},{link:{text:"Frontiers LinkedIn",url:"https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Ffrontiers",target:n,ariaLabel:f},type:y,color:D,icon:"LinkedIn",size:E,hiddenText:h},{link:{text:"Frontiers Instagram",url:"https:\u002F\u002Fwww.instagram.com\u002Ffrontiersin_",target:n,ariaLabel:f},type:y,color:D,icon:"Instagram",size:E,hiddenText:h}],copyright:"Frontiers Media S.A. All rights reserved",termsAndConditionsUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Flegal\u002Fterms-and-conditions",privacyPolicyUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Flegal\u002Fprivacy-policy"},newsletterComponent:f,snackbarItems:[]},mainHeader:{title:e,image:L,breadcrumbs:[],linksCollection:{total:j,items:[]},metricsCollection:{total:j,items:[]}},user:{loggedUserInfo:L},journals:[{id:bK,name:bL,slug:bM,abbreviation:bN,space:{id:k,domainName:m,__typename:b},__typename:a},{id:2445,name:bL,slug:bM,abbreviation:bN,space:{id:c,domainName:d,__typename:b},__typename:a},{id:P,name:"Test SSPH Journal",slug:"test-ssph-journal",abbreviation:"testjournal",space:{id:u,domainName:F,__typename:b},__typename:a},{id:bO,name:"TEST ALF Journal",slug:"test-alf-journal",abbreviation:"talfj",space:{id:t,domainName:Q,__typename:b},__typename:a},{id:k,name:bP,slug:bQ,abbreviation:bR,space:{id:k,domainName:m,__typename:b},__typename:a},{id:2360,name:bP,slug:bQ,abbreviation:bR,space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Smoke Test Field",slug:"smoke-test-field",abbreviation:"FJST",space:{id:R,domainName:bS,__typename:b},__typename:a},{id:bO,name:bT,slug:bU,abbreviation:bV,space:{id:u,domainName:F,__typename:b},__typename:a},{id:2077,name:bT,slug:bU,abbreviation:bV,space:{id:c,domainName:d,__typename:b},__typename:a},{id:P,name:bW,slug:bX,abbreviation:bY,space:{id:t,domainName:Q,__typename:b},__typename:a},{id:P,name:bW,slug:bX,abbreviation:bY,space:{id:c,domainName:d,__typename:b},__typename:a},{id:bZ,name:b_,slug:b$,abbreviation:ca,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3776,name:b_,slug:b$,abbreviation:ca,space:{id:c,domainName:d,__typename:b},__typename:a},{id:cb,name:cc,slug:cd,abbreviation:ce,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3765,name:cc,slug:cd,abbreviation:ce,space:{id:c,domainName:d,__typename:b},__typename:a},{id:14,name:cf,slug:cg,abbreviation:ch,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3414,name:cf,slug:cg,abbreviation:ch,space:{id:c,domainName:d,__typename:b},__typename:a},{id:20,name:ci,slug:cj,abbreviation:ck,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3754,name:ci,slug:cj,abbreviation:ck,space:{id:c,domainName:d,__typename:b},__typename:a},{id:R,name:cl,slug:cm,abbreviation:cn,space:{id:k,domainName:m,__typename:b},__typename:a},{id:2444,name:cl,slug:cm,abbreviation:cn,space:{id:c,domainName:d,__typename:b},__typename:a},{id:co,name:cp,slug:cq,abbreviation:cr,space:{id:u,domainName:F,__typename:b},__typename:a},{id:co,name:cp,slug:cq,abbreviation:cr,space:{id:c,domainName:d,__typename:b},__typename:a},{id:k,name:"GSL Test",slug:"gsl-test",abbreviation:"gslt",space:{id:r,domainName:S,__typename:b},__typename:a},{id:2356,name:"Frontiers in the Internet of Things",slug:"the-internet-of-things",abbreviation:"friot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:656,name:"Frontiers in Zoological Science",slug:"zoological-science",abbreviation:"fzoos",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1720,name:"Frontiers in Zoological Research",slug:"zoological-research",abbreviation:"fzolr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3162,name:"Frontiers in Wound Care",slug:"wound-care",abbreviation:"fwoca",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3136,name:"Frontiers in Worm Science",slug:"worm-science",abbreviation:"fwors",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3583,name:"Frontiers in Wind Energy",slug:"wind-energy",abbreviation:"fwinde",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1451,name:"Frontiers in Water",slug:"water",abbreviation:"frwa",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1561,name:"Frontiers in Virtual Reality",slug:"virtual-reality",abbreviation:"frvir",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2000,name:"Frontiers in Virology",slug:"virology",abbreviation:"fviro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:649,name:"Frontiers in Veterinary Science",slug:"veterinary-science",abbreviation:"fvets",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2176,name:"Frontiers in Urology",slug:"urology",abbreviation:"fruro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3099,name:"Frontiers in Tuberculosis",slug:"tuberculosis",abbreviation:"ftubr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1843,name:"Frontiers in Tropical Diseases",slug:"tropical-diseases",abbreviation:"fitd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2417,name:"Frontiers in Transplantation",slug:"transplantation",abbreviation:"frtra",space:{id:c,domainName:d,__typename:b},__typename:a},{id:473,name:"Frontiers in Toxicology",slug:"toxicology",abbreviation:"ftox",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2105,name:"Frontiers in Thermal Engineering",slug:"thermal-engineering",abbreviation:"fther",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3190,name:"Frontiers in The Neurobiology of Pain",slug:"the-neurobiology-of-pain",abbreviation:e,space:{id:c,domainName:d,__typename:b},__typename:a},{id:1967,name:"Frontiers in Test_Field_Science_Archive",slug:"testfieldsciencearchive",abbreviation:"fntesc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1347,name:"Frontiers in Test_Field_Humanities_Archive",slug:"testfieldhumanitiesarchive",abbreviation:"fntes",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3573,name:"Frontiers in Taxonomy",slug:"taxonomy",abbreviation:"Front. Taxon.",space:{id:c,domainName:d,__typename:b},__typename:a},{id:u,name:"Frontiers in Systems Neuroscience",slug:"systems-neuroscience",abbreviation:"fnsys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1721,name:"Frontiers in Systems Biology",slug:"systems-biology",abbreviation:"fsysb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3381,name:"Frontiers in Synthetic Biology",slug:"synthetic-biology",abbreviation:"fsybi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:22,name:"Frontiers in Synaptic Neuroscience",slug:"synaptic-neuroscience",abbreviation:"fnsyn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2299,name:"Frontiers in Sustainable Tourism",slug:"sustainable-tourism",abbreviation:"frsut",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2483,name:"Frontiers in Sustainable Resource Management",slug:"sustainable-resource-management",abbreviation:"fsrma",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1335,name:"Frontiers in Sustainable Food Systems",slug:"sustainable-food-systems",abbreviation:"fsufs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2726,name:"Frontiers in Sustainable Energy Policy",slug:"sustainable-energy-policy",abbreviation:"fsuep",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1468,name:"Frontiers in Sustainable Cities",slug:"sustainable-cities",abbreviation:"frsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1397,name:"Frontiers in Sustainable Business",slug:"sustainable-business",abbreviation:"fisb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1547,name:"Frontiers in Sustainability",slug:"sustainability",abbreviation:"frsus",space:{id:c,domainName:d,__typename:b},__typename:a},{id:604,name:"Frontiers in Surgery",slug:"surgery",abbreviation:"fsurg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2504,name:"Frontiers in Structural Biology",slug:"structural-biology",abbreviation:"frsbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:W,name:"Frontiers in Stroke",slug:"stroke",abbreviation:"fstro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3434,name:"Frontiers in Stem Cells",slug:"stem-cells",abbreviation:"fstce",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1482,name:"Frontiers in Sports and Active Living",slug:"sports-and-active-living",abbreviation:"fspor",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1695,name:"Frontiers in Space Technologies",slug:"space-technologies",abbreviation:"frspt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3519,name:"Frontiers in Solar Energy",slug:"solar-energy",abbreviation:"fsoln",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1718,name:"Frontiers in Soil Science",slug:"soil-science",abbreviation:"fsoil",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2346,name:"Frontiers in Soft Matter",slug:"soft-matter",abbreviation:"frsfm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1213,name:"Frontiers in Sociology",slug:"sociology",abbreviation:"fsoc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:T,name:"Frontiers in Society Journal Archive",slug:"society-journal-archive",abbreviation:U,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2690,name:"Frontiers in Social Psychology",slug:"social-psychology",abbreviation:"frsps",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2819,name:"Frontiers in Smart Grids",slug:"smart-grids",abbreviation:"frsgr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2288,name:"Frontiers in Sleep",slug:"sleep",abbreviation:"frsle",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2552,name:"Frontiers in Skin Cancer",slug:"skin-cancer",abbreviation:"fskcr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1786,name:"Frontiers in Signal Processing",slug:"signal-processing",abbreviation:"frsip",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1704,name:"Frontiers in Sensors",slug:"sensors",abbreviation:"fsens",space:{id:c,domainName:d,__typename:b},__typename:a},{id:u,name:"Frontiers in Science archive",slug:"science-archive",abbreviation:G,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3737,name:"Frontiers in Science Diplomacy",slug:"science-diplomacy",abbreviation:"fsdip",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2766,name:"Frontiers in Science",slug:"science",abbreviation:"fsci",space:{id:c,domainName:d,__typename:b},__typename:a},{id:657,name:"Frontiers in Robotics and AI",slug:"robotics-and-ai",abbreviation:"frobt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1606,name:"Frontiers in Research Metrics and Analytics",slug:"research-metrics-and-analytics",abbreviation:"frma",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1479,name:"Frontiers in Reproductive Health",slug:"reproductive-health",abbreviation:"frph",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1830,name:"Frontiers in Remote Sensing",slug:"remote-sensing",abbreviation:"frsen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:659,name:"Frontiers in Rehabilitation Sciences",slug:"rehabilitation-sciences",abbreviation:"fresc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3550,name:"Frontiers in Regenerative Medicine",slug:"regenerative-medicine",abbreviation:"fregm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1949,name:"Frontiers in Radiology",slug:"radiology",abbreviation:"fradi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3189,name:"Frontiers in RNA Research",slug:"rna-research",abbreviation:"frnar",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2306,name:"Frontiers in Quantum Science and Technology",slug:"quantum-science-and-technology",abbreviation:"frqst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:T,name:"Frontiers in Public Health Archive",slug:"public-health-archive",abbreviation:U,space:{id:u,domainName:F,__typename:b},__typename:a},{id:v,name:s,slug:w,abbreviation:$,space:{id:c,domainName:d,__typename:b},__typename:a},{id:36,name:"Frontiers in Psychology",slug:"psychology",abbreviation:"fpsyg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:71,name:"Frontiers in Psychiatry",slug:"psychiatry",abbreviation:"fpsyt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3267,name:"Frontiers in Protistology",slug:"protistology",abbreviation:"frpro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2452,name:"Frontiers in Proteomics",slug:"proteomics",abbreviation:"fprot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3171,name:"Frontiers in Prosthetics and Orthotics",slug:"prosthetics-and-orthotics",abbreviation:"fpror ",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3643,name:"Frontiers in Polymer Science",slug:"polymer-science",abbreviation:"fplms",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1558,name:"Frontiers in Political Science",slug:"political-science",abbreviation:"fpos",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3615,name:"Frontiers in Polar Science",slug:"polar-science",abbreviation:"fposc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:373,name:"Frontiers in Plant Science",slug:"plant-science",abbreviation:"fpls",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3477,name:"Frontiers in Plant Physiology",slug:"plant-physiology",abbreviation:"fphgy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3589,name:"Frontiers in Plant Genomics",slug:"plant-genomics",abbreviation:"fpgen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3579,name:"Frontiers in Plant Ecology",slug:"plant-ecology",abbreviation:"fpley",space:{id:c,domainName:d,__typename:b},__typename:a},{id:210,name:"Frontiers in Physiology",slug:"physiology",abbreviation:"fphys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:616,name:"Frontiers in Physics",slug:"physics",abbreviation:"fphy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1803,name:"Frontiers in Photonics",slug:"photonics",abbreviation:"fphot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3604,name:"Frontiers in Photobiology",slug:"photobiology",abbreviation:"fphbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:176,name:"Frontiers in Pharmacology",slug:"pharmacology",abbreviation:"fphar",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3388,name:"Frontiers in Personality Disorders",slug:"personality-disorders",abbreviation:"fprsd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:606,name:"Frontiers in Pediatrics",slug:"pediatrics",abbreviation:"fped",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2554,name:"Frontiers in Pediatric Dermatology",slug:"pediatric-dermatology",abbreviation:"fpdm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:T,name:"Frontiers in Pathology and Oncology Archive",slug:"pathology-and-oncology-archive",abbreviation:U,space:{id:t,domainName:Q,__typename:b},__typename:a},{id:610,name:cs,slug:ct,abbreviation:cu,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3351,name:cs,slug:ct,abbreviation:cu,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2705,name:"Frontiers in Parasitology",slug:"parasitology",abbreviation:"fpara",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1727,name:"Frontiers in Pain Research",slug:"pain-research",abbreviation:"fpain",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2679,name:"Frontiers in Organizational Psychology",slug:"organizational-psychology",abbreviation:"forgp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1702,name:"Frontiers in Oral Health",slug:"oral-health",abbreviation:"froh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2232,name:"Frontiers in Ophthalmology",slug:"ophthalmology",abbreviation:"fopht",space:{id:c,domainName:d,__typename:b},__typename:a},{id:451,name:"Frontiers in Oncology",slug:"oncology",abbreviation:"fonc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3123,name:"Frontiers in Ocean Sustainability",slug:"ocean-sustainability",abbreviation:"focsu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2612,name:"Frontiers in Occupational Therapy",slug:"occupational-therapy",abbreviation:"froct",space:{id:c,domainName:d,__typename:b},__typename:a},{id:628,name:"Frontiers in Nutrition",slug:"nutrition",abbreviation:"fnut",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2062,name:"Frontiers in Nuclear Medicine",slug:"nuclear-medicine",abbreviation:"fnume",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2172,name:"Frontiers in Nuclear Engineering",slug:"nuclear-engineering",abbreviation:"fnuen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in Neuroscience",slug:"neuroscience",abbreviation:"fnins",space:{id:c,domainName:d,__typename:b},__typename:a},{id:O,name:"Frontiers in Neurorobotics",slug:"neurorobotics",abbreviation:"fnbot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3056,name:"Frontiers in Neuropsychiatry",slug:"neuropsychiatry",abbreviation:"fnpsy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:141,name:"Frontiers in Neurology",slug:"neurology",abbreviation:"fneur",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cv,name:"Frontiers in Neuroinformatics",slug:"neuroinformatics",abbreviation:"fninf",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3283,name:"Frontiers in Neuroinflammation",slug:"neuroinflammation",abbreviation:"fnein",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1973,name:"Frontiers in Neuroimaging",slug:"neuroimaging",abbreviation:"fnimg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1833,name:"Frontiers in Neuroergonomics",slug:"neuroergonomics",abbreviation:"fnrgo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:N,name:"Frontiers in Neuroengineering",slug:"neuroengineering",abbreviation:"fneng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cw,name:"Frontiers in Neuroenergetics",slug:"neuroenergetics",abbreviation:"fnene",space:{id:c,domainName:d,__typename:b},__typename:a},{id:t,name:"Frontiers in Neuroanatomy",slug:"neuroanatomy",abbreviation:"fnana",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cb,name:"Frontiers in Neural Circuits",slug:"neural-circuits",abbreviation:"fncir",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2021,name:"Frontiers in Network Physiology",slug:"network-physiology",abbreviation:"fnetp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3130,name:"Frontiers in Network Neuroscience",slug:"network-neuroscience",abbreviation:"fnnsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2357,name:"Frontiers in Nephrology",slug:"nephrology",abbreviation:"fneph",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2320,name:"Frontiers in Natural Products",slug:"natural-products",abbreviation:"fntpr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1528,name:"Frontiers in Nanotechnology",slug:"nanotechnology",abbreviation:"fnano",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2882,name:"Frontiers in Musculoskeletal Disorders",slug:"musculoskeletal-disorders",abbreviation:"fmscd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3275,name:"Frontiers in Multiple Sclerosis",slug:"multiple-sclerosis",abbreviation:"fmscr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3152,name:"Frontiers in Mollusk Science",slug:"mollusk-science",abbreviation:"fmlsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2031,name:"Frontiers in Molecular Neuroscience",slug:"molecular-neuroscience",abbreviation:"fnmol",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2086,name:"Frontiers in Molecular Medicine",slug:"molecular-medicine",abbreviation:"fmmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:698,name:"Frontiers in Molecular Biosciences",slug:"molecular-biosciences",abbreviation:"fmolb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2807,name:"Frontiers in Microbiomes",slug:"microbiomes",abbreviation:"frmbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:310,name:"Frontiers in Microbiology",slug:"microbiology",abbreviation:"fmicb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2327,name:"Frontiers in Metals and Alloys",slug:"metals-and-alloys",abbreviation:"ftmal",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2307,name:"Frontiers in Membrane Science and Technology",slug:"membrane-science-and-technology",abbreviation:"frmst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:602,name:"Frontiers in Medicine",slug:"medicine",abbreviation:"fmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1573,name:"Frontiers in Medical Technology",slug:"medical-technology",abbreviation:"fmedt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3135,name:"Frontiers in Medical Engineering",slug:"medical-engineering",abbreviation:"fmede",space:{id:c,domainName:d,__typename:b},__typename:a},{id:950,name:"Frontiers in Mechanical Engineering",slug:"mechanical-engineering",abbreviation:"fmech",space:{id:c,domainName:d,__typename:b},__typename:a},{id:608,name:"Frontiers in Materials",slug:"materials",abbreviation:"fmats",space:{id:c,domainName:d,__typename:b},__typename:a},{id:655,name:"Frontiers in Marine Science",slug:"marine-science",abbreviation:"fmars",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2100,name:"Frontiers in Manufacturing Technology",slug:"manufacturing-technology",abbreviation:"fmtec",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2931,name:"Frontiers in Mammal Science",slug:"mammal-science",abbreviation:"fmamm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2896,name:"Frontiers in Malaria",slug:"malaria",abbreviation:"fmala",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3107,name:"Frontiers in Lupus",slug:"lupus",abbreviation:"flupu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:435,name:"Frontiers in Linguistics",slug:"linguistics",abbreviation:"fling",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2636,name:"Frontiers in Language Sciences",slug:"language-sciences",abbreviation:"flang",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2670,name:"Frontiers in Lab on a Chip Technologies",slug:"lab-on-a-chip-technologies",abbreviation:"frlct",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cx,name:"Frontiers in Integrative Neuroscience",slug:"integrative-neuroscience",abbreviation:"fnint",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1723,name:"Frontiers in Insect Science",slug:"insect-science",abbreviation:"finsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3093,name:"Frontiers in Influenza",slug:"influenza",abbreviation:"finfl",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3073,name:"Frontiers in Inflammation",slug:"inflammation",abbreviation:"finmn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3200,name:"Frontiers in Industrial Microbiology",slug:"industrial-microbiology",abbreviation:"finmi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3291,name:"Frontiers in Industrial Engineering",slug:"industrial-engineering",abbreviation:"fieng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2765,name:"Frontiers in Impact Journals",slug:"impact-journals",abbreviation:e,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3078,name:"Frontiers in Immunotherapeutics",slug:"immunotherapeutics",abbreviation:"fimms",space:{id:c,domainName:d,__typename:b},__typename:a},{id:276,name:"Frontiers in Immunology",slug:"immunology",abbreviation:"fimmu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2379,name:"Frontiers in Imaging",slug:"imaging",abbreviation:"fimag",space:{id:c,domainName:d,__typename:b},__typename:a},{id:629,name:"Frontiers in ICT",slug:"ict",abbreviation:"fict",space:{id:c,domainName:d,__typename:b},__typename:a},{id:16,name:"Frontiers in Humanities and Social Sciences Archive",slug:"humanities-and-social-sciences-archive",abbreviation:G,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3759,name:"Frontiers in Human Rights",slug:"human-rights",abbreviation:e,space:{id:c,domainName:d,__typename:b},__typename:a},{id:1588,name:"Frontiers in Human Neuroscience",slug:"human-neuroscience",abbreviation:"fnhum",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1533,name:"Frontiers in Human Dynamics",slug:"human-dynamics",abbreviation:"fhumd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2733,name:"Frontiers in Horticulture",slug:"horticulture",abbreviation:"fhort",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3316,name:"Frontiers in Histology",slug:"histology",abbreviation:"frhis",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2378,name:"Frontiers in High Performance Computing",slug:"high-performance-computing",abbreviation:"fhpcp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2456,name:"Frontiers in Hematology",slug:"hematology",abbreviation:"frhem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2063,name:"Frontiers in Health Services",slug:"health-services",abbreviation:"frhs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:t,name:"Frontiers in Health Archive",slug:"health-archive",abbreviation:G,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3508,name:"Frontiers in Green Chemistry",slug:"green-chemistry",abbreviation:"fgrch",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1728,name:"Frontiers in Global Women's Health",slug:"global-womens-health",abbreviation:"fgwh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2918,name:"Frontiers in Geochemistry",slug:"geochemistry",abbreviation:"fgeoc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1540,name:"Frontiers in Genome Editing",slug:"genome-editing",abbreviation:"fgeed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:240,name:"Frontiers in Genetics",slug:"genetics",abbreviation:"fgene",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3496,name:"Frontiers in Genetic Microbiology",slug:"genetic-microbiology",abbreviation:"fgemi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3227,name:"Frontiers in Genetic Disorders",slug:"genetic-disorders",abbreviation:"frged",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2333,name:"Frontiers in Gastroenterology",slug:"gastroenterology",abbreviation:"fgstr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1529,name:"Frontiers in Future Transportation",slug:"future-transportation",abbreviation:"ffutr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1725,name:"Frontiers in Fungal Biology",slug:"fungal-biology",abbreviation:"ffunb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2826,name:"Frontiers in Fuels",slug:"fuels",abbreviation:"ffuel",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3207,name:"Frontiers in Freshwater Science",slug:"freshwater-science",abbreviation:"ffwsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1366,name:"Frontiers in Forests and Global Change",slug:"forests-and-global-change",abbreviation:"ffgc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2689,name:"Frontiers in Forensic Science",slug:"forensic-science",abbreviation:e,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2289,name:"Frontiers in Food Science and Technology",slug:"food-science-and-technology",abbreviation:"frfst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3559,name:"Frontiers in Fluorescence",slug:"fluorescence",abbreviation:"fflur",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2987,name:"Frontiers in Fish Science",slug:"fish-science",abbreviation:"frish",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3489,name:"Frontiers in Fire Science and Technology",slug:"fire-science-and-technology",abbreviation:"firtc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2749,name:"Frontiers in Financial Economics",slug:"financial-economics",abbreviation:"ffecn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in FSHIP Test Journal",slug:"fship-test-journal",abbreviation:"ftest",space:{id:k,domainName:m,__typename:b},__typename:a},{id:bZ,name:"Frontiers in Evolutionary Neuroscience",slug:"evolutionary-neuroscience",abbreviation:"fnevo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2955,name:"Frontiers in Ethology",slug:"ethology",abbreviation:"fetho",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3032,name:"Frontiers in Epigenetics and Epigenomics",slug:"epigenetics-and-epigenomics",abbreviation:"freae",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2394,name:"Frontiers in Epidemiology",slug:"epidemiology",abbreviation:"fepid",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3450,name:"Frontiers in Environmental Toxicology",slug:"environmental-toxicology",abbreviation:"fentx",space:{id:c,domainName:d,__typename:b},__typename:a},{id:627,name:"Frontiers in Environmental Science",slug:"environmental-science",abbreviation:"fenvs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2888,name:"Frontiers in Environmental Health",slug:"environmental-health",abbreviation:"fenvh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2851,name:"Frontiers in Environmental Engineering",slug:"environmental-engineering",abbreviation:"fenve",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2547,name:"Frontiers in Environmental Economics",slug:"environmental-economics",abbreviation:"frevc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1697,name:"Frontiers in Environmental Chemistry",slug:"environmental-chemistry",abbreviation:"fenvc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2756,name:"Frontiers in Environmental Archaeology",slug:"environmental-archaeology",abbreviation:"fearc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:15,name:"Frontiers in Engineering archive",slug:"engineering-archive",abbreviation:G,space:{id:k,domainName:m,__typename:b},__typename:a},{id:626,name:"Frontiers in Energy Research",slug:"energy-research",abbreviation:"fenrg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3115,name:"Frontiers in Energy Efficiency",slug:"energy-efficiency",abbreviation:"fenef",space:{id:c,domainName:d,__typename:b},__typename:a},{id:106,name:"Frontiers in Endocrinology",slug:"endocrinology",abbreviation:"fendo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1696,name:"Frontiers in Electronics",slug:"electronics",abbreviation:"felec",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1800,name:"Frontiers in Electronic Materials",slug:"electronic-materials",abbreviation:"femat",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2998,name:"Frontiers in Educational Psychology",slug:"educational-psychology",abbreviation:"fepys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1239,name:"Frontiers in Education",slug:"education",abbreviation:"feduc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:625,name:"Frontiers in Economics",slug:"economics",abbreviation:"fecon",space:{id:c,domainName:d,__typename:b},__typename:a},{id:471,name:"Frontiers in Ecology and Evolution",slug:"ecology-and-evolution",abbreviation:"fevo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in Earth Science Archive",slug:"earth-science-archive",abbreviation:"gslfj",space:{id:r,domainName:S,__typename:b},__typename:a},{id:654,name:"Frontiers in Earth Science",slug:"earth-science",abbreviation:"feart",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3309,name:"Frontiers in Earth Observation and Land Monitoring",slug:"earth-observation-and-land-monitoring",abbreviation:"feolm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2161,name:"Frontiers in Drug Safety and Regulation",slug:"drug-safety-and-regulation",abbreviation:"fdsfr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2137,name:"Frontiers in Drug Discovery",slug:"drug-discovery",abbreviation:"fddsv",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2136,name:"Frontiers in Drug Delivery",slug:"drug-delivery",abbreviation:"fddev",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2775,name:"Frontiers in Disaster and Emergency Medicine",slug:bB,abbreviation:"femer",space:{id:c,domainName:d,__typename:b},__typename:a},{id:788,name:"Frontiers in Digital Humanities",slug:"digital-humanities",abbreviation:"fdigh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1534,name:"Frontiers in Digital Health",slug:"digital-health",abbreviation:"fdgth",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2999,name:"Frontiers in Developmental Psychology",slug:"developmental-psychology",abbreviation:"fdpys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2873,name:"Frontiers in Detector Science and Technology",slug:"detector-science-and-technology",abbreviation:"fdest",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3611,name:"Frontiers in Design Engineering",slug:"design-engineering",abbreviation:"fdese",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2550,name:"Frontiers in Dermatological Research",slug:"dermatological-research",abbreviation:"fdmre",space:{id:c,domainName:d,__typename:b},__typename:a},{id:607,name:"Frontiers in Dental Medicine",slug:"dental-medicine",abbreviation:"fdmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2597,name:"Frontiers in Dementia",slug:"dementia",abbreviation:"frdem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1785,name:"Frontiers in Control Engineering",slug:"control-engineering",abbreviation:"fcteg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1724,name:"Frontiers in Conservation Science",slug:"conservation-science",abbreviation:"fcosc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3454,name:"Frontiers in Condensed Matter",slug:"condensed-matter",abbreviation:"fconm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1511,name:"Frontiers in Computer Science",slug:"computer-science",abbreviation:"fcomp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3566,name:"Frontiers in Computational Physiology",slug:"computational-physiology",abbreviation:"fcphy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:bK,name:"Frontiers in Computational Neuroscience",slug:"computational-neuroscience",abbreviation:"fncom",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3234,name:"Frontiers in Complex Systems",slug:"complex-systems",abbreviation:"fcpxs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1787,name:"Frontiers in Communications and Networks",slug:"communications-and-networks",abbreviation:"frcmn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1238,name:"Frontiers in Communication",slug:"communication",abbreviation:"fcomm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2535,name:"Frontiers in Cognition",slug:"cognition",abbreviation:"fcogn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2857,name:"Frontiers in Coatings, Dyes and Interface Engineering",slug:"coatings-dyes-and-interface-engineering",abbreviation:"frcdi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3222,name:"Frontiers in Clinical Microbiology",slug:"clinical-microbiology",abbreviation:"fclmi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1729,name:"Frontiers in Clinical Diabetes and Healthcare",slug:"clinical-diabetes-and-healthcare",abbreviation:"fcdhc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2551,name:"Frontiers in Clinical Dermatology",slug:"clinical-dermatology",abbreviation:"fcldm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1490,name:"Frontiers in Climate",slug:"climate",abbreviation:"fclim",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3338,name:"Frontiers in Chromosome Research",slug:"chromosome-research",abbreviation:e,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2587,name:"Frontiers in Child and Adolescent Psychiatry",slug:"child-and-adolescent-psychiatry",abbreviation:"frcha",space:{id:c,domainName:d,__typename:b},__typename:a},{id:601,name:"Frontiers in Chemistry",slug:"chemistry",abbreviation:"fchem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1532,name:"Frontiers in Chemical Engineering",slug:"chemical-engineering",abbreviation:"fceng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3038,name:"Frontiers in Chemical Biology",slug:"chemical-biology",abbreviation:"fchbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3322,name:"Frontiers in Ceramics",slug:"ceramics",abbreviation:"fceic",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1440,name:"Frontiers in Cellular and Infection Microbiology",slug:"cellular-and-infection-microbiology",abbreviation:"fcimb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1523,name:"Frontiers in Cellular Neuroscience",slug:"cellular-neuroscience",abbreviation:"fncel",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3084,name:"Frontiers in Cellular Immunology",slug:"cellular-immunology",abbreviation:"fcimy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:403,name:"Frontiers in Cell and Developmental Biology",slug:"cell-and-developmental-biology",abbreviation:"fcell",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3178,name:"Frontiers in Cell Signaling",slug:"cell-signaling",abbreviation:"fcsig",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2655,name:"Frontiers in Cell Death",slug:"cell-death",abbreviation:"fceld",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1901,name:"Frontiers in Catalysis",slug:"catalysis",abbreviation:"fctls",space:{id:c,domainName:d,__typename:b},__typename:a},{id:755,name:"Frontiers in Cardiovascular Medicine",slug:"cardiovascular-medicine",abbreviation:"fcvm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2662,name:"Frontiers in Carbon",slug:"carbon",abbreviation:"frcrb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3513,name:"Frontiers in Cancer Interception",slug:"cancer-interception",abbreviation:"fcint",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3433,name:"Frontiers in Cancer Control and Society",slug:"cancer-control-and-society",abbreviation:"fcacs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:921,name:"Frontiers in Built Environment",slug:"built-environment",abbreviation:"fbuil",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1418,name:"Frontiers in Blockchain",slug:"blockchain",abbreviation:"fbloc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2971,name:"Frontiers in Bird Science",slug:"bird-science",abbreviation:"fbirs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3300,name:"Frontiers in Biophysics",slug:"biophysics",abbreviation:"frbis",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2222,name:"Frontiers in Biomaterials Science",slug:"biomaterials-science",abbreviation:"fbiom",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1722,name:"Frontiers in Bioinformatics",slug:"bioinformatics",abbreviation:"fbinf",space:{id:c,domainName:d,__typename:b},__typename:a},{id:452,name:"Frontiers in Bioengineering and Biotechnology",slug:"bioengineering-and-biotechnology",abbreviation:"fbioe",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1380,name:"Frontiers in Big Data",slug:"big-data",abbreviation:"fdata",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1589,name:"Frontiers in Behavioral Neuroscience",slug:"behavioral-neuroscience",abbreviation:"fnbeh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2432,name:"Frontiers in Behavioral Economics",slug:"behavioral-economics",abbreviation:"frbhe",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2796,name:"Frontiers in Bee Science",slug:"bee-science",abbreviation:"frbee",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3214,name:"Frontiers in Batteries and Electrochemistry",slug:"batteries-and-electrochemistry",abbreviation:"fbael",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3011,name:"Frontiers in Bacteriology",slug:"bacteriology",abbreviation:"fbrio",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3040,name:"Frontiers in Audiology and Otology",slug:"audiology-and-otology",abbreviation:"fauot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:603,name:"Frontiers in Astronomy and Space Sciences",slug:"astronomy-and-space-sciences",abbreviation:"fspas",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1437,name:"Frontiers in Artificial Intelligence",slug:"artificial-intelligence",abbreviation:"frai",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2940,name:"Frontiers in Arachnid Science",slug:"arachnid-science",abbreviation:"frchs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2834,name:"Frontiers in Aquaculture",slug:"aquaculture",abbreviation:"faquc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:981,name:"Frontiers in Applied Mathematics and Statistics",slug:"applied-mathematics-and-statistics",abbreviation:"fams",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3417,name:"Frontiers in Applied Environmental Microbiology",slug:"applied-environmental-microbiology",abbreviation:"faemi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2714,name:"Frontiers in Antibiotics",slug:"antibiotics",abbreviation:"frabi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3443,name:"Frontiers in Anti-Cancer Therapies",slug:"anti-cancer-therapies",abbreviation:"facth",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3253,name:"Frontiers in Antennas and Propagation",slug:"antennas-and-propagation",abbreviation:"fanpr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1719,name:"Frontiers in Animal Science",slug:"animal-science",abbreviation:"fanim",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2513,name:"Frontiers in Anesthesiology",slug:"anesthesiology",abbreviation:"fanes",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1989,name:"Frontiers in Analytical Science",slug:"analytical-science",abbreviation:"frans",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2909,name:"Frontiers in Amphibian and Reptile Science",slug:"amphibian-and-reptile-science",abbreviation:"famrs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1705,name:"Frontiers in Allergy",slug:"allergy",abbreviation:"falgy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1541,name:"Frontiers in Agronomy",slug:"agronomy",abbreviation:"fagro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3631,name:"Frontiers in Agricultural Engineering",slug:"agricultural-engineering",abbreviation:"faeng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2477,name:"Frontiers in Aging Neuroscience",slug:"aging-neuroscience",abbreviation:"fnagi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1566,name:"Frontiers in Aging",slug:"aging",abbreviation:"fragi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2449,name:"Frontiers in Aerospace Engineering",slug:"aerospace-engineering",abbreviation:"fpace",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2195,name:"Frontiers in Adolescent Medicine",slug:"adolescent-medicine",abbreviation:"fradm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3426,name:"Frontiers in Acoustics",slug:"acoustics",abbreviation:"facou",space:{id:c,domainName:d,__typename:b},__typename:a},{id:979,name:bI,slug:"frontiers-for-young-minds",abbreviation:"frym",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3260,name:"Frontiers In Ocean Engineering",slug:"frontiers-in-ocean-engineering",abbreviation:"focen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:O,name:"FSHIP Test Journal 2",slug:"fship-test-journal-2",abbreviation:"FTJ2",space:{id:k,domainName:m,__typename:b},__typename:a},{id:k,name:cy,slug:cz,abbreviation:cA,space:{id:R,domainName:bS,__typename:b},__typename:a},{id:3746,name:cy,slug:cz,abbreviation:cA,space:{id:c,domainName:d,__typename:b},__typename:a},{id:cv,name:cB,slug:cC,abbreviation:cD,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3231,name:cB,slug:cC,abbreviation:cD,space:{id:c,domainName:d,__typename:b},__typename:a},{id:r,name:cE,slug:cF,abbreviation:cG,space:{id:r,domainName:S,__typename:b},__typename:a},{id:2078,name:cE,slug:cF,abbreviation:cG,space:{id:c,domainName:d,__typename:b},__typename:a},{id:cx,name:cH,slug:cI,abbreviation:cJ,space:{id:k,domainName:m,__typename:b},__typename:a},{id:2359,name:cH,slug:cI,abbreviation:cJ,space:{id:c,domainName:d,__typename:b},__typename:a},{id:8,name:cK,slug:cL,abbreviation:cM,space:{id:k,domainName:m,__typename:b},__typename:a},{id:2446,name:cK,slug:cL,abbreviation:cM,space:{id:c,domainName:d,__typename:b},__typename:a},{id:10,name:cN,slug:cO,abbreviation:cP,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3230,name:cN,slug:cO,abbreviation:cP,space:{id:c,domainName:d,__typename:b},__typename:a},{id:r,name:cQ,slug:cR,abbreviation:cS,space:{id:k,domainName:m,__typename:b},__typename:a},{id:2358,name:cQ,slug:cR,abbreviation:cS,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3660,name:"Advanced Optical Technologies",slug:"advanced-optical-technologies",abbreviation:"aot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cw,name:cT,slug:cU,abbreviation:cV,space:{id:k,domainName:m,__typename:b},__typename:a},{id:3659,name:cT,slug:cU,abbreviation:cV,space:{id:c,domainName:d,__typename:b},__typename:a},{id:N,name:cW,slug:cX,abbreviation:"abp",space:{id:k,domainName:m,__typename:b},__typename:a},{id:3695,name:cW,slug:cX,abbreviation:"ABP",space:{id:c,domainName:d,__typename:b},__typename:a}]},serverRendered:h,routePath:"\u002Fjournals\u002Fpublic-health\u002Farticles\u002F10.3389\u002Ffpubh.2025.1508793\u002Ffull",config:{baseUrl:"https:\u002F\u002Fwww.frontiersin.org",appName:"article-pages-2022",spaceId:c,spaceName:A,domain:d,loopUrl:"https:\u002F\u002Floop.frontiersin.org",ssMainDomain:d,googleRecaptchaKeyName:"FrontiersRecaptchaV2",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase\u003E\u003E article",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Review Editor\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country\u002Fregion\",\"frontiersDefaultTerm\":\"country\u002Fregion\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries\u002Fregions\",\"frontiersDefaultTerm\":\"countries\u002Fregions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Review Editors\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"}]}'\n",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmServerUrl:"https:\u002F\u002Ftag-manager.frontiersin.org",gtmPreview:"env-1",faviconSize512:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002Fed3f9ce840a03d7\u002Ffavicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002F1c8bcb536c789e11\u002FGuidelines-Frontiers_Logo_1200x628_1-91to1.png",_app:{basePath:"\u002F",assetsPath:"\u002Farticle-pages\u002F_nuxt\u002F",cdnURL:f}},apollo:{contentfulJournalsDelivery:Object.create(null),contentfulJournalsPreview:Object.create(null),contentfulHomeDelivery:Object.create(null),contentfulHomePreview:Object.create(null),frontiersGraph:Object.create(null)}}}("journal_journal","public_space",1,"frontiersin.org","",null,"_self",true,false,0,3,"Ghana","frontierspartnerships.org","_blank","citation_author","citation_author_institution","Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana",2,"Frontiers in Public Health",4,5,609,"public-health","West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana","Link","description","Frontiers","West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Ghana","Help center","Grey","Medium","ssph-journal.org","fship","image","landscape","Front. Public Health","2296-2565",void 0,"Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana",18,13,1920,"por-journal.com",7,"escubed.org",1918,"fipp","https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002Fwebimage-F7837330-160A-426F-A7EBDF4B8DECDD06.png",2497,"22C10171-81B3-4DA6-99342F272A32E8BB","jpg","https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F7CCE4235-8BF4-4D52-8022020C57AC98C1\u002FD992F897-6BC2-466D-90902EADFBEAB887\u002FWebsiteWebP_XL-FPUBH_Main Visual_Cyan_Website.webp","2022-06-27T10:00:52Z","fpubh",70,"journal_field","10.3389\u002Ffpubh.2025.1508793","Anthony T.",2088681,"James O.","Medical and Scientific Research Center, University of Ghana Medical Center",1254504,"Helena","Christopher Z.-Y.","Araba","Darius N. K.",1427882,"Seth",1952821,"Yaw","Gloria",2397851,"Joseph",1791348,"Vincent","Department of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana",1308622,"George B.","Peter",1307387,"Evelyn Y.",2815320,"Benard",355398,"Olivier",581433,{},3460,"Infectious Diseases: Epidemiology and Prevention","infectious-diseases-epidemiology-and-prevention","Frontiers | Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana","https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fpublic-health\u002Farticles\u002F10.3389\u002Ffpubh.2025.1508793\u002Ffull","og:title","og:description","keywords","og:site_name","og:image","og:type","og:url","twitter:card","citation_volume","citation_journal_title","citation_publisher","citation_journal_abbrev","citation_issn","citation_doi","citation_firstpage","citation_language","citation_title","citation_keywords","citation_abstract","citation_pdf_url","citation_online_date","citation_publication_date","Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Ghana","Department of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana, Ghana","dc.identifier","articles","editors","research-topics","https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002F0B4B1380-42EB-4FD5-9D7E2DBC603E79F8\u002Fwebimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png","Man ultramarathon runner in the mountains he trains at sunset","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fresearch-integrity","How we publish","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fhow-we-publish","Research Topics","Fee policy","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Ffee-policy","https:\u002F\u002Fforum.frontiersin.org\u002F","Frontiers Planet Prize","https:\u002F\u002Fwww.frontiersplanetprize.org\u002F","this link will take you to the Frontiers Planet Prize website","Career opportunities","https:\u002F\u002Fcareers.frontiersin.org\u002F","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fcontact","disaster-and-emergency-medicine","Author guidelines","Editor guidelines","https:\u002F\u002Fwww.frontiersin.org\u002Fjournals","https:\u002F\u002Fwww.frontiersin.org\u002Farticles","Articles","https:\u002F\u002Fhelpcenter.frontiersin.org","Frontiers for Young Minds","Frontiers Facebook",9,"Transplant International","transplant-international","ti",1921,"Spanish Journal of Soil Science","spanish-journal-of-soil-science","sjss","ebm-journal.org","Public Health Reviews","public-health-reviews","phrs","Pathology and Oncology Research","pathology-and-oncology-research","pore",21,"Pastoralism: Research, Policy and Practice","pastoralism-research-policy-and-practice","past",11,"Oncology Reviews","oncology-reviews","or","Journal of Pharmacy & Pharmaceutical Sciences","journal-of-pharmacy-pharmaceutical-sciences","jpps","Journal of Cutaneous Immunology and Allergy","journal-of-cutaneous-immunology-and-allergy","JCIA","Journal of Abdominal Wall Surgery","journal-of-abdominal-wall-surgery","jaws",1919,"International Journal of Public Health","international-journal-of-public-health","ijph","Frontiers in Pathology","pathology","fpath",12,17,6,"Experimental Biology and Medicine","experimental-biology-and-medicine","EBM","European Journal of Cultural Management and Policy","european-journal-of-cultural-management-and-policy","ejcmp","Earth Science, Systems and Society","earth-science-systems-and-society","esss","Dystonia","dystonia","dyst","British Journal of Biomedical Science","british-journal-of-biomedical-science","bjbs","Aerospace Research Communications","aerospace-research-communications","arc","Advances in Drug and Alcohol Research","advances-in-drug-and-alcohol-research","adar","Acta Virologica","acta-virologica","av","Acta Biochimica Polonica","acta-biochimica-polonica"));</script><script src="/article-pages/_nuxt/e397d1a.js" defer></script><script src="/article-pages/_nuxt/a5e7651.js" defer></script><script src="/article-pages/_nuxt/f548f7f.js" defer></script><script src="/article-pages/_nuxt/e3c5a8f.js" defer></script><script src="/article-pages/_nuxt/0d6d8e5.js" defer></script><script src="/article-pages/_nuxt/ed7fc59.js" defer></script><script src="/article-pages/_nuxt/2abb6c5.js" defer></script><script src="/article-pages/_nuxt/701e3a3.js" defer></script><script src="/article-pages/_nuxt/71728a1.js" defer></script><script data-n-head="ssr" src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" data-body="true" async></script><script data-n-head="ssr" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" data-body="true" async></script><script data-n-head="ssr" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" data-body="true" async></script><script data-n-head="ssr" src="https://api.altmetric.com/v1/doi/10.3389/fpubh.2025.1508793?callback=_altmetric.embed_callback&amp;domain=www.frontiersin.org&amp;key=3c130976ca2b8f2e88f8377633751ba1&amp;cache_until=14-15" data-body="true" async></script><script data-n-head="ssr" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" data-body="true" async></script>
</body>

</html>